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Streptococcus pneumoniae is a leading cause of pneumonia and one of 
the most common causes of death globally. Nevertheless, the impact of S. 
pneumoniae on host molecular processes that lead to detrimental pulmonary 
consequences are not fully understood. Here, we show that S. pneumoniae 
induces toxic DNA double strand breaks (DSBs) in human alveolar epithelial cells, 
as indicated by ataxia telangiectasia mutated (ATM) kinase-dependent 
phosphorylation of histone H2AX and co-localization with 53BP1. S. pneumoniae 
is able to induce genotoxicity via streptococcal pyruvate oxidase (SpxB)-
mediated production of H2O2 and DNA damage can occur in a bacterial contact-
independent fashion. The extent of S. pneumoniae-induced DNA damage 
correlates with the extent of apoptosis and precedes it. Further, both addition of 
catalase, which neutralizes H2O2, during in vitro infection and knockout of the 
spxB gene in S. pneumoniae, greatly suppress pneumococci-induced DNA 
damage and apoptosis. Importantly, a H2O2-producing S. pneumoniae serotype 
induces DSBs in the lungs of animals with acute pneumonia and H2O2 production 
by S. pneumoniae in vivo contributes to bacterial genotoxicity and virulence.  
The conserved cholesterol-dependent cytolysin (CDC) toxin, pneumolysin, 
which is mainly released after pneumococcal lysis, is found to be a major 
genotoxic factor in bacterial lysate. Purified pneumolysin can induce DSBs in 
alveolar cells, which is associated with cell cycle arrest. Interestingly, a 
monoclonal antibody that targets the oligomerizing domain of pneumolysin is 
able to prevent the genotoxicity of the purified toxin, indicating that pneumolysin 




Components of the host-inflammatory response, such as neutrophils, are 
known to be responsible for oxidative stress against pathogens, potentially 
causing collateral damage to host cells. We show that S. pneumoniae serotype 4 
that which is naturally unable to produce H2O2 and has thick capsulation, persists 
longer than less capsulated serotypes and elicits greater neutrophil recruitment 
that are associated with pulmonary DNA damage. Neutrophil accumulation and 
pulmonary DNA damage are found to be strongly associated with animal 
mortality during acute pneumonia.  
One of the major DSB repair pathways is non-homologous end-joining 
(NHEJ) for which Ku70/Ku80 and DNA-PKc are essential. We observe that, 
during pneumolysin toxicity, inhibition of DNA-PK overrides pneumolysin-induced 
transient growth arrest and instead leads to cell death by apoptosis. Importantly, 
we find that deficiency of Ku80 causes an increase in the levels of DSBs and 
apoptosis induced by H2O2-producing S. pneumoniae, underscoring the 
importance of DNA repair in preventing S. pneumoniae-induced genotoxicity. 
Taken together, this thesis work shows that S. pneumoniae-induced damage to 
the host cell genome exacerbates its toxicity and pathogenesis, making DNA 
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1.1   Streptococcus pneumoniae and Pneumococcal Disease  
Streptococcus pneumoniae is gram-positive, capsulated, extracellular 
bacteria and a major pathogen that causes global morbidity and mortality. S. 
pneumoniae is one of the most common cause of community-acquired 
pneumonia (CAP) and is a commensal organism of upper respiratory tract in 20-
50% children and up to 30% in adults (1). Pneumonia and associated invasive 
diseases results in about a million infant deaths every year (2). According to 
WHO (Fact sheet N°331), pneumonia accounts for 15% of deaths of children 
under 5 years old. Center for Disease Control (CDC) states that the case-fatality 
rate is 5-7 % and can be up to 50% for elderly patients. Using bacterial 
invasiveness as an indicator, the annual incidence of pneumococcal disease in 
elderly (≥65 years) is estimated to be 24 to 85 cases/100,000 people in 
industrialized regions (3). In adults, S. pneumoniae accounts for 30-50% of CAP 
associated hospitalizations (3). With such high mortality and hospitalization rates, 
disease burden associated with S. pneumoniae is indeed very serious and hence 
poses an important problem to humans on a global scale 
 Diseases caused by S. pneumoniae, collectively called pneumococcal 
disease, include various important diseases associated with major organs. The 
pneumococci first colonize the nasopharyngeal region and they could infect other 
organs from this region (4). Not all colonizing pneumococci strains have the 
potential to invade vital organs. Indeed, comparative genomic study between 
colonizing and invading strains has shown that presence of certain 
pneumococcal genes correlates with the invasive phenotype of pneumococci (5). 
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In a way, this commensalism can be seen as a predisposing factor for future 
infection where the colonized nasopharynx can additionally act as a reservoir of 
bacteria for carriage and transmission. S. pneumoniae is known to be a common 
cause of middle ear infection (acute otitis media; AOM) in children (6), a frequent 
reason for pediatric consultations (The Pink Book: Course Textbook 2012, CDC). 
AOM is considered as a non-invasive pneumococcal disease, as it is a less 
serious manifestation. Similarly, sinusitis is also considered a non-invasive 
spread of pneumococci from its colonizing centre – the nasopharynx. Pulmonary 
pneumonia is the common clinical manifestation of pneumococcal infection. 
Infection in which S. pneumoniae is isolated from sterile bodily fluids like 
cerebrospinal fluid (CSF) or blood is termed an invasive pneumococcal disease 
(IPD). Pneumococcal bacteremia (pneumococci in blood), which has an average 
fatality rate of around 20% and could be higher (up to 60%) for elderly population 
(The Pink Book: Course Textbook 2012, CDC), can arise due to complications 
from pneumonia or, in rare cases, as a result of direct spread of bacteria from 
nasopharynx (occult bacteremia). Pneumococcal pneumonia that has become 
bacteremic is known to have an increased mortality rate compared to non-
bacteremic pneumonia (7). High-titer bacteremia can in turn lead to 
complications like meningitis, when the pneumococci cross the blood-brain 
barrier and invade CSF to cause inflammation in brain meninges (Figure 1.1) (8). 
Overall, diseases caused by S. pneumoniae pose a serious risk of hospitalization 






Figure 1.1 Pathogenesis of Streptococcus pneumoniae resulting in various 
diseases in different human organs. To establish an effective infection the 
bacteria first needs to colonize the upper respiratory tract (URT). From here, the 
bacteria can cause pneumococcal infection like acute otitis media (AOM) and 
sinusitis. Importantly, depending on the virulence of the bacteria, invasion of 
lower respiratory tract (LRT) results in the common invasive pneumococcal 
disease (IPD) - pneumonia. Further pneumococcal invasion into the blood results 
in bacteremia. From the blood the bacteria can invade into cerebral spinal fluid 
(CSF) and then into brain tissues causing another IPD -meningitis. Figure is 
modified from: https://www.teachervision.com/respiratory-system. 
 
1.2 Streptococcus pneumoniae: Serotypes, Colonization and 
Prevalence 
S. pneumoniae is recognized to have 91 different serotypes (9). Each 
serotype has its own unique makeup of capsular polysaccharides and hence is 
antigenically different among each other. However, a certain degree of cross-
reactivity exists within serotypes and accordingly S. pneumoniae serotypes are 
grouped into 46 serogroups based on their immunological similarities (10). For 
example, serogroup 9 consist of serotypes 9A, 9L, 9N and 9V, all of which have 
one cross reacting antigen designated as “9a” (11, 12). S. pneumoniae serotypes 
vary in their pathogenicity and hence in their ability to be asymptomatically 
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carried or be invasive or be lethal. With such a diverse range of serotypes 
prevailing globally, the serotypes that are associated with IPD or increased case-
fatalities varies across geographical regions (13, 14). While at least 40 
pneumococcal serogroups are known to be potentially pathogenic, only certain 
groups are frequently associated with invasive diseases (13, 15). For example, 
studies have shown that some 10 serogroups are frequent causes of IPD in 
children (10) and serotypes 3, 6B and 9N have been constantly associated with 
increased case-fatalities (16-18). This interesting prevalence of certain serotypes 
that cause majority of IPD has helped in designing vaccines targeting particular 
serotypes.  
 Historically, the first vaccine that used pneumococcal polysaccharides to 
elicit active immune response was licensed in 1977 and later on replaced in 1983 
by another polysaccharide-based vaccine that covered 23 prevalent serotypes: 1, 
2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 
22F, 23F, and 33F. This vaccine is still being used today as Pneumovax23 
(Merck). However, since most of the pneumococcal diseases are occurring in 
children (< 5 years old), polysaccharide-activated B-cell response was deemed to 
be insufficient to provide robust protection. A breakthrough in pneumococcal 
vaccine development came about with the use of a polysaccharide conjugate- 
based vaccine that elicits robust and effective T-cell dependent immune 
response in children, in addition to the polysaccharide-activated B-cell response 
(19). Pneumococcal conjugate vaccine (PCV) covering seven common serotypes: 
4, 6B, 9V, 14, 18C, 19F, and 23F, introduced in 2000 was improved in 2010 by 
another PCV that covers additional six serotypes (1, 3, 5, 6A, 7F and 19A). Use 
of these conjugate vaccines has indeed decreased the pneumococcal disease 
burden significantly in the past decade (9, 20). In addition to these prevalent and 
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invasive serotypes, certain factors including co-morbidities like HIV-infection (14) 
and cardiopulmonary disorders (21) have been shown to modulate the 
prevalence of pneumococcal serotypes at a given time and region.  
Pneumococcal serotypes differ in the composition of surface capsular 
polysaccharides and hence potentially differ in their ability to colonize the 
nasopharynx (21, 22). Although nasopharyngeal colonization is not sufficient to 
cause invasive disease, colonization is a crucial and necessary step for both 
pneumococcal carriage and pathogenesis (4). The rate of carriage for all of the 
pneumococcal serotypes and their ability to cause disease varies, but the reason 
behind this is not fully understood (23). Here, the molecular adaptations of 
different serotypes that enable them to persist during host colonization could be a 
determining factor. It would be instructive to think that the ability of an incoming 
serotype to establish itself in the competitive environment of upper respiratory 
tract (called pneumococcal acquisition) that hosts other pneumococcal serotypes, 
as well as varieties of commensal microorganisms, could subsequently 
determine its duration of asymptomatic carriage, its multiplication and its potential 
to be invasive. Up to four different serotypes have been reported to colonize 
upper respiratory tracts of an individual at a given time (24).  
Studies of AOM in infants have shown that pre-existing serotypes in 
nasopharynx of pneumococcal carriers does not predispose the infant to middle 
ear infection, but instead acquisition of new serotypes in the nasopharynx (weeks 
or months before the onset of symptoms) as well as in middle ear was found to 
be strongly associated with subsequent infection (25, 26). This suggests that the 
disease-causing acquired serotype would have some selective advantage to 
become virulent over the serotypes being carried. One such advantage could be 
the ability to persist and multiply faster in the nasopharynx to overwhelm the 
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mucosal immunity and invade the host. Indeed, the pneumococcal burden in 
nasopharyngeal samples of adult patients with CAP has been found to be much 
greater (~5 logs) than in asymptomatic carriers (27), suggesting that excess 
colonization could help in disease invasion, most likely via microaspiration of 
infectious droplets from the upper respiratory tract (28).  
Although it is logical to conclude that the prevalence of a particular 
serotype isolated during invasive disease is associated with prevalence in its 
carriage form (29), certain important studies that disagree with this conclusion. 
One such example is that some serotypes are found to be highly invasive 
(causing IPD) without being detected commonly in the colonization/carrier state. 
For example, serotypes 1 and 5 are frequently found to cause IPD than predicted 
by prevalence of their colonization (4, 13). This could be due to very short 
duration of carriage of these serotypes (possibly affected by capsule thickness, 
discussed in section on page 81.3.1 Capsule) or non-dominant type of carriage 
(thus easily escaping detection).  
Since S. pneumoniae can naturally take up exogenous DNA, colonization 
of different serotypes can also facilitate serotype (capsule) switching between 
non-colonizing invasive serotypes with colonizing carriage serotypes (30), 
thereby increasing the invasive fitness of pneumococci. This kind of horizontal 
transfer of capsule-synthesis gene could result in different pneumococcal 
genotypes acquiring advantageous and virulent serotype. Here, genotype means 
sequence type determined by sequencing of 7 housekeeping genes, excluding 
the capsule loci (29). Indeed, different genotypes (clones) of the same serotype 
has been found to have different potential for causing invasive disease in 
humans (31, 32). While some reports suggest that the capsular serotype could 
be more important than the pneumococcal genotype in causing invasive disease 
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(29) [also evident by the success of capsular polysaccharide-based vaccines in 
suppressing prevalence of virulent serotypes (9, 33)], it is likely that the 
combination of genotype as well as capsule type determines pneumococcal 
persistence and virulence (34, 35). Taken together, it can be said that 
pneumococcal serotype contributes to bacterial colonization and disease 
prevalence in a human population. 
 
1.3       Streptococcus pneumoniae: Virulence Factors 
 The genome of S. pneumoniae codes for various proteins that help the 
bacteria in colonization as well as invasion and hence act as virulence factors 
during pneumococcal pathogenesis. In terms of evolution of S. pneumoniae’s 
virulence, it has been suggested that the pneumococcal virulence factors could 
be first considered as colonization factors since the bacteria exist as successful 
colonizers in greater human population than as an invasive pathogen (36). 
Although evidence from whole genome sequencing of S. pneumoniae isolates 
has shown the presence of a core pneumococcal genome (comprising of ~1,450 
genes), which could help in colonization and transmission and is shared by most 
isolates (37, 38), S. pneumoniae strains vary in their ability to invade tissues and 
organs (38). Genetic regulation of known virulence factors plays could explain 
the difference observed in virulence of strains (37). In this section, three major 
virulence factors of pneumococci (capsule, hydrogen peroxide and pneumolysin) 





 Almost all of the S. pneumoniae strains that are found to cause invasive 
disease express the polysaccharide capsule that determines its serotype. 
Uncapsulated pneumococcal serotypes have been shown to be less virulent and 
invasive in infection models (39, 40). The capsule is a high molecular weight 
polysaccharide measuring 200-400 nm in thickness (41) and consisting of 
various types of monosaccharide linked in different combinations, giving each 
serotype its unique capsular structure. The capsular polysaccharide layer is 
linked by partial covalent bond to the inner bacterial cell wall. The common 
monosaccharide that makes up the capsule is hexoses (glucose, galactose) and 
N-acteyl glucosamine (42). The capsule also has phosphates, uronic acids and 
pyruvates that can confer negative charge to the polysaccharide. Different 
arrangements of the monosaccharide with different glycosidic linkages constitute 
most of the pneumococcal capsules. However, very few serotypes, such as 
serotype 3, have simple primary structure of capsule, comprising disaccharides 
repeats of D-glucuronic acid (GlcA) and D-glucose (Glc) linked by  (14) bonds 
(Figure 1.2) (43).  
 The capsule biosynthesis loci in almost all of the known S. pneumoniae 
serotypes are conserved in the 5’ region. This region is comprised of four 
sequences forming an operon called cpsABCD. The sequences downstream of 
this region vary between serotypes and are considered to be responsible for 
assembly of serotype-specific polysaccharides (44).       
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Figure 1.2 Repeating units that form the capsule structures of S. pneumoniae 
serotype 3, 4 and 19F. Glc, glucose; Gal, galactose; Rha, rhamnose; ManNAc, 
N-acetyl-mannosamine; GlcA, glucuronic acid; FucNAc, N-acetyl-fucosamine; 
GalNAc, N-acetyl-galactosamine; GlcNAc, N-acetyl-glucosamine; p, pyranose. 
Adapted from Kim et.al, Analytical Biochemistry 347 (2005) 262–274. 
 
Role of pneumococcal capsule in virulence 
 It is well established fact that the presence and amount of capsule greatly 
contribute to the virulence of S. pneumoniae (45). Virulence arises as a 
consequence of protection (against host immunity) conferred by the capsule and 
ultimately allowing the bacteria to evade host defense mechanisms and persist to 
cause disease. The sole presence of capsule reduces the deposition of opsonins 
“C3b” and its degraded form “iC3b” (inactive C3b) on the pneumococcal surface, 
thereby allowing the bacteria to escape opsonophagocytosis (46). The 
complement factor C3b is a central player in the complement pathway activation 
that binds covalently to cell wall or capsule of S. pneumoniae and interacts with 
phagocytic receptors (CR1 and CR3) of host immune cells to facilitate 
10 
 
phagocytosis (47). It has been proposed that binding of C3b to pneumococcal 
capsule may result in its degradation into fragments that no longer interact with 
phagocytic receptors and this ability to degrade C3b is serotype-dependent (47). 
The capsule can also prevent direct binding of Immunoglobulin G (IgG) to the 
bacteria and thus prevent IgG-mediated phagocytosis (46). A thicker capsule has 
been shown to mask the virulent pneumococcal surface antigen in certain 
serotypes, thus blocking the accessibility of surface antigens to host 
immunoglobulin (48).        
 While the pneumococcal capsule is crucial during stage of colonization as 
well as invasion of the host, its presence could modulate the carriage and the 
invasion states differently. The present literature suggests that the role of capsule 
in virulence not only depends on the capsular type but also on phenotypic 
capsular thickness (22). While it has been shown in an animal model of 
colonization that capsule production is required to help the bacteria colonize the 
nasopharynx (49), there is report that suggests pneumococci with a lesser 
degree of capsulation (transparent colony phenotype) are more efficient 
colonizers than the ones with greater capsular polysaccharides (opaque colony 
phenotype) (50). Studies based on capsule-switch strains have also shown that 
capsular type is important to determine proper exposure of pneumococcal 
surface adhesins and thereby affecting pneumococcal adherence to epithelia of 
respiratory tract for colonization and virulence (51). During invasive disease, a 
thicker capsule could prove beneficial for bacterial survival, as thicker capsules 
may confer greater resistance to neutrophil-mediated phagocytosis (22). The 
degree of encapsulation in a serotype could be affected by the availability of 
capsular polysaccharides subunits, and hence is suggested to be regulated by 
bacterial sugar metabolism (22, 52). As discussed in the above paragraph, 
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thicker capsule can also help the bacteria to evade other host defenses like 
complement activation. Indeed, serotypes with thicker capsular polysaccharides 
are shown to be more virulent in animal model (45) and more prevalent in 
invasive diseases in humans (22). 
 
1.3.2    Hydrogen peroxide and its toxicity 
 Streptococcus species are one of the few bacteria that are known to 
secrete high amounts of hydrogen peroxide (H2O2) during bacterial metabolism. 
While certain species of Lactobacillus and Enterococcus genera (residing in 
intestine) are also reported to produce H2O2 (53, 54), species of Streptococcus 
such as S. mitis, S. oralis and S. pyogenes, which resides in the upper 
respiratory tract, are well known to produce H2O2 (55-57). However, these 
species do not commonly cause disease and have been reported to be 
associated with secondary infection during viral infection (56) or cancer-related 
neutropenia (57). S. pneumoniae is the most common respiratory pathogen, 
which secretes significant amount of H2O2 during its growth and causes invasive 
diseases. The amount of H2O2 produced by S. pneumoniae is thought to be 
comparable to the amounts secreted by neutrophils (up to 1 mM) and hence has 
the potential to cause toxicity to a range of biomolecules (58), thereby making 
H2O2 an important pneumococcal virulence factor.   
 Historically, S. pneumoniae was shown to produce peroxides in culture 
condition by James McLeod and John Gordon in 1922 (59, 60). Later in 1990s, 
pneumococcal H2O2 was shown to be produced by aerobic decarboxylation of 
pyruvate to acetyl-phosphates by an enzyme called pyruvate oxidase (SpxB) (61). 
SpxB is a flavoprotein, with putative binding sites for co-factors flavin adenine 
dinucleotide (FAD) and thiamine pyrophosphate (TPP) (61). It oxidizes pyruvate 
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to H2O2, carbondioxide and acetyl-phosphate. In this context, H2O2 could be seen 
as a by-product of this enzymatic reaction since the metabolic function of this 
reaction is most likely the production of acetyl phosphate [source of acetyl-
coenzyme A and ATP (61)] rather than production of H2O2 (considering that S. 
pneumonaie lacks H2O2-neutralizing enzyme catalase). However, in terms of 
host virulence and carriage, production of H2O2 by SpxB activity plays a 
significant role not only in disease outcome but also potentially during 
pneumococcal carriage in animal models.  
Biochemical consequence of endogenous H2O2 in pneumococci 
 S. pneumoniae has been shown to produce up to 1-2 mM of H2O2 under 
aerobic conditions (62). H2O2 toxicity arises due to its reaction with ferrous (Fe
2+) 
ions resulting in production of highly reactive hydroxyl radicals (OH) that can 
cause serious and immediate damage to DNA (62) (H2O2–associated DNA 
damage has been discussed in Section 1.6.2). In this reaction (called Fenton 
reaction), the amount of Fe2+ available in bacterial cells is the rate-limiting step 
(63), hence H2O2-producing bacteria has evolved to produce their own anti-
oxidant enzymes that regulate availability of free Fe2+. In S. pneumoniae, 
orthologs of intracellular Fe2+ sequestering proteins such as Dps-like peroxidase 
resistance (Dpr) and alcohol dehydrogenase (AdhE) are present that could 
chelate Fe2+ and possibly prevent occurrence of Fenton reactions (64). One 
pneumococcal thiol peroxidase called TpxD (or pneumococcal surface antigen D) 
has also been shown to directly contribute to scavenging of some portion of 
endogenously produced H2O2, most likely by catalytic cycle of cysteine (-SH) to 
sulfenic acid (-SOH) to disulfide bonds (-S-S-) (65). Similarly, the membrane 
lipoprotein TlpA is also known to act as a thiol-specific antioxidant. However, this 
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protein protects the bacteria only from external hydrogen peroxide stress and not 
intracellular stress (66).  
 Besides these bacterial anti-oxidant strategies, other indirect pathways 
have also been implicated to help the bacteria in surviving the harmful levels of 
H2O2. Absence of a common class of ATP-dependent caseinolytic proteases 
(ClpP) is shown to sensitize S. pneumoniae to exogenously added H2O2 (67). 
Surprisingly, bacteria with inactive pneumococcal surface antigen A (psaA), 
which is a highly immunogenic virulent factor, have also been shown to be 
sensitive to H2O2-mediated killing (68). During both of these experiments, it is 
likely that the regulation of the anti-oxidants TpxD and Dpr are being adversely 
affected in the mutant bacteria and affect their resistance to H2O2 (67, 68). 
Interestingly, SpxB, which is responsible for pneumococcal H2O2, itself has been 
shown to be necessary in protection against assault by exogenous H2O2 (62). It 
has been proposed that the acetyl phosphate that is produced with H2O2 during 
activity of SpxB, acts as a major source of ATP that is required to keep the 
bacteria alive during H2O2-mediated stress (62). In most of the above cited 
studies, it is important to note that the H2O2-sensitivity assay is performed by 
exposing bacteria to excess H2O2 concentration (>20 mM), that could result in 
damage to not only nucleic acids but non-specifically to lipids and proteins as 
well (69). Nevertheless, these studies demonstrate the presence of 
pneumococcal antioxidant systems that modulates the stress caused by H2O2.  
Regev-Yochay et. al. have demonstrated that constant production of 
endogenous H2O2 (~1 mM) could be toxic to the bacteria and can eventually lead 
to apoptosis-like death during stationary growth phase, independent of the known 
autolytic enzyme LytA (70). The endogenous H2O2 in S. pneumoniae is shown to 
have an effect on the bacterial membrane composition as well. Under low 
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anaerobic condition (where low H2O2 is being produced) or in the absence of 
SpxB, S. pneumoniae is shown to have increased levels of unsaturated fatty 
acids and longer fatty acid chains in their membrane (71). The endogenously 
produced H2O2 is reported to interfere with fatty acid synthase (FASII) pathway 
by directly inactivating the enzyme FabF that elongates the fatty acid chain. H2O2 
oxidizes the cysteine-thiol active site of FabF, thereby inhibiting its function in 
fatty acid synthesis (72). Overall, pneumococcal H2O2 can have potential effect 
on bacterial metabolism and the pneumococci are equipped with molecular 
mechanisms to cope with H2O2 stress. However, the significance of 
pneumococcal H2O2-mediated change in bacterial membrane composition and 
how it would affect bacterial adaptation in host environment is open to further 
studies.  
Role of pneumococcal H2O2 in virulence 
 H2O2, being membrane permeable, can cause severe damage to 
host bio-molecules by generation of OH through Fenton chemistry. These 
radicals can cause severe damage to DNA as well as to lipids. Depending upon 
concentration, H2O2 can cause either apoptotic or necrotic cell death in vitro. It is 
known that, at lower to moderate concentrations, H2O2 generally induces 
features of apoptotic cell death while higher concentration of H2O2 can trigger 
necrotic cell death (73). This concentration-dependent choice of cell death varies 
with the cell type studied. For example, certain fibroblasts have been shown to 
undergo necrosis by exposure to 1-10 mM H2O2 (73, 74), while even 0.3 mM of 
H2O2 has been shown to be enough to induce necrosis in hepatocytes (75). 
Mechanistically, H2O2-induced apoptosis could follow caspase-dependent 
pathways (76), while necrosis is generally associated with over-activation of poly 
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(ADP-ribose) polymerase (PARP) that can cause ATP depletion leading to cell 
death (73, 76). With such severe biochemical consequence to H2O2-exposure, 
H2O2 secreted by S. pneumoniae in vitro is indeed shown to cause cytotoxicity in 
rat alveolar epithelium, that could have serious consequence in pulmonary 
membrane structure (58).  Pneumococcal H2O2 has also been shown to partly 
contribute to host mitochondrial damage that leads to S. pneumoniae-induced 
apoptosis of human microglial cells (77). Hence, H2O2 produced by S. 
pneumoniae is one of an important toxic factor against host cells. 
In an animal infection model, virulence of pneumococcal H2O2 is mainly 
demonstrated by using spxB knock out bacteria that are phenotypically deficient 
in H2O2 production. Several studies have shown that spxB mutant bacteria are 
less virulent in animal infection model of pneumonia (61, 78). These spxB 
mutants are unable to replicate in lungs as efficiently as their wild type (61, 78) 
and are equally ineffective in invading into the circulatory system (78). While from 
the latter observation we can expect that the absence of pneumococcal H2O2 in 
infected pulmonary regions to reduce the virulence and invasiveness of the spxB 
mutant bacteria. Interestingly, the former observation suggests the requirement 
of functional spxB for bacterial survival and multiplication during pneumococcal 
infection. 
It is possible that spxB knock out could have pleotropic effects besides 
H2O2-deficieny, as there would be concomitant decrease in acetyl phosphate, a 
precursor of acetyl CoA as well as an important intracellular messenger that can 
regulate global bacterial metabolism (79). It is possible that reduction in acetyl 
phosphate can constrict global bacterial metabolism, resulting in less replication 
of these mutants in tissues. In Streptococcus mutans, inactivation of spxB has 
been associated with changes in genes regulating cell division and fatty acid 
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metabolism (80).  Reduced production of acetyl CoA in spxB mutant has also 
been implicated in reduced adhesivness of acapsular pneumococcal strains (61). 
Although reduced adhesion of spxB mutant is not reported in capsular strains, 
spxB inactivation in type 2 capsular strain has been shown to increase its sugar 
metabolism efficiency resulting in increased glucuronic acid and hence capsule 
production (81). If SpxB does modulate bacterial adhesion pathways, then it 
could affect the bacterial ability to colonize the upper respiratory tract where 
binding to host epithelium is crucial step to establish carriage and subsequent 
infection. Indeed, animal studies have shown that spxB mutants are not able to 
effectively colonize the nasopharynx and persist in the respiratory tracts (61, 78, 
82). mRNA levels of spxB are also known to be 4 to 5 times higher during 
nasopharynx colonization than during invasion in lungs and blood (83).  
The mechanisms that make the spxB mutants a poor colonizer and 
invader could be partly dependent on H2O2 and partly on the other metabolic 
influence of SpxB. One possible way by which H2O2 secreted by S. pneumoniae 
can affect bacterial colonization and invasion is by affecting the ciliary beat 
frequency of epithelium that lines vital organ tracts. Pneumococcal H2O2 has 
been shown to delay the frequency of ciliary beats of nasal epithelium in vitro 
(84), thereby lowering the chances of bacterial clearance and enhancing 
pneumococcal colonization and possible invasion. H2O2 has also been shown to 
reduce ciliary movements of ependymal cells in brains and spinal cord ex vivo 
(85, 86). Given that the pneumococcal H2O2 is known to be toxic towards host 
cells as well as to disrupt defensive barriers, H2O2 is indeed an important 
virulence factor of S. pneumoniae during pathogenesis. 
 In addition to the cytotoxic effect of H2O2 towards host cells, it has been 
proposed that S. pneumoniae has evolved to produce H2O2 as a competitive 
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advantage against other commensal organism during colonization of upper 
respiratory tracts. In this context, epidemiological study has found that the 
prevalence of S. pneumoniae carriage is inversely related to S. aureus carriage 
in children (87). Indeed, in vitro it has been shown that H2O2 produced by S. 
pneumoniae is bactericidal to S. aureus and inhibits their growth (88). Such toxic 
effect of pneumococcal H2O2 has also been demonstrated in vitro against other 
respiratory tract organisms like Haemophilus influenzae and Neisseria 
meningitides (89). However, study of animal model of co-colonization of S. 
pneumoniae and S. aureus has not been able to replicate the in vitro bactericidal 
effect of pneumococcal H2O2 on S. aureus (90). Nevertheless, the ability of S. 
pneumoniae to secrete H2O2 on a level that is similar to activated phagocytes (58) 
could hold some advantage to expansion of pneumococcal colony in their natural 
niche – the nasopharynx. Taken together, it is evident that the production of 
pneumococcal H2O2 is very important during invasion as well as carriage of S. 
pneumoniae.    
 
1.3.3  Pneumolysin and its toxicity 
 Pneumolysin is a 53 kDa, highly conserved protein that is present in 
almost all of the clinical isolates of S. pneumoniae (91). Pneumolysin is one of 
the most important virulence factors produced by S. pneumoniae during 
pneumococcal pathogenesis as it can weaken and destroy various host defenses. 
It belongs to a family of cholesterol-dependent cytolysins (CDC) that includes 
listeriolysin O,  perfringolysin O and streptolysin O and it lyses mammalian cells 
by first binding to membrane cholesterol and then oligomerizing (30-50 
monomers) to form membrane pores of 35-45 nm diameter (92). This ability of 
pneumolysin has been used to measure its activity in a classical hemolytic assay, 
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except for the pneumolysin produced by serotype 1 that is non-hemolytic (93). 
Structurally, the toxin can be divided into four domains, with C-terminal domain 4 
(residues 360–469) needed for cholesterol-dependent membrane binding of the 
toxin and the N- terminal domains 1 (residues 6–21, 58–147, 198–243, 319–342) 
and 3 (residues 148–197, 244–318) are required for oligomerization to form 
pores, while domain 2 (residues 22–57, 343–359) connects these functional 
terminals (94). Pneumolysin is a unique CDC toxin as it lacks any secretory N-
terminal signal peptide (95) and thus cannot be actively secreted. This has led to 
a widely held assumption that pneumolysin is mostly cytoplasmic in location and 
is released only during autolysis of bacteria mediated by bacterial autolysin 
enzyme LytA (96) or during antibiotic-mediated bacterial lysis (97). There are 
studies that have reported that pneumolysin could be possibly exported as it can 
be found in bacterial cell wall (98) as well as passively secreted into culture 
supernatant during active bacterial growth of certain strains (99).  
Role of pneumococcal pneumolysin in virulence  
 The biological effect of pneumolysin on host cells is known to be 
dependent on the concentration of the toxin as well as on the type of cells in vitro. 
Pneumolysin when present in higher concentration that is sufficient enough to 
oligomerize and form membrane pores, can result in necrosis (with membrane 
disruption) in alveolar epithelium (100) and neuronal cells (77, 101). Pneumolysin 
has been shown to induce apoptosis in most of the host cells encountered by 
bacteria during pathogenesis. At sufficiently higher concentration (> 500 ng/ml), 
in vitro pneumolysin causes effective apoptosis in alveolar epithelial cells (100), 
endothelial cells (102), brain endothelial cells (the blood-brain barrier) (103) and 
brain cells (neurons and microglia) (77, 101). Pneumolysin-induced apoptosis 
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seems to operate via different pathways in different cell types. In rat neuronal 
cells, pneumolysin is shown to increase calcium influx in the cytoplasm (77, 101, 
104), localize to mitochondrial membrane and induce the release of apoptosis-
inducing factor (AIF) from mitochondria that causes large-scale genomic DNA 
fragmentation resulting in apoptosis (77, 101). The pneumolysin-induced 
apoptotic pathway in neuronal cells has been shown to involve p38 mitogen 
activated protein kinase (MAPK) pathway (104) and occur independent of 
caspase-8 (the extrinsic apoptotic pathway) (101). In endothelial cells, 
pneumolysin induces apoptosis via p38 MAPK pathway with activation of 
caspase-8 (102). Pneumolysin is also shown to cause apoptosis in immune cells 
like macrophages by caspase-3 dependent pathways (105, 106). Interestingly, 
pneumolysin-induced apoptosis in macrophages could occur without the need of 
the toxin (domain 4) to bind to host membrane and instead apoptosis is 
associated with lysosomal membrane permeabilization and most likely occurs via 
mitochondrial pathway (105).  
In the above-cited observations of apoptosis/necrosis, pneumolysin is 
used in higher concentration (> 500 ng/ml) and, depending on cell-type, possibly 
lyses the cells by oligomerizing to form membrane pores. In contrast, at sub-lytic 
concentrations, pneumolysin is known to modulate various cellular functions. 
Such sub-lytic concentrations range from 100 ng/ml to 1 ng/ml in vitro, depending 
on cell type (107). In neutrophils, sub-lytic concentrations of pneumolysin (< 100 
ng/ml) could potentially form non-lytic membrane pores that increase intracellular 
calcium influx and consequently increase production of pro-inflammatory factors 
like prostaglandin E2, leukotriene B4 (108) and phosholipase A2, increase 
degranulation by releasing elastase and increase intracellular superoxide 
production by activation of NADPH oxidase (109, 110). The immuno-modulatory 
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function of pneumolysin is also observed in macrophages, where it has been 
shown to upregulate inflammatory cytokines and chemokines like tumor necrosis 
factor (TNF-) and interleukin (IL-1) (111), IL-8 and MIP-1 (112), as well as 
induce production of nitric oxide (NO) via inducible NO synthase (iNOS) pathway 
(113). Pneumolysin can also upregulate expression of intercellular adhesion 
molecules (ICAM-1) in macrophages (at > 200 ng/ml pneumolysin) that can 
enhance monocyte recruitment to infection sites (114). Pneumolysin is also 
shown to be required for efficient migration of CD4+ T cells (115) and domain 4 
of the toxin is shown to induce activation and proliferation of CD4+ T cells as well 
(116). Taken together, it can be said that pneumolysin is not only an offensive 
virulence factor of S. pneumoniae but also a potent bacterial factor that can 
interfere with host-inflammatory response. The role of inflammation in 
pneumococcal disease pathogenesis has been discussed in 1.422. 
Pneumolysin is also widely known for its ability to bind complement 
factors. Both classical and alternative complement pathways have been shown to 
play important roles in host defense against pneumococcal infection (117, 118), 
as complement mediates opsonophagocytosis, direct bacterial lysis or 
chemotaxis. While pneumolysin residues 384 and 385 (in domain 4) are known 
to be critical for complement activation, the structural homology of domain 4 with 
Fc region of immunoglobulins could facilitate complement binding and activation 
(119). Pneumolysin is known to directly activate complement factor C3 (120, 121), 
and hence the bacteria could use pneumolysin as a “decoy” to deplete the 
complement factors in the infected areas (122), thereby interfering with the host 
complement system and allowing the bacteria to persist. Indeed, pneumolysin 
has been directly shown to be essential to reduce C3 (opsonin) deposition in 
bacteria and allow pneumococcal septicemia in mice model (123). Hence, 
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pneumolysin functions in a multiple ways to increase the virulence of 
pneumococci during pathogenesis. 
In addition to complement activation, the cytotoxicity and pro-
inflammatory effect of pneumolysin (as discussed above) definitely contribute to 
pneumococcal carriage and virulence in vivo. Like pneumococcal H2O2 (84), 
pneumolysin’s ability to reduce ciliary beat frequency of human respiratory 
mucosa and loosen the tight junction between epithelial cells (124), could help in 
bacterial colonization of upper respiratory tract and invasion into lower respiratory 
tracts to cause pneumonia. Recently, a novel role of pneumolysin in helping to 
aggregate pneumococci to form biofilms, also indicates additional function of 
pneumolysin in nasopharyngeal colonization and carriage (125). In animal model 
of pneumonia infection, pneumolysin is associated with increased apoptosis of 
immune cells and broncho-epithelium (107). Purified pneumolysin alone is known 
to be as lethal as live bacteria in an animal model of lung injury (126), and 
causes severe pulmonary injury, including vascular leakage and edema, as the 
toxin is damaging to lung vascular barrier (127).  
In vivo pneumolysin production has been shown to be required for 
efficient bacterial multiplication in lungs and for sustaining bacterial invasion in 
the blood and CSF (128, 129). Indeed, the mRNA transcript levels of 
pneumolysin are found to be similar in all of the major pneumococcal niches 
(nose, lungs, blood), indicating that pneumolysin production could be constantly 
required during progression of pneumonia(83). It is also important to note that 
pneumolysin is toxic to microvascular endothelium that forms blood-brain (CSF) 
barrier (103) and inhibits the ciliary motion of ependymal cells that forms barrier 
between CSF and neuronal tissues (130). These ability of pneumolysin could 
help the bacteria in blood to invade brain tissue and cause meningitis in host.  
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Taken together, pneumolysin can be considered as one of the key virulent 
factors of S. pneumoniae that could influence the overall disease outcome. 
 
1.4 Pneumococcal pathogenesis: Inflammation and pulmonary damage 
S. pneumoniae does not have any environmental reservoir and the 
human upper respiratory tract (URT) is the most suitable ecological niche for the 
bacteria (131). The translocation of pneumococci to the lower respiratory tract 
(LRT) is due to a series of complicated host-pathogen interactions in which the 
bacteria has overwhelmed the physical and immunological defense mechanisms 
of URT (132), eventually leading to rapid and aberrant inflammatory response in 
the lungs called pneumonia (133, 134). Most of the understanding of cellular and 
molecular events that lead to pneumonia has come from studying animal models.  
In the alveolar spaces, pneumococcal assault on the alveolar epithelium 
and interaction with alveolar macrophages results in production of early cytokines 
and chemokines (135) and, if the bacterial numbers are low enough to be cleared 
by alveolar macrophages. Further immune cell infiltration are not required (136). 
There could be leakage of RBCs into the alveolar spaces called red hepatization 
(137). If the pneumococci is virulent enough to persist (by virtue of their virulence 
factors), the alveolar macrophages could get overwhelmed by the pneumococcal 
population, resulting in further inflammatory response that is initiated by elevated 
production of cytokines and migration of neutrophils within 24 hours of invasion 
(131, 133). Pro-inflammatory cytokines like TNF-, IL-6 and IL-1 are detected in 
the lungs and bronchoalveolar lavage fluid of infected animals within few hours of 
bacterial invasion in the alveoli (133).  
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Role of neutrophils in lung inflammation and injury: 
While immune cells such as cytotoxic CD8+T cells (138) and natural killer 
(NK) cells (139) are known to contribute to immunopathology during pulmonary 
viral infection, the precise roles of these immune cells in pneumococcal 
pneumonia have not been studied in great detail. There are, however, some 
reports that suggest the protective roles of CD8 T cells and NK cells during 
bacterial pneumonia (140).  
In the pneumococcal pneumonia model, neutrophils are the major cellular 
infiltrates in the lungs after 12-24 hours (133, 134) and become the main 
phagocytic cells while macrophages (recruited later) (133) help to clear out 
apoptotic cells (including neutrophils) (141). Neutrophil recruitment to the infected 
lungs seems to a double-edged sword, since, on one hand, they are required to 
clear the pathogens and, on the other hand, their excess accumulation could 
induce inflammation-associated lung injury (142, 143). Indeed, depending on the 
virulence of the infecting pneumococci, the neutrophil-mediated inflammation 
could to be one of the key host factors in determining pneumococcal infection of 
lungs. In model, depletion of neutrophils during intranasal infection of serotype 4 
has been shown to allow the bacteria to grow and worsen the disease (144), 
while during serotype 8 infection neutrophil-depletion prolonged animal survival 
without affecting bacterial number (145). Protection from lethal dose of S. 
pneumoniae has been associated with reduced inflammation, reduced neutrophil 
numbers, and reduced transcript levels of inflammatory cytokines and 
chemokines such as TNF-α, MIP-2 and INF- (146). Similarly, animals recovering 
from non-lethal pneumococcal infection are known to have reduced numbers of 
bacteria in lungs and bronchoalveolar fluid that is associated with diminished 
neutrophil recruitment and mild levels of cytokines (IL-1, IL-6) and 
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chemoattractants (146, 147). In animal models of pneumonia, death has been 
associated with increased and persistent inflammatory cytokines and neutrophil 
infiltration in lungs even after 48 hours of infection (147). In line with these animal 
models, pneumonia patients admitted to hospital after 48 hours of developing 
symptoms are known to have persistent levels of inflammatory cytokines (mainly 
TNF-α) in blood and this also correlated with bacterial invasion in blood (148).  
Accumulation of neutrophils is also implicated as an instigating factor in 
the common outcome of pneumonia: acute lung injury (ALI) characterized by 
increased lung edema due to disruption of alveolar-blood barrier (143, 149, 150). 
Neutrophils mediate lung injury by 1) producing inflammatory cytokines (TNF-, 
IL-1); 2) releasing neutrophilic granules (151) including myeloperoxidase (that 
forms reactive radicals) (152); 3) matrix metalloproteinases (that modulates 
extracellular matrix and inflammation) (153); 4) secreting proteases like elastase 
(that disintegrate endothelium) and proteinase 3 (that destroys alveolar 
surfactant proteins) and 5) reactive oxygen (ROS) and nitrogen species (RNS) 
that cause non-specific damages to biomolecules (149).  
Role of pneumolysin in lung inflammation and injury 
The pneumococcal toxin pneumolysin has been shown to play a central 
role in the pathogenesis of pneumonia. As discussed in 1.3.3  Pneumolysin 
and its toxicity, pneumolysin is a potent inflammation-inducing factor by its 
interaction with neutrophils and macrophages. In line with its immune-modulatory 
function, pneumolysin has been shown to directly cause excess and prolonged 
infiltration of neutrophils (134) and increase pulmonary inflammation in animal 
model of pneumonia (107). The pro-inflammatory aspect of pneumolysin has 
been shown to cause severe lung damage when pneumolysin is administered to 
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mice, leading to acute lung injury (107, 126, 127). The direct toxic effect of 
pneumolysin has been shown to cause lung edema, increased permeability of 
alveolocapillary barrier and to cause acute pulmonary hypertension by direct 
interaction with endothelium cells (127). In line with these observations, 
antibodies that neutralize the membrane binding or the oligomerizing ability of 
pneumolysin have been shown to ameliorate lung injury and increase the survival 
rate in lethal model of S. pneumoniae (154). Overall, during pneumococcal 
pneumonia, pneumolysin directly contributes to the immunopathology mediated 
by the dysregulated inflammatory cells. 
 
1.5 Oxidative Stress during Pneumococci-induced Inflammation 
Oxidative stress generally develops because of over-production of radical 
forms of oxygen and nitrogen, such as superoxide radical (O2
-), hydroxyl radical 
(OH) and nitric oxide (NO), at levels that are not being quenched or neutralized 
by the antioxidant systems of the tissue (155). Endogenously, ROS such as 
superoxide radicals (O2
-) or their reactive by-products that are produced in cells 
during metabolism of oxygen (via electron transport chain) by mitochondria (156) 
or by action of cytochrome P450 (157), are eliminated by effective cellular 
antioxidants. The human lung antioxidant defense system is comprised of mainly 
epithelial lining fluid (on the surface of alveolar sacs) containing non-enzymatic 
small molecule antioxidants such as glutathione, ascorbic acid, albumin, mucins 
and cellular enzymes such as superoxide dismutase (SOD), catalase, glutathione 
peroxidases (GPxs), thioredoxin, glutaredoxin, and peroxiredoxins (158). Each of 
the enzymatic antioxidants acts specifically to neutralize the ROS (Figure 1.3). 
While ROS produced intracellularly plays some role in signal transduction during 
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redox homeostasis, excess exogenous oxidants and their collaborative reactions 
with the endogenous ones are mainly responsible for oxidative stress.  
 During infection, reactive radicals (O2
-, OH, NO) and their reactive by-
products such as peroxynitrite (ONOO- from NO and O2
-) and H2O2 are produced 
in excess during “respiratory burst” by the actively recruited neutrophils and 
macrophages at the sites of infection (149, 159). The main function of the 
respiratory burst is to attack and destroy the pathogenic bacteria either 
immediately in vicinity of the immune cells by unstable radicals such as O2
-, OH 
or by formation of membrane permeable oxidants such as H2O2, NO. Both 
neutrophils and macrophages that are recruited during pulmonary inflammation 
produce high amounts of superoxide radicals (O2
-) during respiratory burst by 
activated NADPH oxidase system present on the plasma membrane or in the 
phagolysosomal membrane (160). Superoxides can be further converted to 
stable H2O2 by the antioxidant superoxide dismutase (SOD) enzymes. 
Neutrophils specifically release myeloperoxidase (MPO) from their azurophilic 
granules during respiratory burst. MPO uses H2O2 to catalyze the production of 
reactive hypochlorus acid (HOCl) from Cl-. Similarly, MPO uses H2O2 to oxidize 
tyrosines to reactive tyrosyl radicals and nitrites to nitrogen dioxide (NO2
) 
radicals (152). Elastase, produced by neutrophils, has also been shown to induce 
conversion of xanthine dehydrogenase to xanthine oxidase in endothelial cells 
(161), and the latter efficiently catalyzes the conversion of hypoxanthine and 
xanthine to produce O2
- and uric acid (162). Peroxynitrite (HOONO) is also 
known to decompose to radicals OH and NO2
  that can easily oxidize the bio-
molecules (Figure 1.3Figure 1.3) (163, 164). 
In addition to the ROS and RNS produced during acute inflammatory 
response, the presence of pneumococcal cell wall and pneumolysin could further 
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activate the iNOS pathway in recruited macrophages resulting in production of 
RNS (113). Pneumolysin is also known to directly stimulate the production of 
intracellular O2
- in neutrophils by an influx of calcium ions that activates NAPDH 
oxidase (110). The presence of O2
- during stress can make the Fe-containing 
proteins to release free ferrous ions (Fe2+), which can react with H2O2 to produce 
highly unstable and reactive OH by the Fenton reaction (165). In this scenario, 
direct production of H2O2 by a persistent population of S. pneumoniae during 
successful pneumococcal infection could directly contribute to the pulmonary 
oxidative stress (Section 1.3.2    Hydrogen peroxide and its toxicity).  
In a mouse model of pneumonia, it has been shown that MPO 
concentration in lungs coincides with neutrophil infiltration and decreases only 
after 48 hours while levels of NO peaks up in lungs after 48 hours coinciding with 
late recruitment of macrophages (133). It is important to note that in a meningitis 
model, host cell-generated NO is known to synergize with pneumococci-
generated H2O2 to inflict more tissue damage, most likely by producing 
peroxynitrite (ONOO-) (166). During pneumococcal pneumonia, increased 
pulmonary oxidative stress has been demonstrated by decrease in ratio of 
reduced glutathione (GSH) to oxidized glutathione (GSSG) in lungs (167). Indeed, 
decrease in levels of antioxidants such asGSH, SOD and Gpx in blood of 
children with acute pneumonia (168) could be reflective of the increase in 





Figure 1.3 Reactive oxygen species (ROS: O2
-, OH, HOCl, H2O2) and reactive 
nitrogen species (RNS: NO, ONOO-, NO2
), produced mainly by neutrophils and 
macrophages, are responsible for oxidative stress that causes damage to host 
bio-molecules (DNA, lipid and proteins). During oxidative stress, most reactive 
oxidants are produced by various enzymatic reactions mediated by NADPH 
oxidase (NOX), myeloperoxidase (MPO), xanthine oxidase (XO) and inducible 
nitric oxide synthase (iNOS). The highly reactive OH are formed by various non-
enzymatic reactions shown by red line. ROS and RNS overwhelm the host anti-
oxidant mechanisms mediated by superoxide dismutase (SOD), catalase and 
glutathione peroxidase (GPx) to create oxidative stress. 
 
Role of Oxidative Stress in Lung Injury and Inflammation 
 While the host-derived oxidative stress has evolved to eliminate the 
invading pathogens more effectively, an overwhelming presence of pathogens 
could elicit excess oxidative stress response that is harmful even to the host bio-
molecules and overall cellular function. The major inflammatory and oxidant 
generating cell, the neutrophil, plays an important role in lung injury (discussed 
above in 1.4), and there is considerable evidence for the damaging effect of 
reactive oxidants in lung tissues. One striking example is that, in an animal model 
of pneumonia, NADPH-oxidase derived ROS has been shown to be redundant 
for pneumococci killing and instead is shown to cause greater lung injury, as 
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NADPH-oxidase defective animals mounted effective inflammatory response to 
kill pulmonary bacteria without significant injury (169). The collateral pulmonary 
damage during oxidative stress could arise due to the non-specificity (mainly of 
OH) and inter-conversion of the reactive oxygen and nitrogen species involved 
at the sites of infection (Figure 1.3). 
 Most bio-molecules, such as nucleic acids, lipids and proteins, are 
susceptible to damage by free radicals such asO2
- and OH (170). DNA can be 
attacked at the bases and phosphodiester backbones by reactive oxidants that 
could result in base modification or strand breaks (discussed in 1.6) (170). Such 
damage to genomic DNA can cause nuclear instability leading to cell cycle arrest 
or apoptosis (discussed in 1.7). The unsaturated fatty acids of phospholipids are 
also easily oxidized by free radicals to form peroxyl radicals that can cause lipid 
peroxidation, resulting in formation of toxic aldehyde products such as 
malondialdehyde (MDA), hydroxynonenal (HNE) and isoprostanes (171). While 
lipid peroxidation can affect the membrane permeability and integrity (172), the 
aldehyde by-products are also known to cause damage to DNA (171). Oxidized 
phospholipids have also been shown to inhibit phagocytic ability of alveolar 
macrophages (173). In proteins, the amino-acid side chains and even the peptide 
bond are also sensitive to O2
- and OH radicals (171). Although damage to 
protein molecules might not be lethal (171), reversible oxidation of certain 
residues such as the thiol group of cysteine could impact redox signal 
transduction. The reactive oxidants may affect the signaling pathways by 
activating transcription factors such as NF-kB (by enhanced phosphorylation of 
NF-kB inhibitors and escape of NF-kB to nucleus), AP-1 (thiol oxidation or 
disulfide linkages of the DNA binding subunit) and MAP kinases (oxidation of 
cysteine residues), ultimately leading to upregulation of proinflammatory 
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cytokines (174). During inflammation, neutrophil MPO can react with nitrites to 
form reactive nitrogen dioxide (NO2
) that causes lipid peroxidation and oxidizes 
tyrosine residues to nitrotyrosines (175). Importantly, HOCl produced by MPO 
has been shown to damage the extracellular matrix around endothelial cells and 
reduce cell adhesion, which could contribute to vascular permeability during 
oxidative stress (176). Given the broad spectrum of damage that can be inflicted 
by ROS and RNS, oxidative stress that is strongly associated with inflammation 
is a source of direct lung injury during pneumonia.  
ROS can activate various signaling pathways including the extracellular 
signal regulated MAP kinases such as c-Jun N-terminal kinase (JNK) and p38 
kinase, and PI-3K/Akt pathways that eventually lead to increased transcription of 
pro-inflammatory and pro-apoptotic genes (174). One such gene is 
cyclooxygenase-2 (COX-2) that plays an important role in metabolism of 
arachidonic acid into inflammatory factors such as prostaglandin E2 (PGE2) that 
can increase vascular permeability (177). Moreover, ROS activate phospholipase 
A2 to release arachidonic acids from membrane phospholipids (165). ROS-
mediated activation of transcription factors NF-B and AP-1 also leads to 
increased transcription of pro-inflammaotry cytokines such asTNF- and IL-4 
(165). The inflammatory cytokines such asTNF- and IL-1 can in turn stimulate 
production of intracellular ROS in non-phagocytic cells (178). Taken together, 
ROS generation during oxidative stress can amplify the inflammatory response 
making it more dysregulated and eventually exacerbating the tissue injury and 




Figure 1.4 Inflammatory responses generated during S. pneumoniae infection 
orchestrate pulmonary oxidative stress. Inflammatory cells produce excess ROS 
and RNS against the pneumococci, which are capable of producing H2O2 during 
their aerobic metabolism. In addition, bacterial virulence factors such as 
pneumolysin also induce production of oxidants from host cells. Together, these 
events initiate a pulmonary oxidative stress. Moreover, the pro-inflammatory 
factors such as cytokines (TNF, IL-1, IL-4 etc), cyclooxygenase 2 (COX2), 
phospholipase A2 and prostaglandin 2(PGE2) secreted by activated immune 
cells can in turn drive the process of oxidative stress. Figure is modified from the 
original one in Tuomanen, E.I. et. al., N Engl J Med, 1995. 332(19):p.1280-4. 
 
1.6 DNA Damage during Oxidative stress 
A major impact of RONS is to damage genomic DNA. Genomic DNA 
damage during oxidative stress is important as the integrity and stability of DNA 
determines the cellular fate. The ROS/RNS-mediated damage done to the bases 
and phosphodiester backbone of DNA can result in mutations, deletions, and 
insertions in genes. Such major alterations induced by ROS/RNS can lead to 
loss or inactivation of genes that could impact major cellular pathways and lead 
to cell death (179). DNA damage is also known to cause permanent cellular 
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senescence due to prolonged signaling responses to damage (180). Misrepair of 
ROS- and RNS-induced DNA base damage and breaks could also result in 
harmful genomic rearrangements and translocations that could result in cellular 
transformation (179).Hence, damage to genomic DNA during oxidative stress is 
crucial as it can lead to detrimental cellular outcomes.  
DNA damage due to ROS: 
 ROS include oxygen-derived reactive radicals such as O2
-, OH, 
peroxyl (RO2
), alkoxyl (RO) and non-radicals that can be converted to radicals 
such as HOCl, H2O2, ONOO
-, singlet oxygen (1O2) (179). Both O2
- and H2O2 are 
unable to interact with DNA directly and to cause either base modification or 
strand breaks (179). O2
- can be enzymatically converted by SOD to H2O2, which 
can then produce OH via Fenton reaction (63, 181). O2
- and H2O2 can also 
interact with each other in the presence of iron ions via the Haber-Weiss 
Reaction (181) to produce OH, which can easily and spontaneously react with 
DNA bases (182) and cause strand breaks (183). O2
- is also known to release 
Fe3+ from the iron-storing protein ferritin as well as Fe2+ from iron-sulfur clusters 
(184). Thus, OH is the most common ROS radical that can induce DNA damage. 
                (Toxicology 149 (2000);43–50) 
a. DNA Base Modifications: OH can be produced by various redox reactions of 




 and RO radicals (185). Due to the indiscriminant nature of OH 
radical, it can form a wide range of oxidized DNA bases (> 50 base 
alterations) or even baseless (apurine or apyrimidine) sites, if the damage is 
unstable (184-186) (Figure 1.5). For example, one of the most sensitive DNA 
bases to damage by OH is guanine, resulting in 8-hydroxyguanine (8-
oxoguanine), a commonly used marker of oxidative DNA damage. All of 
these oxidized bases can impair the functional essence of DNA by affecting 
the structure of the DNA strands, the hydrogen bonding in DNA, the fidelity of 
DNA polymerase that could affect DAN replication (187). There are various 
ways by which these lesions are repaired by the cell and they are discussed 
in 1.7.2.  
  
  
Figure 1.5 Some common DNA base modifications that are formed as a result of 
oxidative damage by OH radical. Adapted from Mutation Research 443 
(1999):37–52.  
 
b. DNA Strand Breaks: While ROS-mediated radical attack on the sugar-
phosphate backbone of DNA could result in direct breaks of covalent bonds, 
oxygen radical-induced disruption of the 2-deoxyribose sugar ring could also 
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lead to strand breaks (188). Hence, DNA strand breaks associated with 
oxygen radicals are more than simple hydrolytic breaks and can contain 3’ or 
5’ modification (like aldehydes) as well as fragments of sugar (glycolyates) 
residues at the site of breaks (Figure 1.6). The single strand breaks (SSBs or 
nicks) that occur in DNA either from direct attack of radicals or indirect 
conversion of damaged base during DNA synthesis (189), can result in 
double strand breaks (DSBs) when a replication fork encounters and 
collapses at the nick sites (Figure 1.7) (190). The accumulation of DSBs 
formed in such ways, if not repaired, could be cytotoxic. Non-radical ROS 
such as HOCl can react with the bases and form semi-stable or unstable 
chloramines that can disrupt the hydrogen bonds between bases and 
mediate strand breaks (191). HOCl can also cause base damage indirectly 
via secondary products derived from lipid peroxidation such as MDA (192). 
Besides the damage inflicted on DNA, HOCl and their chloramine derivatives 
are also known to act as inhibitor during repair of damaged DNA, especially 
of the nucleotide-excision repair pathway (193, 194), thereby aggravating the 




         
Figure 1.6 Effect of ROS-mediated damage on 5’ and 3’ termini of DNA after 
strand breaks. Modified groups such as aldehydes and glycolates are formed 
during strand breaks by ROS. These abnormal modifications need to be 
processed by enzymes during DNA repair to allow ligation of broken ends 




Figure 1.7 Formation of the cytotoxic DSBs as a result of direct oxidative attack 
or via process of replication from SSBs or base lesions. Replication stress due to 
replication fork stall at SSBs activates ATR-response pathway that attempts to 
inhibit further damage and repair the breaks. Replication fork collapse into DSBs 





DNA damage due to RNS: 
 RONS collectively defines nitrogen-based oxidants such as NO, ONOO-, 
NO2
 (179). While NO has no activity against DNA, ONOO- and NO2
 are known 
to nitrate and deaminate bases as well as cause strand breaks (195). 
Deamination can also result in various mutagenic process. For example, 
deamination of adenine to hypoxanthine can result in transition mutation from AT 
to GC. In vitro, ONOO- is known to cause nitration of guanine to 8-nitroguanine 
and DNA strand breaks, as well as oxidative base modifications such as 8-
hydroxyguanine (196). ONOO- is known to decompose to NO2
 and OH, which 
causes DNA damage (163) . In addition, both ONOO- and NO are also shown to 
inhibit DNA repair protein that repairs the oxidized bases during base excision 
repair (197). 
 
1.7 DNA Damage and Cellular Responses  
Mammalian cells have evolved to preserve genomic stability and integrity 
in the face of constant exposure of genomic DNA to RONS. DNA damaging 
lesions or breaks activate cell cycle checkpoint pathways that allow the time 
required to counteract and repair the damage, or if the damage is irreparable, 
direct the cells to undergo permanent cell cycle arrest or death (mostly by 
apoptosis). These signaling pathways that co-ordinate the transcription and 
execution of DNA repair pathways, cell cycle progression and apoptotic 
pathways are collectively called the DNA damage response (DDR) (Figure 1.8) 
(198, 199). Although the sensor proteins that detect damage to DNA and relay 
signal transduction have not been accurately identified, certain DDR proteins 
such as PARP, Ku70/80, MRN (Mre11-Rad50-Nbs1) are considered to be 
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sensors of DSBs (199). In addition, checkpoint protein complexes like 9-1-1 
complex (Rad9-Rad1-Hus1) that detects replication stress as well as BRCA1-
associated genome surveillance complex (BASC) that contains BRAC1, ATM, 
MRN, mismatch repair proteins (MSH2/6 and MLH2), and the Bloom's helicase 
(BLM) have been proposed as potential sensor molecules (200). The initial signal 
transduction from the sensor molecules is mainly performed by members of 
phosphatidylinositol 3-kinase-like protein kinases (PI3KK) family: ATM, ATR 
(Ataxia telangiectasia and Rad3-related protein) and DNA-PK (DNA-Protein 
kinase) as well as PARP (Poly ADP ribose polymerase)-1 and PARP-2 of PARP 
family (199).  
        
Figure 1.8 DNA damage induces a coordinated network of DNA damage 
response that acts locally (in nucleus and mitochondria) and determines global 
cellular fate. The major signal transduction of DNA damage depends on kinase 
activity of ATM and ATR, which initiate and regulate the intricate DNA repair 
mechanisms (1.7.2) as well as decisions on cell cycle progression. In addition, 
p53 plays a central role in executing an appropriate response depending on the 
degree of DNA damage, whether it is transient cell arrest to repair DNA for 





ATM pathway and H2AX phosphorylation (H2AX) during response to DSBs 
ATM kinase is known to have hundreds of substrates and regulates 
crucial DNA damage response pathways following DNA DSBs. DSBs are one of 
the most toxic forms of DNA damage since they can cause loss of genetic 
information or chromosomal rearrangements (201-203). DSBs are either formed 
by direct oxidative damage on both strands, or during replication, where base 
lesions and SSBs can get converted to DSBs due to replication fork collapse 
(Figure 1.7) (190, 204). Under normal conditions, ATM exists in an inactive 
dimeric form and, following creation of DSBs, autophosphorylation of ATM at 
Ser1981 activates the kinase. However, in transgenic mouse model, the 
autophosphorylation site for activation has been found to be different than in 
human cells (205). DSBs sites are at first recognized and bound by MRN (Mre11-
Rad50-Nbs1) complex (206). Nbs1 is known to recruit ATM to the damaged 
region (207) and its interaction with Mre11 has been shown to be crucial for DNA 
damage response and survival in animal model (208). At the sites of DSBs, ATM 
phosphorylates the nearest histone variant H2AX at serine 139 (called H2AX) 
(209) to facilitate formation of robust DNA repair foci that amplifies the DDR as 
well as prevents any possible chromosomal translocations (210). ATM also 
regulates phosphorylation of important DNA repair proteins, including BRAC1 
and Rad51 (during homologous recombination repair), Nbs1 (of MRN complex) 
and Ku70/80 dimer (during non-homologous end-joining repair) (198, 211). 
Besides the repair proteins, major substrates that ATM kinase regulates are “the 
genome guardian” p53 and crucial checkpoint protein Chk2 that can drive the 
cellular decision between cell cycle arrest and apoptosis.  
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           Phosphorylation of H2AX (H2AX) is a key event in a robust DDR and is 
widely used as a marker of DSBs, as each DSB induces phosphorylation of 
~2000 H2AX molecules on either side of the break (visible as a H2AX foci) (212). 
Following ionizing radiation, H2AX foci formation is known to be distinct within 
~30 mins of DSB induction (212). Animal knock out of H2AX is known to be 
defective in DNA repair, has impaired recruitment of 53BP1 and Nsb1 and are 
sensitive to radiation-induced damage (213). Hence, H2AX and its 
phosphorylation is critical in amplification of DDR signals and recruitment of DNA 
repair proteins at the site of damage (214). H2AX initiates its signaling cascade 
by directly binding the scaffolding protein MDC1 to its phosphorylated region 
(215). H2AX/MDC1 complex then promotes accumulation and sustains 
interactions of DDR proteins at DSBs (215). H2AX/MDC1 complex amplifies the 
ATM signaling pathway by first interacting with Nbs1 protein that helps in further 
recruitment of MRN complex and ATM (216, 217). Phosphorylation of MDC1 by 
chromatin-bound ATM then recruits E3 ubiqutin ligases (RNF 8/RNF 168) that 
ubiqutinates histone H2A (at lysine 13/15) (218) as well as methyltransferase 
MMSET that methylates histone H4 (at lysine 20) (219), for recruitment of 
another repair protein 53BP1 (Figure 1.9). 53BP1 antagonizes the binding of 
BRCA1 (specific for homologous recombination repair) and prevents DNA strand 
resection and subsequently guides the repair pathway for DSBs towards non-
homologous end joining (NHEJ) repair (Section 1.7.2) (218).  
While DNA-PKs are involved in regulation of specific NHEJ repair 
pathway (Section 1.7.2), they are also able to phosphorylate H2AX during DDR 
to DSBs (220). In addition, there is increasing evidence that indicates the role of 
PARP protein during response to DSBs, potentially by promoting an alternative 
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non-homologous end joining repair pathway (199). PARP has been shown to be 
recruited to sites of DSBs where it helps in initial and rapid accumulation of MRN 
complex by interacting with Mre11 protein (221). Hence, besides ATM, DNA-PK 
also contributes to H2AX phosphorylation following DSBs formation while PARP 
can function to sustain the MRN complex required for stable H2AX foci. 
        
Figure 1.9 Role of phosphorylated H2AX (H2AX) during DNA damage response 
to DSBs. DSBs result in activation of ATM from its inactive dimer form. Activated 
ATM localizes to the DSB site and phosphorylates H2AX at ser139 (H2AX). 
DNA-PK also gives rise to H2AX foci, where MDC1 is one of the earliest protein 
to be recruited. H2AX/MDC1 then amplifies the ATM and MRN 
(Mre11/Rad50/Nbs1) signal and initiates recruitment of repair factors including 
chromatin modification enzymes such as methyltransferase. ubiquitin ligase and 
CtIP (C-terminal binding protein interacting protein)-MRN. Depending on the cell 
cycle phase, recruitment of either 53BP1 or BRCA1 to the site of DSBs plays a 
crucial role in determining the type of repair pathway. 53BP1, like DNA-PK, 
potentially restrict the resection of 5’ DNA strands, thereby inhibiting homologous 
recombination pathway, which indispensably requires formation of free 3’ single 
strands for repair. 
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ATR and PARP pathways during response to SSBs 
During increased replication stress (i.e. replication fork stall due to SSBs 
or oxidative lesions), there are higher chances of formation of DSBs unless the 
single strand DNA are coated with replication protein A (RPA) that activates and 
accumulates ATR kinase along with its partner protein ATRIP (Figure 1.7) (198, 
204). Activation of ATR eventually leads to activation of p53 and checkpoint 
protein Chk1. Both the ATR and ATM pathways are also able to cross-talk during 
DNA damage, thus forming an intricate DDR (198). At single stranded and stalled 
replication forks, ATR is also known to phosphorylate H2AX which help in 
stabilizing the accumulation of ATR in the repair foci (222, 223). PARP1 and 2 
are known to be recruited at SSBs where they add poly ADP-ribose (PAR) units 
to partner proteins that facilitate repair of strand breaks. PARP activity also helps 
in local structural reorganization by recruitment of chromatin  modifying 
complexes like polycomb proteins to facilitate repair activities (199). Thus, both 
ATR and PARP proteins play key role in cellular response to SSBs formation. 
 
1.7.1 Cell Cycle arrest 
The DNA damage response, at its core, has checkpoints that are required 
to integrate DNA repair with the cell cycle progression in order to maintain proper 
genomic stability. As mentioned above, the ATM/Chk2 pathway responds to 
DSBs while ATR/Chk1 responds to SSBs during replicative stress. Central to the 
control of cell cycle progression is the class of proteins that are activated by 
cyclins and are called cyclin-dependent kinases (CDK) (224). Mainly, Cyclin B-
CDK1 and Cyclin E-CDK2 are responsible for transition into G2/M and G1/S 
phase respectively. DDR eventually leads to activation or inhibition of CDKs 
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during cell cycle checkpoints that decides whether there should be any transient 
arrest at G1/S or G2/M checkpoints (225).  
CDKs are regulated by inhibitory phosphorylation of kinases such as 
Wee1 and by activating dephosphorylation by Cdc25 phosphatase (224). 
Through ATM and ATR pathways, both Chk1 and Chk2 are able to 
phosphorylate Cdc25a for degradation, which results in reduced CDK activity and 
hence the cells are arrested at G1 or G2 phase. This checkpoint does not require 
synthesis of new proteins and is very rapid. However, if the damage persists, a 
second wave of checkpoint signaling occurs and is mediated by p53 signaling 
pulses. p53 can be stabilized by phosphorylation from ATM, Chk1 and Chk2 (226, 
227). In the case of prolong DDR signal, activated levels of p53 can upregulate 
p21, which is known to inhibit CDKs including CDK1 and 2, thereby sustaining 
the cell arrest signals during damage (Figure 1.10) (228). 
 
Figure 1.10 Cell cycle check points during DNA damage response. DNA damage 
induces ATM and ATR activation that results in phosphorylation and activation of 
checkpoint proteins Chk2 and Chk1 respectively. Chk1/2 regulates the stability of 
CDC25 phosphatase that activates CDKs required for cell cycle progression. In 
addition, activation of p53-p21 pathway provides a sustained level of cell cycle 
regulation during DNA damage. p53 also upregulates various cell cycle protein 
such as GADD45, 14-3-3 that controls the levels of CDKs directly or indirectly. 
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In addition to the above-mentioned checkpoints during G2/M transition, 
other checkpoints are functioning as well. One of them is upregulation of Wee1 
due to Chk1/2-mediated inhibition of Wee1-inhibitor (224). This further reduces 
the activity of CDK1 and enforces the cell cycle arrest at G2/M transition in case 
of DNA damage at G2. In addition, phosphorylation of Cdc25 phosphatase by 
Chk1/2 creates binding sites for 14-3-3 protein that helps in nuclear exclusion 
and cytoplasmic sequestration of CdC25, thereby depriving activation of CDK1 
for G2/M transition. Activation of p53 is also known to induce the production of 
GADD45 that destabilizes Cyclin B-CDK1 complex and reinforces cell arrest at 
G2/M (225). 
               DDR during S-phase inhibits or delays the replication process via a less 
understood S-phase checkpoint mediated by either ATM/Chk2 in case of DSBs 
during DNA synthesis or by ATR/Chk1 in case of stalled replication fork, with 
more stringent cells arrest occuring at G2/M checkpoint (229). While DDR at 
G1/S checkpoint ensures that damaged DNA is not synthesized in the S-phase, 
DDR at G2/M checkpoint prevents damaged DNA from being inherited by 
daughter cells (225).  
 
1.7.2 DNA Repair 
Repair of damaged bases 
 DNA bases that are damaged by ROS/RNS (such as 8-oxoguanine) can 
be repaired by series of enzymatic reactions that are part of the base excision 
repair (BER) pathway. The damaged base is removed by a DNA glycosylase that 
cleaves the N-glycosidic bond linking base to the sugar-phosphate backbone 
leaving an apurine or apyrimidine (AP) site. The AP site is then processed either 
by AP endonuclease (APE) or by certain glycosylase that hydrolyse 
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phosphodiester bond generating SSBs. The SSBs arising during BER repair, as 
well as SSBs generated during oxidative DNA damage, are then repaired by Pol 
polymerase (211). To repair bulky base lesions such as pyrimidine dimers and 
intra-strand crosslinks, the whole nucleotide is removed as part of a longer 
oligonucleotide by inducing significant distortion in the DNA helix by nucleotide 
excision repair (NER) pathway. Additionally, the accidental mis-match between 
bases arising by either deamination/oxidation of bases or replication errors are 
recognized by mismatch repair proteins MSH2/6 and then excised and repaired 
(211).  
Repair of SSBs 
 SSBs arising from direct reaction with oxidative radicals or as 
intermediates in BER pathway can activate and bind PARP1 and 2 proteins (199). 
PARP can then add poly ADP ribose (PAR) moieties to a number of DNA repair 
proteins (p53, MSH6, Ku70, DNA-PKc and to itself) and thereby regulate their 
effector functions. While PAR-ylation of PARP itself can also enhance the 
interaction of the damaged site with BER pathway proteins including the 
polymerase Pol, PAR-ylation of histones can facilitate in modulating the 
chromatin structure during repair (211). Formation of PAR chains is one of the 
earliest event of DDR and can occur within min as well as can disassemble 
rapidly (199).  
Repair of DSBs 
 DDR by the ATM or ATR pathway activates DSB repair. DSBs are the 
most complicated form of DNA damage to repair. As described in Figure 1.7, 
accumulation of SSBs and base lesions could give rise to DSBs during 
replication fork collapse. There are two major pathways for DSB repair, namely 
45 
 
Homologous recombination (HR) and classical Non-homologous end-joining 
(NHEJ). There also exist other pathways called Alternative-NHEJ or 
Microhomology-mediated end-joining (MMEJ) and Single strand annealing (SSA) 
(199).  
Homologous recombination is initiated after DSBs are detected and 
processed by MRN complex that has nuclease and helicase activity (211). ATM 
is recruited to MRN-associated DSBs where it phosphorylates its substrates and 
promotes 5’ resection by MRN-CtIP complex (199, 218). Availability of 3’ single 
strands by extensive 5’ resection is likely to commit the initial repair factors to HR 
pathway (230). The 3’ DNA strands after resection are then bound by Rad52, 
which competes with Ku70/80 complex (of NHEJ) to direct the repair pathway 
towards HR rather than NHEJ (231). BRAC2 and Rad 52 then load the single 
strand DNA with Rad51, and Rad51-coated strand invades into its homologous 
sequence, followed by DNA synthesis and resolution of the strand exchange 
(232). Due to the need of a homologous template for repair, HR occurs 
predominantly during S-phase or G2 phase of cell cycle (211).  
 Unlike HR and other pathways, NHEJ does not require resection of DNA 
breaks to single strands (199) and is more error-prone (since it doesn’t use 
sequence homology) and common than HR in mammalian cells (211). NHEJ 
pathway is activated by recognition and binding of DSBs with the heterodimer 
complex of Ku70-Ku80 that protects breaks from any further nuclease digestion. 
In mouse models, knock out of either Ku70 or Ku80 is known to cause arrests in 
T and B cell development, indicating the crucial importance of NHEJ in animal 
immune system (225). Ku80 of the Ku-complex recruits the important catalytic 
subunit DNA-PKc to form the complete holoenzyme DNA-PK (207). The synapsis 
of DNA-PKcs bound to opposite termini triggers auto-phosphorylation of DNA-
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PKc. Such auto-phosphorylation at specific sites regulates the access of DNA 
ends to processing enzymes and strand resection and potentially regulates either 
the promotion of NHEJ or inhibition of HR (199). Presence of 53BP1 also helps in 
preventing the resection of strands and thereby favoring NHEJ instead of HR 
(218) (Figure 1.9). The non-ligatable 5’ and 3’ termini at DSBs could be 
processed by DNA-PKs-activated enzyme Artemis, MRN complex, 
Polynucleotide Kinase/Phosphatase (PNKP) and exonuclease (230). The ligation 
complex of XRCC4-DNA ligase IV is then recruited to the DSB site for further 
ligation of the processed ends (Figure 1.11) (199, 211). Ligase IV is very 
important to complete the repair process and its deletion is known to cause 
embryonic lethality, as shown in animal models (233). 
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Figure 1.11 Non-homologous end joining repair pathway for DSBs. The free 
ends at break site is bound by Ku70-Ku80 hetero-dimer (Ku complex) and DNA-
PKc is recruited. The kinase activity of DNA-PK facilitates the processing of 
broken DNA ends by enzymes like Artemis, PKNP etc. The processed blunt ends, 




Apoptosis is one of the important outcomes of DDR and is required to get 
rid of cells that are damaged beyond repair. The most cytotoxic form of DNA 
damage is occurrence of DSBs. Even genotoxic chemicals such as methylating 
and crosslinking agents that induces single base lesions in DNA strands by 
modifying the bases as well as crosslinking the bases, eventually could lead to 
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accumulation of DSBs (Figure 1.7) that direct the cell towards apoptotic death 
(204). 
In the case of transient cell cycle arrest, p53 also plays a major role in 
linking the DNA damage response to apoptotic pathways. During severe DNA 
damage, p53 activated by ATM or ATR pathway, upregulates a range of pro-
apoptotic genes such as Bax, Puma, Noxa as well as directly interferes with the 
anti-apoptotic activity of Bcl2 (234). The pro-apoptotic factors (Bax, Puma, Noxa) 
further compromises the mitochondrial membrane, causing the release of 
cytochrome C, formation of apoptosome and subsequent activation of the 
caspase cascade that eventually leads to apoptosis (204). There is also 
possibility of p53-indpendent apoptotic pathways during DNA damage where 
activated caspase 2 mediates mitochondrial-directed apoptosis (235). Thus, 
during DNA damage-induced apoptosis the intrinsic mitochondrial death pathway 
is central to the execution of apoptosis. 
One important process during the choice between cell cycle arrest and 
apoptosis is the fine-tuning of p53 activation depending upon the severity of DNA 
damage. During low levels of DNA damage, if the repair process is not 
completed levels of p53 remain active in short pulses, directing the cell cycle 
arrest and promoting DNA repair (236, 237). However, during high levels of DNA 
damage, p53 is maintained at higher levels for longer periods and mostly 
localized to cytoplasm until cell apoptosis (236-238). Thus, p53 seems to play a 
crucial bimodal role in determining the cellular fate: survival or death, during DNA 




1.8 DNA Damage during Disease 
Genomic instability and defects in most of the major DNA repair pathways 
are associated with increased cancer risk (239). Most carcinogens, such as 
radiation and alkylating agents [for example, derivatives of polycyclic aromatic 
hydrocarbons in tobacco smoke (240)] are also genotoxic mutagens that can 
result in excessive mutant proliferation developing into tumors. DNA damage 
induced by exposure to a carcinogen increases the frequency of error-prone 
DNA repair and if these errors occur in proto-oncogenes or tumor suppressor 
genes, they can promote tumorigenesis (241). Indeed, chromosomal aberrations 
and genomic instability due to DNA damage is common in lung cancer (242, 243), 
where additional genetic impairment of the DNA repair capacity and cell cycle 
checkpoints further promote cancer growth (201). Interestingly, treatment of 
cancer also commonly involves approaches such as radiation therapy that 
induces DNA damage in tumor cells to destroy them. Hence, DNA damage is not 
only the cause of most cancers but is also used as a mechanism to treat them 
(239). 
DNA damage in pulmonary disorders has been widely studied during 
chronic obstructive pulmonary disease (COPD) in human patients, a condition 
mainly caused by cigarette smoking. Cigarette smoke has been shown to cause 
in vitro DNA base oxidation and deamination as well as DNA strand breaks (244). 
Patients with COPD is known to have significant increase in ATM activation and 
H2AX formation in their lung tissues, a classic marker of DNA damage response 
to strand breaks (Figure 1.7) (245, 246) as well as increase in histone 
modifications associated with DNA damage response (247). Peripheral blood 
cells of patients with COPD have also been shown to have DNA damage and 
H2AX in significant amount (248, 249). Oxidative stress induced by severe 
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inflammation has been suspected as the causal factor of DNA damage that 
contributes to pathogenesis of COPD (245, 246).  
In case of host-pathogen interactions during infectious disease conditions, 
investigation on the host DNA damage and its impact on pathogenesis have 
been greatly under-studied. Bacteria such as Pseudomonas aeruginosa (250), 
Klebsiella pneumoniae (251), Mycoplasma pneumoniae (252), Helicbacter pylori 
and Chlamydia trachomatis (253) have been shown to induce DNA damage and 
phosphorylation of H2AX mostly during in vitro studies via various bacteria-
specific mechanisms. Some viruses including Cytomegalo virus (CMV), Adeno-
associated virus (AAV) (254) and Influenza virus (255) are also known to elicit 
DNA damage response in host cells. In addition, certain pathogens like 
Chlamydia and Hepatitis C virus (HCV) have been shown to inhibit effective DNA 
repair responses in host cells during infection (253, 256, 257). Despite the 
increasing body of evidence that has underscored genomic DNA damage as a 
potential host susceptibility factor that is compromised during pathogenesis, very 
few studies have attempted to explore the effect of infection on host genomic 
DNA using animal models. S. pneumoniae is one of the most common infectious 
pathogen causing important diseases worldwide. Given the global pneumococcal 
disease burden, investigation of the host genome stability during S. pneumoniae 
infection could provide additional insights into the fundamental understanding of 






1.9 Aims of the Thesis 
It is well established that pulmonary inflammatory responses during 
pneumococcal infection determine the disease progression, as observed in 
animal models of pneumonia. The dysregulated inflammatory response is 
associated with bacterial invasion in the lungs as well as the ability of the 
bacteria to produce their major virulence factors: H2O2 and pneumolysin. In 
addition, the bacterial persistence to generate excess inflammatory responses is 
highly-dependent on bacterial capsule production. Host-inflammatory responses 
to bacteria and their virulence factors give rise to a very potent oxidative stress 
against the bacterial invasion. Evidence suggests that the collateral damage 
caused by oxidative stress could be the key factor driving pulmonary injury and 
disease pathogenesis. We are interested in the integrity of host genomic DNA 
during pneumococcal pneumonia, as DNA damage is one of the major side effect 
during inflammation-induced oxidative stress. Given the ability of pneumococcal 
virulence factors to modulate host cellular responses and eventual cellular fate, 
we hypothesized that during pneumococcal pneumonia S. pneumonia can 
directly or indirectly contribute to oxidative stress and cause pulmonary DNA 
damage.  
 This thesis is divided into three parts, each based on the types of 
virulence factors that aid in genotoxicity of the bacteria. In the first set of studies, 
we tested our working hypothesis that S. pneumoniae is genotoxic in nature as 
well as explore the contribution of pneumococcal H2O2 in pulmonary genotoxicity 
and virulence in vitro and in vivo. Importantly, we attempted to understand the 
crucial role of DNA repair in host cells during pneumococcal infection. In second 
part, we set out to understand the role of serotype-dependent virulence in 
pulmonary genotoxicity. Finally, in the third part, we aim to explore the ability of 
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pneumococcal toxin pneumolysin to induce a host DNA damage response that 
could affect cellular decision. Overall, these studies increase our present 


















2. Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals and Reagents 
Table 2.1 Commercial sources of media and reagents 






F-12K medium (Kaighn’s modification) 
Trypsin EDTA 
E. coli One shot BL21 (DE3) 
ACK Lysis buffer 
Vivantis Phosphate buffered saline (PBS) 10x 
Hyclone Fetal bovine serum (FBS) 
Sigma Brain Heart Infusion (BHI) broth #53286 
Tryptic Soy Agar 
Oxoid Sheep blood defibrinated #SR0051B 
Biomed 
Diagnostics 
Trypticase™ Soy Agar (TSA) with 5% 
Sheep Blood (TSA II™) 
Immunofluoresence DAKO Target retrieval solution 10x concentrate 
(S1699) 
Invitrogen ProLong Gold Antifade Mountant with 
4',6-Diamidino-2-Phenylindole (DAPI) 
DAPI (powder form) 
Antibodies See Table 2.3 
Chemicals Sigma Catalase #C9322 





Propidium Iodide  
10% Neutral buffered formalin 
Lysozyme (10 mg/ml, -20C) 
Mutanolysin #M9901 (6000 U/ml, -20C) 
FITC-Dextran (2000KDa) 




KU-55933 (ATM Kinase Inhibitor), 
NU7441 (DNA-PK inhibitor) 
Anaspec CSP-1 peptide (#63779) 
Roche Protease inhibitor tablet 




Qiagen Ni-NTA agarose  
Plasmid Miniprep kit 
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Biochemical assays Biovision Hydrogen peroxide assay kit 
Roche In Situ Cell Death Detection (TUNEL) kit 
#11684795910 
Cytotoxicity Detection kit (LDH) 
#11644793001 
R&D systems Mouse TNF-alpha Quantikine kit 
Promega CellTitre Glo #G7570 
Western blotting Biorad Bradford assay 
DC protein estimation assay 
30% polyacrylamide 
20% Sodium dodecyl sulfate (SDS) 
1M Tris-HCl pH8 
1.5M Tris-HCl pH6.8 





Anlene Low fat milk 
Advansta WesternBright ECL HRP substrate  
GE 
lifesciences 
Amersham ECL Prime  
 
Table 2.2 Solutions and Buffers 
Solutions Formulation (reagents from Sigma Aldrich) 
2x Laemmli lysis buffer 100 mM Tris Cl pH 6.8, 50 mM Dithiothrietol , 4% 
SDS,  20% glycerol 
SDS-PAGE Running buffer 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3 
SDS-PAGE Transfer buffer 25 mM Tris, 192 mM glycine, 20% (v/v) ethanol, pH 
8.3 
Citric acid buffer 10mM Citric Acid, pH 6.0 
FITC labeling buffer 0.05 M Sodium Carbonate, 0.1 M Sodium Chloride 
Flow cytometer buffer PBS with 1% BSA 
Cell wall digestion buffer 10 mM Tris pH 7.5, 30% Sucrose, 1x protease 
inhibitor,  
300 U/ml Mutanolysin, 1 mg/ml lysozyme  
Sonication buffer  
(recombinant Protein 
isolation) 
100 mM Potassium Phosphate buffer pH 8, 300 




100 mM Potassium Phosphate buffer pH 8, 300 






2.1.2 Cell and Bacterial culture  
Human lung alveolar carcinoma (type II pneumocyte) cell line A549 was 
maintained in F-12K media (Gibco) with 10% fetal bovine serum at 37 C with 5% 
CO2. Mouse lung adenoma cell line LA-4 was also maintained in F-12K media 
(Gibco) with 10% fetal bovine serum at 37 C with 5% CO2. Pneumococci used in 
all the experiments were in log-phase (i.e. grown to 7-8 h) in BHI media (OD600 
of 0.3-0.35), while A549 cells were seeded onto 8-chamber slides or plates within 
36 h of passaging at 80% confluency. S. pneumoniae serotypes and strains used 
in this study were serotype 3 (Xen 10 A66.1), serotype 4 (TIGR4) and serotype 
19F (clinical isolate). Bacteria were routinely grown in brain heart infusion (BHI) 
broth, supplemented with 10% heat-inactivated horse serum at 37 C and plated 
on TSA plates. Competent E. coli DH5 and E. coli BL21 were grown in Luria 
Bertani (LB) broth and agar using appropriate antibiotic and were used to 
transform plasmids for cloning and expressing protein, respectively. 
 
2.1.3 List of antibodies for Western blot and Immunofluorescence 
Table 2.3 Sources and clones of antibodies used for Western and 
Immunofluorescence 




1 53BP1 (Santa Cruz)  H-300 
2 Gamma-H2AX (Millipore) JBW301  
3 Gamma-H2AX (Cell Signaling)  20E3 
4 CCSP (Santa Cruz)  T-18 
5 SPC (Santa Cruz)  M-20 
7 p53 (Santa Cruz) Bp53-12  
8 Ku86 (Santa Cruz) M-20  
9 Phospho 53BP1 S1778  
(Cell Signaling) 
 #2675 
10 PCNA (Santa Cruz) C-20  
11 PARP-1 (Abcam) Ab6079  





2.1.4 List of antibodies for Flow cytometer 
Table 2.4 Sources and clones of antibodies used for Flow cytometer 
 
 
2.2 Methods and Protocols 
2.2.1  Infection of A549 cells  
Stocks of S. pneumoniae (200 l log phase bacteria + 200 l 70% sterile 
glycerol) were thawed and grown for up to 8 h in 10 ml of BHI medium with 10% 
serum (in 15 ml falcon tubes). The log phase bacteria were then centrifuged at 
1,500 x g for 10 min, washed with PBS and re-suspended in F-12K media. Under 
these conditions, for higher MOIs (200-400), the suspension was always diluted 
10 times in F-12K media and incubated with A549 cells already seeded at 2 x 105 
cells/ml and adherent for at least 8 h in 8-well chamber slides (500 l) or in 12-
well plate (1 ml). For lower MOIs (30-50), the bacterial suspension in F-12K 
media was further diluted 10-times (i.e. total 100-times) and incubated similarly 
13 MDC1 (Abcam)  #ab1169 
14 -actin (Sigma)   
15 Caspase 6 (Cell Signaling) #9762  
16 Phospho KAP-1 S824 (Bethyl 
Labs) 
 #A300-767A 
17 Ref-1 (Santa Cruz) C-4  
18 Rad51 (Santa Cruz) H-92  
19 Donkey Anti-Mouse/Rabbit 
conjugated with AF488/546/647 
(Invitrogen) 
  
20 Donkey Anti-Mouse/Rabbit/Goat 
conjugated with horse radish 
peroxidase (Dako) 
  
S/N Target  Conjugate Conc. used Clones / Catalog Company 
1 F4/80 AF700 1 l / 100 l BM8 / #123130 Biolegend 
2 CD11b FITC 1 l / 100 l M1/70 / #557396 BD Pharmingen 
3 Gr-1 PE-Cy7 0.2 l / 100 l RB6-8C5 / #108416 Biolegend 
4 Anti-Annexin V PE-Cy7 4 l / 100 l #88-8103-74 eBioscience 
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with A549 cells. The bacterial incubation with A549 was up to 7 h, at 37 C. The 
bacterial suspension used in each infection experiment was plated out on to 
trypticase soy blood agar, incubated at 37 C and colonies counted the following 
day. 
 
2.2.2 Treatments of A549 cells  
Catalase (10 mg/ml in F-12K media) treatment was done at 1 mg/ml in F-
12K medium with serum for 7 h during bacterial infection. Bleomycin (1 U/ml in 
DMSO) was used at 0.1 U/ml (100 M) in serum-free F-12K medium for 7 h. 
KU55933 (2 mM in DMSO) was used at 20 M, pre-incubated for 2 h before S. 
pneumoniae infection. KU55933 in DMSO was also used at 40 M, co-incubated 
with recombinant pneumolysin.  
For testing the bacterial supernatant, log phase bacteria were diluted 10 
times in F-12K media in 12-well plate for 7 h, after which they were centrifuged. 
The supernatant was filtered through a 0.2 m filter and incubated with  A549 
cells.  
 
2.2.3 Assays on Bacteria 
Dextran exclusion assay:  Overnight bacterial culture (400 l) was sub-cultured in 
10 ml BHI broth with 10% serum. After 4 h of incubation, 500 l was spun down 
at 1,500 x g for 10 min, and re-suspended in 500 l sterile PBS. This suspension 
(10 l) was mixed with 2 l of 10 mg/ml FITC-dextran (3 mg dissolved in 300 l 




In vitro adhesion assay: Bacterial culture grown for 8 h (2 ml) was pelleted down, 
washed with PBS and incubated with 1ml of 1 mg/ml FITC in Sodium carbonate 
buffer for 1 h in 4 C. Bacteria was spun down and washed with 1ml PBS three 
times and resuspended in 1 ml F12-K media with serum. This FITC-labelled S. 
pneumoniae suspension was diluted 10 times for MOI of 200-400 and 100 times 
for MOI of 30-50, incubated with A549 for 1.5 h. The MOI was determined by 
plating the bacteria in blood agar and counting the colonies next day. A549 cells 
were then washed 4-times with media and then with PBS, fixed with 2.5% 
glutaraldehyde for 10 min at RT and mounted with SloFade. Microscopy was 
done immediately. 
Preparing bacterial lysate: Bacterial culture grown for 8 h (2 ml) was pelleted 
down, washed with PBS and incubated with 100 l of cell wall digestion buffer for 
3 h at 37 C. The protoplast was pelleted down at 3,300 x g for 10 min at 4 C, 
washed with F-12K media and resuspended in 1 ml of F-12K media. 100 l of 0.1 
mm silica beads was added to this suspension and the protoplasts were lysed 
using Tissuelyser II (Qiagen) at 30 beats/second for 10 min. After short spin, 800 
l lysate was pipetted out, centrifuged at 6,000 x g for 5 min at 4 C. The 
supernatant was filtered, made up to 1 ml with F-12K media and incubated 
appropriately with A549 cells. The supernatant was also plated out to confirm 
absence of viable colony. 
Q-PCR for spxB mRNA in bacterial cells: Bacterial pellets grown in F-12K media 
were resuspended in 1ml Purezol (Bio-rad), lyzed with 0.1 mm silica beads using 
Tissuelyser II (Qiagen) at 30 beats/second for 10 min and stored at -80C, until 
RNA extraction. Supernatant was taken out and added with 200 l chloroform per 
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ml of lysate and shaken vigorously for 15 seconds. The mix was then incubated 
at ambient temperature for 5 min (while mixing) and centrifuged at 12,000 x g for 
15 min at 4 C. The aqueous phase (~ 500 l) was transferred to another tube 
and added with 500 l ice-cold isopropanol, mixed and incubated at RT for 5 min. 
The mix was transferred to RNeasy (Qiagen) spin column and manufacturer’s 
protocol was followed to extract RNA. The RNA was eluted out in 40 l RNase-
free water. RNA amount was normalized to 300 ng per 14.5 l of water and 
added with 0.5 l of Random primers (Promega, 500 ng/l). The RNA was 
incubated at 70 C for 5min. Reverese transcriptase (RT) reaction was performed 
by adding 5 l of Promega’s Moloney Murine Leukemia Virus (M-MLV) RT 
reaction buffer, 1.25 l dNTPs (10 mM), 0.75 l of RNasin inhibitor, 1 l of M-
MLV RT and 2 l of water. The mixture was incubated at 37 C for 60 min, then 
diluted 3-times with water and stored at -20 C as cDNA.   
Quantitative PCR (Q-PCR) was carried out in 96-well plate using Bio-
rad’s SsoFast EvaGreen supermix in Bio-Rad CFX system. Supermix (10 l) was 
added with 2 l of each forward and reverse primers (table below) and 6 l of 
cDNA.  
Table 2.5 Primers used for Q-PCR of spxB and 16S genes of S. pneumoniae 
 
 
 Primers Sequence (5’3’) PCR (30 cycles) 
1 spxB_RT_F AATTCGGCGGCTCAATCG 98C: 30 sec 
95C: 30 sec X 40  
60C: 30 sec X 40 
95C: 1 min 
60C: 1 min 
60-95C: 5 sec 
2 spxB_RT_R AAGGATAGCAAGGAATGGAGTG 
   
3 16S_F AAGCAACGCGAAGAACCTTA 
4 16S_R GTCTCGCTAGAGTGCCCAAC 
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2.2.4 Creating spxB mutant bacteria 
spxB mutant bacteria were created by introducing kanamycin resistance 
gene in spxB gene of S. pneumoniae via plasmid transformation. First, spxB 
gene was amplified from genomic DNA of S. pneumoniae TIGR4 strain using 
spxB_EcoRI_F and spxB_SalI_R. The PCR product was then cloned into 
pGEMT easy vector using EcoRI and SalI as restriction digestion sites. Then, the 
kanamycin resistance gene (kanR) was amplified from pET30a vector using 
HindIII_Kan_F2 and HindIII_Kan_R primers. kanR gene was introduced into 
HindIII site of spxB sequence in pGEMT_spxB vector. The pGEMT_spxB_kanR 
plasmid was confirmed by sequencing. All positive clones were confirmed via 
colony PCR and restriction digestion. 
Table 2. 6 Primers and PCR cycle used for making spxB mutants  
Transformation of S. pneumoniae: TIGR4 strain was grown for 4 h in BHI media 
with serum and then diluted 10 times in fresh media that was pre-warmed to 30 
C (1 ml in an eppendorf tube). It was incubated for 15 min at 30 C and then 2 l 
of CSP-1 peptide (stock 200 g/ml) along with 5 l of 500 mM Calcium Chloride 
were added. It was further incubated for 15 min at 30 C. Finally, 1.5 g of 
pGEMT_spxB_kanR plasmid was added into the culture. The tube was incubated 
for 40 min at 30 C and then at 37 C for 90 min. 100 l of the culture was then 
spread plated in Tryptic soy agar with 5% sheep blood and 200 g/ml of 
 Primers Sequence (5’3’) PCR (30 cycles) 
1 spxB_EcoRI_F GCGC GAATTC GCTAAATTCGGCGGCTCAATCG 95C: 30 sec 
63C: 30 sec 
72C: 1 min 
2 spxB_SalI_R GCGC GTCGAC CAGCGTTTGTGAAGTCTACACC 
   
3 HindIII_Kan_F2 GCGC AAGCTT GGATCC CTCGAG 
ATGAGCCATATTCAACGG 
95C: 30 sec 
45C: 30 sec 
72C: 50 sec 4 HindIII_Kan_R 
GCGC AAGCTT TTAGAAAAACTCATCGAGCA 
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kanamycin. Following day colonies were picked and grown in BHI media with 
serum and 200 g/ml of kanamycin to make glycerol stocks. 
2.2.5 Recombinant pneumolysin -production and purification 
Recombinant pneumolysin expression: pET101 vector containing pneumolysin 
sequence with c-terminal His-tag was a gift from Prof. Larry S. McDaniel 
(University of Mississippi Medical Center). The plasmid was transformed into 
competent E. coli One shot BL21 (DE3) (Invitrogen) by heat-shock method. 
Transformed colonies were selected using ampicillin in LB plates. Such colonies 
were made into glycerol stock. For recombinant protein expression, stocks were 
thawed and grown in LB broth with ampicillin overnight. The culture was sub-
cultured into fresh media and allowed to grow for 5 h (OD600=0.6) and then 
protein expression was induced using 1 mM IPTG for 5 h. Then the bacterial 
cells are pelleted down by centrifugation at 1,500 x g for 15 min, 4 C. The 
supernatant was discarded and the pellets are stored at -20 C until purification 
step.  
Protein purification: The frozen bacterial pellets are thawed and resuspended in 
Sonication buffer (10 ml of buffer per 250 ml pellets). Sonication was performed 
in Vibracell (Sonics) at 6 seconds pulse on and off cycle (25-30% amplitude) for 
30 min (for 40 ml lysis volume) keeping the suspension in ice. Sonicated 
suspension was then centrifuged at 19000 rpm for 15 min (Beckman Coulter 
Avanti-J26), 4 C in pre-cooled oakridge tubes. The supernatant was put to 
binding with washed Ni-NTA slurry and 25 mM imidazole at 4 C for 4 h in a 
rotator. Ni-NTA slurry was washed with 50 ml distilled water and equilibrated with 
sonication buffer in a purification column before putting to bind. After incubation 
62 
 
for 4 h, the slurry was put into the column and the flow through was collected. 
The column was washed with Wash buffer (20 ml for 40 ml lysate) and the wash 
out was collected. The recombinant pneumolysin bound to the column was then 
eluted using increasing concentration of imidazole -75, 100, 150, 200 mM in 10 
ml volume of 100 mM Phosphate buffer and 300 mM NaCl. The elutes were 
stored at 4 C and SDS-PAGE was run on each elution to check purity of protein. 
The elutions containing pure protein (single band in SDS-PAGE) was mixed 
together and dialysed overnight at 4 C in 10 kDa membrane against 50 mM Tris-
Cl pH 8 and 20% glycerol (200X the volume of protein solution being dialyzed). 
Following day, the protein solution was further concentrated >10X using Amicon 
ultra filter (3 kDa cutoff), 3ml in each tube centrifuged for 30 min at 3,300 x g, 4 
C. The protein concentration was then measured using Biorad protein assay 
and diluted appropriately with 50 mM Tris-Cl pH 8, 150 mM NaCl, 20% glycerol, 
aliquoted and stored in -20 C. 
 
2.2.6 Recombinant pneumolysin -hemolytic and neutralization assay 
Hemolysis assay: The number of RBC used in hemolytic and neutralization 
assay was determined by appropriately diluting RBS stock in PBS such that 200 
l of RBC suspension lysed with 200 l of ACK lysis buffer gives OD541 = 1. 
Generally, the number of RBC used was approx. 2 x 108 cells/ml. Recombinant 
pneumolysin (stock 0.5 mg/ml) was diluted to 100 ng/ml and then serially diluted 
twice to give 50, 25, 12.5 and 6.25 ng/ml. 200 l of diluted pneumolysin was then 
incubated with 200 l of RBC for 20 min at 37 C. Similarly, RBC was also 
incubated with lysis buffer. After incubation, tubes were spinned at 500 g for 5 
min and the supernatant was transferred to 96 well plate and absorbance was 
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read at 541 nm (Biotek Synergy 4). Hemolytic activity was expressed as 
percentage hemolysis = Abs. of pneumolysin sample/Abs. of lysed  RBC x 100. 
Anti-Pneumolysin antibody: Monoclonal antibody against recombinant 
pneumolysin (named as MG12) was created by Prof. Jimmy Kwang’s lab at 
Temasek Lifescience Laboratories (TLL), Singapore. The antibody was found to 
target linear epitope of Domain I of Pneumolysin. 
Neutralization assay: Neutralizing effect of anti-pneumolysin antibody MG12 was 
tested against 25 ng/ml pneumolysin. MG12 antibody was diluted to 100 g/ml 
and then serially diluted as 1:2 to get: 50 g/ml to 97 ng/ml. 100 l of such 
dilution was added to 100 l of 100 ng/ml recombinant pneumolysin and 
incubated at RT for 5 min. 200 l of RBC suspension was then added to this 
mixture and incubated at 37 C for 20 min. After which, the cells are spun down 
and absorbance of the supernatant was measured at OD541. Percentage 
hemolysis was calculated as stated above. 
 
2.2.7 ELISA to detect anti-Pneumolysin antibody 
ELISA was developed to detect anti-Pneumolysin antibody in serum 
samples of animals. Firstly, recombinant pneumolysin was coated wells (100 
l/well) of 96-well plate (Greiner Bio-one #65509) by diluting in 0.1 M sodium 
bicarbonate buffer and incubating overnight at 4 C. Following day, the buffer 
was discarded and the wells were blocked with 200 l of 1% BSA in PBS-0.05% 
Tween 20 (PBST) for 1 h at ambient temperature in shaker. The wells were 
washed once with PBST and incubated with either 200 l sera sample (diluted 50 
times in PBS) or positive control antibody (PLY-4 from Abcam). After incubation, 
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the wells were washed three times with PBST and incubated with anti-mouse 
(HRP conjugated) secondary antibody at 1:1000 dilution for 30 min. The wells 
were washed three times with PBST and 100 l of TMB substrate was added per 
well. After few min, the reaction was stopped using 2 M sulphuric acid and OD450 
was read (Biotek Synergy 4).  
2.2.8  Infection of mice and tissue collection 
Animal protocols were conducted in strict accordance with National 
Advisory Committee for laboratory Animal Research (NACLAR) Guidelines 
(Guidelines on the Care and Use of Animals for Scientific Purposes) in facilities 
licensed by the Agri-Food and Veterinary Authority of Singapore (AVA), the 
regulatory body of the Singapore Animals and Birds Act. The protocol was 
approved by the Institutional Animal Care and Use Committee (IACUC), National 
University of Singapore (Permit Number: IACUC 117/10, 050/11). 
7-8 weeks old Balb/c mice were anaesthetized with 75 mg/kg of ketamine 
and 1 mg/kg of medatomidine, and then infected with a lethal dose of S. 
pneumoniae by intratracheal instillation of 2 x 107 CFU in 50 l sterile PBS, while 
uninfected controls were administered with equal volume of sterile PBS. Animals 
were then injected with 1 mg/kg of atipamezole as reversal. Lungs were 
harvested every 24 h for up to 3 d post infection (dpi). Whole left lung was fixed 
in 10% neutral buffered formalin overnight and next day embedded in paraffin for 
histology, while right lungs were snap frozen in liquid nitrogen or lavaged with 0.8 
ml ice-cold PBS to collect bronchoalveolar lavage fluid (BALF). During dissection, 
blood was also collected via cardiac puncture in Biomed Diagnostic (BD) 
microtainer with lithium heparin. The tubes were kept in 4 C until the blood was 
plated out for bacterial count. 
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2.2.9 Lung homogenization, bacterial count and histology 
Frozen tissues were put in Gentle MACS M-tubes (Miltenyi Biotec) with 2 
ml sterile PBS and homogenized in Gentle MACS homogenizer using RNA_01 
program for 24 seconds. The tube was briefly spun down and the supernatant 
was divided for different assays and experiments. For preparing protein sample, 
800 l of supernatant was mixed with equal volume of 2X lysis buffer, heated at 
100 C for 10 min, centrifuged at 16,000 x g for 10 min and the supernatant was 
stored at -80 C until protein measurement. Supernatant was also appropriately 
diluted and plated out in blood agar for CFU count.  200 l of the supernatant 
was also mixed with glycerol to make stock in case bacterial count need to be 
repeated. Lungs embedded in paraffin were sectioned transversely into 5 m thin 
layers and stained with Haematoxylin and Eosin (H&E). Stained sections were 
scanned using Zeiss Mirax Midi scanner and images were viewed using 
Pannoramic viewer. 
 
2.2.10 Western blotting 
After appropriate incubation with bacteria or recombinant pneumolysin, 
A549 cells in 12 well plates were washed twice with 1ml cold PBS and incubated 
with 200 l of 1X lysis buffer (50 mM Tris Cl pH 6.8, 25 mM Dithiothrietol , 2% 
SDS, 10% glycerol) for 10 min. The lysate was collected and spun at 16,000 x g 
for 10 min at 4 C. The supernatant was then put in heat block at 100 C for 
10min. After cooling, the lysate was stored at -20 C. Bio-Rad DC protein assay 
was used to measure the protein concentration in the lysate and was run in SDS-
PAGE for 2 h at 100V. After transfer to nitrocellulose paper for 1.5 h at 100 V, 
primary antibodies were used to probe the blot at 4 C, overnight. After washing 
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with PBS 3x 10 min, blot was incubated with secondary antibody (Dako) 
conjugated with HRP and later developed by adding Advansta reagent. Following 
this procedure, western blot on protein samples from lung homogenate was 
performed as well. 
2.2.11 Biochemical measurements 
After required time of incubation of bacteria or recombinant pneumolysin 
with A549 cells, the media was pipetted out from the wells of chamber slides or 
plates, centrifuged and filtered through 0.2 m filter and stored at -80 C (up to 2-
3 d). Hydrogen peroxide assay kit (Biovision) was used to measure hydrogen 
peroxide in samples, which were diluted 10 times in assay buffer. Some filtered 
supernatant was also stored at 4 C overnight, diluted in distilled water, and 
measured free Lactate Dehydrogenase (LDH) within 48 h using Cytotoxicity 
assay kit (Roche). To measure TNF- in isolated BALF supernatant, Mouse 
TNF-alpha Quantikine ELISA Kit (R&D systems) was used and manufacturer’s 
protocol was followed. In experiments with pneumolysin treatment, ATP was also 
measured in adherent cells using Celltitre Glo assay (Promega). 
 
2.2.12 Immunofluorescence assay 
For In vitro samples: The adherent cells after treatment were washed twice with 
sterile PBS, fixed with formaldehyde for 10 min, washed twice with PBS and 
finally stored at 4 C with PBS until staining. The cells were then permeabilized 
with 0.2% TritonX-100 in PBS for 10 min, blocked with 3% bovine serum albumin 
(BSA) solution in PBS for 40 min and washed once with PBS. Primary antibodies 
were used in 1:100 dilution in PBS and incubated for 1 h covered with paraffin 
paper, at room temperature. Slides were washed with PBS 3x 1 min and further 
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incubated with secondary antibody labeled with either Alexa fluor dyes in PBS 
and DAPI for 1 h at ambient temperature in dark. For TUNEL staining, the dUTP 
labeling enzyme was incubated similarly for 1 h at 37 C. The slides were then 
washed with PBS 3x 1 min, and the TUNEL stained cells were mounted with 
cover slip in SlowFade DAPI and stored at 4 C until confocal microscopy was 
done.  
For lung sections: Paraffin-embedded lung sections were dewaxed in two 
changes of xylene (5 min each) and subsequently hydrated in decreasing 
concentration of 100%, 90%, 70%, 50 % ethanol (1 minute each) and distilled 
water. Depending on the antigen being probed, two antigen retrieval method was 
used: (a) Proteinase K method (for TUNEL staining) - Tissue sections are 
covered with working proteinase K solution (20 µg/ml in TE Buffer, pH 8.0) for 30 
min at 37 C  (b) Heating method (for H2AX, CC10) - Tissue sections are heated 
in pre-boiled Citrate buffer or DAKO antigen retrieval buffer for 25 min at low 
microwave heat (non-boiling temperature). Sections are then washed in PBS and 
blocked with 3% BSA, 0.3% Triton x-100 for at least 1 h at ambient temperature. 
Primary antibody diluted 100 times in 0.3% BSA, 0.3% Triton x-100  are then 
added (75 l per lung section) and incubated overnight at 4C. Following day, 
sections are washed with PBS and incubated with appropriate secondary 
antibody at 1:200 dilution (with DAPI) and incubated for 1 h at ambient 
temperature. The sections are then washed and mounted with SlowFade 
containing DAPI (Invitrogen). For TUNEL staining in lung sections, 
manufacturer’s protocol was followed. Briefly, the labeling enzyme was diluted 
10-times in buffer and each slide was incubated with 35-50 l of diluted enzyme 
(with DAPI) at 37 C for 1 h. The sections were washed and mounted on DAPI. 
68 
 
For co-staining of H2AX and TUNEL assay, the sections were first stained with 
TUNEL assay, mounted in PBS containing DAPI and scanned using Carl Zeiss 
slide scanner. After this, the slides were treated with heat retrieval technique to 
stain for H2AX and mount in SlowFade (Invitrogen) and scanned again. 
For BALF cells: The cytospin cup was washed with 200 l PBS at 500 x g for 5 
min, ambient temperature. Then, 100 l of fixed BALF cells (~50,000 cells), 
remaining after flow cytometer, was cytospun onto the slide. The cells were air-
dried overnight and then permeabilized with 0.1% Triton-X 100 (25 l per slide) 
for 10 min, ambient temperature. Blocking was done with 3% BSA (25 l) for 40 
min at RT. Then the cells were stained for H2AX (Cell Signaling, 15 l of 1:100 
dilution in PBS per slide) for 1 h at ambient temperature. After washing three 
times with PBS, secondary antibody was added with DAPI and incubated at RT 
for 1 h. Finally, the slides were washed three times and mounted in Slowfade 
DAPI and stored at 4 C until microscopy was done. 
 
2.2.13 Microscopy and image quantification 
All the stained slides were studied under confocal microscope, and every 
time 9 images (at 3x3 sites) or 15 images (at 5x3 sites) of each chamber were 
taken under 60X Olympus FV1000 (for in vitro bacterial experiments) or 20 
images of each lung section under 40X Carl Zeiss microscope (for pneumolsyin 
and in vivo experiment). For comparisions between different serotypes and 
treatment, all the images were taken with same microscope settings and on 
same day.  
Olympus FV10 2.0 viewer or Zeiss Zen was used for imaging of in vitro 
chamber slides, and to count the stained cells in dark room. At least 9-15 images 
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(>200 cells) were counted for each condition in a blinded manner. DAPI-stained 
cells were counted as those with (a) >5 distinct foci of H2AX or 53BP1 per 
nucleus regardless of co-localization, (b) nuclei with co-localized >5 foci of 
H2AX and 53BP1 were counted as “overlap”, and (c) pan-staining of H2AX. 
Cells that showed co-localization of TUNEL dye (FITC channel) and DAPI were 
counted as TUNEL positive cells. All images were taken blindly by focusing 
random fields in DAPI channel. DAPI stain for images of lung sections was 
machine-counted using IMARIS 7.6.5 software and Zeiss Zen software was used 
to examine and count H2AX positive cells. All counting was done in a blinded 
fashion. 
 
2.2.14 Flow cytometry  
Apoptosis in cell culture: Cells infected in 12-well plate, were washed twice with 
PBS, and incubated with warm trypsin (0.025%) 500 l/well. After 5 min, equal 
volume of F-12K media was added, pipette out and the cells spun down at 400 x 
g for 5min. The cells were washed once with PBS then with binding buffer and 
incubated with Annexin V- PeCy7 in 100 l binding  buffer (eBioscience) for 
20min. If propidium iodide staining was not necessary, cells were fixed with 4% 
PFA and kept at 4 C until analysis. For co-staining with propidium iodide, further 
100 l binding buffer was added to the tube, propidium iodide was then added to 
2 g/ml concentration and incubated for 20 min at RT. Binding buffer (500 l) 
was added, cells are spun down at 400 x g for 5 min and resuspended in 250 l 
binding buffer + 250 l 2% PFA. Cell are allowed to be fixed overnight at 4 C 
and added with 500 l PBS and washed. RNAse (3 l of stock 10 mg/ml) was 
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then added and incubated for 15 min at 37 C and later analyzed in flow 
cytometer (BD LSR II). 
Cell cycle analysis: Trypsinized cells were washed and resuspended in 500 l 1% 
PFA and incubated on ice for 1 h. Then the cells are washed with 1 ml of PBS 
and resuspended in 200 l of PBS and added with 1 ml of 70% ethanol dropwise. 
Cells are then kept overnight at 4 C , after which cells are washed with 1 ml PBS 
and resuspended in 500 l propidium iodide solution (60 g/ml PI, 100 g/ml 
RNAse in PBS) for 30 min at 37 C. The cells were then analyzed after washing 
off the stain in BD LSR II. 
Broncho-alveolar lavage (BAL) cells: BAL cells are collected by spinning down 
BALF collected on that day at 400 x g for 10 min at 4 C. Supernatant was stored 
at -80 C for assays. The cells were resuspended in 1 ml ACK lysis buffer for 5 
min at ambient temperature to lyse RBCs. BAL cells were then centrifuged, the 
cells are then resuspended in 200 l flow buffer and kept on ice while the cells 
were being counted using hemocytometer (diluted 2X with trypan blue). Cells are 
washed again and resuspended in 100 l flow buffer containing antibody (Table 4) 
for 30 min at ambient temperature. 1ml flow buffer was added and cells were 
washed to be fixed with 100 l 4% PFA. Cells were washed and resuspended in 






3. S. pneumoniae induces DNA Damage and Apoptosis via 
H2O2 production  
3.1.1 Introduction 
It is known that S. pneumoniae-induced cytotoxicity underlies pulmonary 
tissue injury during pneumonia and determines outcome of infection (258). 
Furthermore, toxicity to alveolar epithelium disintegrates pulmonary architecture 
as well as weakens the alveolar-blood barrier, facilitating systemic bacterial 
dissemination. Indeed, persistence of cytotoxicity has been associated with non-
resolving pneumonia in an animal model (258). While we have some 
understanding of bacterial virulence that contributes to S. pneumoniae-induced 
cytotoxicity (58, 84, 107, 259), the underlying molecular processes in mammalian 
host cells that mediate pathogenicity are not fully understood, which limits the 
development of novel mitigation strategies. 
There is significant data supporting a role for inflammation as a cause for 
cytotoxicity during infection (1.4). S. pneumoniae is known to induce a robust 
inflammatory response at the site of infection that culminates with infiltration and 
accumulation of inflammatory cells including neutrophils and macrophages (135, 
147, 260). To defend against infection, activated inflammatory cells produce high 
levels of genotoxic reactive oxygen and nitrogen species (ROS and RNS) 
including hydroxyl radical, superoxide, peroxide, and nitric oxide. ROS/RNS-
induced DNA lesions, such as base damage, single strand breaks (SSBs) and 
double strand breaks (DSBs), can be cytotoxic and thus damaging to host tissue 
function (Section 1.6) (261, 262). DSBs are one of the most toxic forms of DNA 
damage (202, 203). In response to DSBs, the Ataxia telangiectasia mutated 
(ATM) kinase pathway is activated leading to Ser 139 phosphorylation of histone 
72 
 
H2AX, forming H2AX (209). The presence of H2AX at DSBs recruits 
downstream DNA repair proteins, including 53BP1 and the Mre11/Rad50/Nbs1 
(MRN) complex, to the site of DSBs (216, 263). The major DSBs repair pathway 
in non-dividing cells is non-homologous end-joining (NHEJ), described in Figure 
1.11 (264). Early in NHEJ, Ku70/Ku80 heterodimer binds the damaged DNA 
ends. Ku80 plays a vital role in further recruitment and binding of the catalytic 
DNA-PKc subunit (207). The DNA strands are then processed by nuclease 
activity of MRN complex and the DNA-PK holoenzyme recruits additional 
enzymes that complete the repair process. Despite the presence of efficient 
DSBs repair, under conditions of excessive ROS and RNS, DNA damage can 
lead to cell death.    Although studies have been done to explore the damaging 
potential of RONS associated with the host response (265, 266) by observing the 
effect of anti-oxidants in animal models, these studies are so far restricted to 
pneumococcal meningitis and moreover do not address the molecular 
consequences of excess ROS like DNA damage in pathogenesis. The possibility 
that S. pneumoniae might directly induce pulmonary oxidative damage to DNA 
had not been explored. Studies focused on respiratory, as well as intestinal 
pathogens (252, 267), call attention to the importance of microbial-induced DNA 
damage as an important dimension of pathogenicity. For example, Pseudomonas 
aeruginosa has been shown to induce oxidative DNA damage in lung cells 
accompanied by significant tissue injury (268). These findings raise the possibility 
that S. pneumoniae may also induce DNA damage as a means for triggering host 
cell cytotoxicity. 
Although induction of cell death is key to pathogenicity, the underlying 
mechanisms by which S. pneumoniae induces apoptosis (100, 269, 270) and 
necrosis (100, 271) in host cells is not yet well-understood. Pneumococcal 
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virulence factors such as cell wall (peptidoglycan), hydrogen peroxide and 
pneumolysin, have been shown to contribute to apoptosis in these in vitro studies 
(100, 269-272). Depending on cell type it is suspected that mitochondria-
dependent caspase activation could be the common pathway mediating 
pneumococci-induced apoptosis (100, 269-273). However, the earliest cellular 
responses to S. pneumoniae that could trigger the execution of apoptosis has not 
been studied. While it is known that certain pneumococcal proteins such as 
pneumolysin elicit a potentially cytotoxic inflammatory response (1.3.3 
 Pneumolysin and its toxicity) (106, 107), in this study, we asked whether 
S. pneumoniae or its secreted factors could directly generate DNA damage 
responses that could contribute to cell death. One of such secreted factors could 
be pneumococcal hydrogen peroxide (H2O2), produced by action of pyruvate 
oxidase (encoded by spxB) in S. pneumoniae (1.3.2    Hydrogen peroxide and its 
toxicity). H2O2 secreted by S. pneumoniae could potentially contribute to 
pneumococci-induced oxidative stress and elicit DNA damage response during 
infection. 
 We used in vitro approaches to control H2O2 levels, as well as knock out 
of the spxB gene, to reveal the impact of pneumococcal H2O2 in cells and 
animals. Specifically, we show that S. pneumoniae indeed has the potential to 
induce significant levels of DNA damage via secretion of H2O2 in vitro, that the 
levels of induced DNA damage contributes significantly to S. pneumoniae-
induced toxicity, and that genotoxicity is associated with disease severity in an 
animal model. Furthermore, we found that the key NHEJ repair protein Ku80 
plays an important role in suppressing cytotoxicity. Together, the studies 
described here show that the ability of S. pneumoniae to produce H2O2 
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determines its genotoxicity as well as cytotoxicity and reveals host DNA damage 
and repair as novel factors in pneumococcal pathogenesis. 
 
3.2   Results 
3.2.1 S. pneumoniae induces DNA damage responses in alveolar 
epithelial cells 
To learn whether S. pneumoniae has the ability to induce DNA damage in 
host cells, using immunohistochemistry, we measured the frequency of H2AX 
foci, that form at sites of DSBs. We also quantified 53BP1 foci, which often co-
localizes with H2AX at sites of DSBs. As expected, for untreated human lung 
epithelial cells, there were very few H2AX or 53BP1 foci. In contrast, there were 
abundant foci in the nuclei of cells exposed to bleomycin, a known inducer of 
DSBs (Fig. 3.1A) (274). In addition to H2AX appearing as punctate foci in 
bleomycin-exposed cells, we also observed nuclei with nearly uniform staining for 
H2AX (Fig. 3.1B), which is consistent with studies showing that exposure to high 
levels of a DNA-damaging agent can result in nuclear-wide staining of H2AX 
(pan-H2AX) (275). To determine if S. pneumoniae can induce DNA DSBs, 
alveolar epithelial cells were co-cultured with three virulent serotypes of S. 
pneumoniae, namely, serotype 19F (clinical isolate), serotype 3 (Xen 10 strain) 
and serotype 4 (TIGR4) for 7 h. Strikingly, the presence of S. pneumoniae 
resulted in a significant increase in the frequency of DSBs, indicated by the 
presence of both H2AX and 53BP1 foci, most of which co-localized (Fig. 3.1A). 
Interestingly, serotype 4 showed the strongest ability to induce DSBs. 
Quantification of the percentage of cells harboring significant increase in DSBs 
[defined as having ≥ 5 foci of either H2AX or 53BP1 (276)], revealed that for 
75 
 
serotype 4, ~30% and ~15% of cells have increased H2AX and 53BP1 foci, 
respectively (Fig. 3.1B). In addition to cells having punctate foci, there were also 
a significant number of cells pan-stained for H2AX (~45% of the total H2AX 
positive cells, Fig. 3.1C), similar to what had been observed following exposure 
to bleomycin. Unlike cells showing clear repair foci, where H2AX and 53BP1 
mostly co-localize, 53BP1 did not stain in H2AX pan-stained cells, which is 
consistent with previous observations (253, 275, 277). For serotypes 19F and 3, 
there was a greater frequency of H2AX-positive cells compared to uninfected 
cells, although the ability of these serotypes to induce DSBs foci was clearly 
reduced compared to serotype 4 (Fig. 3.1B).  
To further explore the potential for S. pneumoniae to induce DNA damage, 
alveolar epithelial cells were exposed to a higher concentration of S. pneumoniae. 
Given that up to ~108 CFU/ml of S. pneumoniae have been reported to be 
present in infected human lungs (278), alveolar epithelial cells are likely to be 
exposed to high levels of S. pneumoniae during acute infections at focal lung 
regions. Therefore, we adjusted the MOI range between 200-400 for infection of 
all three serotypes, and found that all three induced DNA damage in more than 
20% of cells, with serotype 4 inducing DNA damage in over 50% of the cells (Fig. 
3.1E). In contrast to the experiments at MOI of 30-50, most cells that were 
positive for H2AX were pan-stained (Fig. 3.1D) suggesting that at higher MOI, 
elevated levels of DNA damage were induced by all three serotypes (275). As an 
alternative approach, we also analyzed the levels of H2AX phosphorylation by 
Western blot. Consistent with immunofluorescence analysis, we observed 
significantly increased H2AX protein levels in lysates of epithelial cells exposed 
to all three S. pneumoniae serotypes, with the H2AX protein level being 
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distinctly higher in cells exposed to serotype 4 (Fig. 3.1F). Furthermore, to 
explore the possibility that H2AX phosphorylation was induced as a response to 
DSBs, we targeted the canonical DNA damage response pathway centrally 
regulated by Ataxia telangiectasia mutated (ATM) kinase. When cells were pre-
treated with specific ATM kinase inhibitor (KU55933) and then exposed to 
serotype 4, the frequency of cells with H2AX staining (both punctate and pan) 
decreased significantly with respect to mock treated cells (Fig. 3.1G), indicating 
activation of ATM pathway in response to S. pneumoniae. Taken together, these 
results demonstrate that S. pneumoniae is able to induce DSBs in human 
alveolar epithelial cells, that DNA damage responses depend in part on ATM 





Figure 3.1 S. pneumoniae induces DNA damage in human alveolar (A549) cells 
in the form of double strand breaks (DSBs). (A) Representative images of 
alveolar epithelial cells showing DSBs (indicated by H2AX and 53BP1 foci) after 
exposure to S. pneumoniae serotypes 19F, 3 and 4 for 7 hours at MOI 40 (Low 
MOI). Bleomycin (100 M) serves as a positive control. H2AX and 53BP1 
positive cells (≥ 5 foci per nucleus) were quantified for (B) Bleomycin treatment 
and (C) S. pneumoniae treatment, and expressed as percentage positive. (D-F) 
Alveolar epithelial cells were exposed to serotypes 19F, 3 and 4 at MOI 200-400 
(High MOI). (D) Representative images of alveolar epithelial cells after exposure 
to S. pneumoniae at MOI 300. (E) H2AX and 53BP1 positive cells were 
quantified for each condition. (F) The alveolar epithelial cells were also lysed and 
analyzed by western for H2AX. (G) Alveolar epithelial cells were pretreated with 
ATM inhibitor KU55933 (20 M for 2 hours) and then exposed to serotype 4 
(Type 4) at MOI 40 for 7 hours. H2AX positive cells were quantified for each 
condition. For (B) and (D), each data point represents mean  SEM for four 
experiments. For (F) each data point represents mean  SEM for three 
experiments. For B, D and F, *p < 0.05, unpaired Student’s t-test. 
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3.2.2 S. pneumoniae-induced DNA damage levels correlate with levels of 
apoptosis  
Apoptosis induction in host cells is a key feature of S. pneumoniae 
pathogenicity (100, 258, 269-272). To elucidate the ability of the three serotypes 
of S. pneumoniae to induce apoptosis, we cultured them with alveolar epithelial 
cells for 7 hours, and analyzed cells for two key events of apoptosis, namely 
externalization of phospholipids (an early event detected by Annexin V) and late 
apoptotic fragmentation of DNA (detected by TUNEL). All three serotypes 
induced apoptosis, as quantified using Annexin V (Fig. 3.2A, C), with serotype 4 
inducing the highest proportion of Annexin V positive cells (~65% apoptotic cells). 
All three serotypes also caused an increase in the proportion of propidium iodide 
(PI) positive necrotic cells (25-35%) (Fig. 3.2B, C). Additionally, serotype 4 had 
the highest proportion of Annexin V and PI dual positive cells (late apoptotic or 
secondary necrotic, ~20%) (Fig. 3.2C). Consistent with these results, exposure to 
serotype 4 also resulted in a higher percentage of TUNEL positive cells 
compared to serotypes 19F and 3 (Fig. 3.2D and E). As significant levels of cell 
death were already observed at MOI 200-400; and hence MOI > 400 was not 
used. In addition, bacterial incubation for up to 24 hours resulted in similar 
frequency of apoptotic cells induced by all three serotypes (data not shown), 
indicating that prolonged in vitro exposure to pneumococci is toxic and 
independent of strains. The higher level of Annexin V staining compared to 
TUNEL could be due to the reason that most cells at 7 hours post-infection may 
still be in the early stage of apoptosis (279). For both Annexin V and TUNEL 
assays, serotype 4 was a much more potent inducer of apoptosis compared to 
serotypes 19F and 3. Importantly the levels of apoptosis correlate with the levels 
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of DNA damage, which is consistent with a model wherein S. pneumoniae-
induced DNA damage leads to apoptosis. 
 
Figure 3.2 S. pneumoniae induces apoptosis in alveolar epithelial cells and the 
extent of apoptosis relates to the genotoxicity of each serotype. Alveolar 
epithelial cells were exposed to S. pneumoniae at high MOI (200-400) for 7 hours, 
and then analyzed by anti-Annexin V, propidium iodide (PI) and TUNEL staining. 
(A) Representative histograms for cell count versus Annexin V staining. (B) 
Representative contour plots showing exposed cell populations analyzed by 
Annexin V and PI staining. (C) Annexin V, PI, and dual positive cells were 
quantified. (D-E) Exposed cells were fixed and analyzed by the TUNEL assay. (D) 
Representative images of cells at late apoptotic stage (green TUNEL positive). (E) 
TUNEL positive cells were quantified. For (C) and (E), results show mean  SEM 
for three independent experiments. *p < 0.05, unpaired Student’s t-test.  
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3.2.3 S. pneumoniae-induced DNA damage precedes apoptosis 
It is well established that DNA DSBs act as a signal to initiate apoptosis, 
which is then followed by execution of apoptosis, a process that can take many 
hours (202, 280). In the above experiments, DNA damage levels and apoptosis 
were evaluated at the same time (7 hours after co-incubation of alveolar 
epithelial cells and S. pneumoniae), making it unclear as to whether the observed 
DSBs could have signaled for apoptosis. To further explore the possibility that S. 
pneumoniae-induced DNA damage induces apoptosis, we analyzed the levels of 
both DNA damage and apoptosis at 1, 4 and 7 hours post-infection. Analysis 
shows that all three serotypes caused a significant increase in DNA damage as 
early as one hour post-infection (Fig. 3.3A). The damage levels were then 
sustained or increased at 4 and 7 hours post-infection depending on the serotype, 
with serotype 4 being the most damaging as indicated by Immunostaining and 
Western (Fig. 3.3A and B). Importantly, we observed that apoptosis was 
significantly increased only at 7 hours after infection (Fig. 3.3C), which is 
significantly later than the induction of DNA damage observed at 1 and 4 hours 
post infection. These results are consistent with delayed execution of apoptosis 






Figure 3.3 S. pneumoniae-induced DNA damage response occurs prior to 
apoptosis. (A) Alveolar epithelial cells exposed to S. pneumoniae at high MOI 
(200-400) were analyzed and quantified for H2AX at various times after 
exposure (1, 4 and 7 hours). (B) Lysate of alveolar epithelial cells similarly 
exposed to S. pneumoniae were probed with anti-H2AX antibodies at 1, 4 and 7 
hours post-infection. Bleomycin (100 M) and H2O2 (1 mM) serve as positive 
controls. Representative blot showing H2AX response from three independent 
experiments. (C) Exposed cells were also analyzed for Annexin V and quantified 
by flow cytometry at 1, 4 and 7 hours post-infection. For (A) and (B), each data 
point represents mean  SEM from three experiments. *p < 0.05, unpaired 
Student’s t-test. 
 
3.2.4 S. pneumoniae can induce DNA damage in a contact-independent 
fashion 
Recently, it was shown that the intestinal pathogen Helicobacter pylori 
requires direct contact with host cells to induce DSBs (267). In contrast, the 
related pathogenic species H. hepaticus is able to induce DNA damage in a 
contact-independent fashion by secreting a DNase-like factor that penetrates 
host cells (281). In order to understand the molecular basis for S. pneumoniae-
induced DSBs, we explored the possibility that DNA damage is induced by any 
pneumococcal secreted factor. As a first step, we assessed growth of all three 
serotypes in the culture media (F12-K) used for alveolar epithelial cells, to 
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determine its efficacy for culture of S. pneumoniae. All three serotypes showed 
similar doubling times in 7 hours (Fig. 3.4A). Then, to study the DNA-damaging 
potential of secreted factors, supernatant isolated from log-phase S. pneumoniae 
cultured in F12-K media was incubated with alveolar epithelial cells for 7 hours. 
For conditioned media of all three serotypes of S. pneumoniae, we observed 
induction of H2AX and 53BP1 foci (Fig. 3.4B), and quantification revealed a 
statistically significant increase in DNA damage foci (Fig. 3.4C). Interestingly, 
these results from conditioned media of serotype 4 are similar to the results for 
studies where mammalian cells were grown in the presence of live serotype 4 
(Fig. 3.1B and D). Overall, these data indicate that secreted pneumococcal 
factors lead to DNA damage in host cells without necessity of bacterial contact. 
           
Figure 3.4 S. pneumoniae induced DNA damage is independent from physical 
contact with host cells. (A) Analysis of culture density (CFU/ml) shows that all 
three strains of S. pneumoniae grow similarly well in F12-K culture media. (B-C) 
Alveolar cells were exposed to bacteria-free supernatant (Conditioned Media) 
from cultures of S. pneumoniae Type 4, Type 19F and Type 3 grown in F12-K 
media. Exposed cells were analyzed for H2AX and 53BP1. (B) Representative 
images of epithelial cells showing H2AX and 53BP1 foci. (C) Quantification of 
H2AX and 53BP1 positive cells. Results show mean  SEM from three 
experiments. *p < 0.05, unpaired Student’s t-test. 
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3.2.5 S. pneumoniae secretes H2O2 at genotoxic levels 
Previous studies show that some strains of S. pneumoniae produces 
H2O2 during aerobic metabolism. Given the known genotoxic potential of H2O2, 
we measured the levels of H2O2 in supernatant from all three serotypes of S. 
pneumoniae. We found that the ability to produce H2O2 by these serotypes 
during infection of human alveolar epithelial cells was variable among serotypes. 
For serotype 4, within 4 hours post-infection of host cells, the concentration of 
H2O2 in the bacteria-free supernatant was more than 100 M, and gradually the 
concentration increased up to 500 M when measured after three hours (Fig. 
3.5A). The difference in H2O2 production among serotypes was not a reflection of 
bacterial number (Fig. 3.4A). In S. pneumoniae, the pyruvate oxidase gene (spxB) 
produces H2O2 via pyruvate metabolism (61). To understand whether regulation 
of spxB gene contributes to the observed phenotypic difference in H2O2 
production among the three serotypes, we quantified spxB mRNA change in 
Type 3 and 19F relative to Type 4. We found that Type 19F has significantly less 
spxB mRNA transcripts compared to Type 4, where as there was no difference 
between Type 3 and 4 spxB mRNA levels. This result indicates that regulation of 
H2O2 production in pneumococci may be serotype-dependent. Overall, these 
data confirm that S. pneumoniae secretes H2O2 in a serotype-dependent manner, 
and further demonstrates that H2O2 reaches DNA damaging levels (upwards of 
500 M) under co-culture conditions.  
To determine if the concentration of H2O2 produced by S. pneumoniae is 
biologically significant on its own, we analyzed the DNA-damaging potential of 
H2O2 at a concentration similar to what was observed under co-culture conditions. 
When alveolar epithelial cells were exposed to pure 100 M H2O2 in media, we 
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observed that there is a significant induction of DNA damage in 15-20% of the 
exposed cells (Fig. 3.5C). Furthermore, H2O2 production for serotype 4 infection 
at 4 and 7 hours parallels our previous observation that H2AX is induced by 
serotype 4 (as observed in Figure 3.3), suggesting that H2O2 contributes to the 
induction of DNA damage. Interestingly, despite the relatively low level of H2O2 
detected in the supernatants of serotypes 19F and 3 (Fig. 3.5A), these serotypes 
were nevertheless able to induce DNA damage (Figure 3.3) (discussed in 
Discussion section). Taken together, these results suggest a significant role for 
H2O2 in pneumococci-induced DNA damage, while also calling attention to other 
microbial factors that can induce DNA damage. 
 
 









production was quantified in the bacteria-free culture supernatant at 1, 4 and 7 
hours post-infection with S. pneumoniae at high MOI (200-400). (B) Bacterial 
pellets at 7 hours post-infection were lysed and RNA was extracted for 
quantitative-PCR of spxB. CT values were normalized against those obtained for 
the 16S rRNA control. The quantitative difference for spxB mRNA with respect to 
Type 4 was determined using the 2-ΔΔCT method. Results show mean (as bar) of 





and analyzed for H2AX and 53BP1. Results show mean  SEM for 





3.2.6 H2O2  secreted by S. pneumoniae causes DNA damage and 
cytotoxicity 
To further explore the significance of H2O2 produced by S. pneumoniae, 
we exploited catalase, an enzyme that neutralizes H2O2 to water. We observed 
that catalase reduces the frequency of DNA damage positive cells by 50% or 
more in cultures of epithelial cells exposed to all three serotypes of S. 
pneumoniae (Fig. 3.6A). The impact of catalase on the percentage of cells that 
are positive for H2AX was greatest in serotype 4 infection, which is consistent 
with the observation that this serotype produces the highest H2O2 levels during 
infection. We then incubated the bacteria-free serotype 4 supernatant with 
epithelial cells in the presence and absence of catalase. Consistent with the co-
culture results, we found that bacteria-free serotype 4 supernatant also induced 
DNA damage that could be suppressed by catalase (Fig. 3.6B). Importantly, 
catalase treatment also suppressed the frequency of apoptotic cells during 
infection by all three S. pneumoniae serotypes as measured by Annexin V assay 
(Fig. 3.6C) and TUNEL for serotype 4 (Fig. 3.6D). Given the specificity of 
catalase, these results provide definitive evidence that H2O2 secreted by S. 
pneumoniae induces a significant level of DNA damage and apoptosis.  
In S. pneumoniae, the pyruvate oxidase gene (spxB) produces H2O2 via 
pyruvate metabolism (61). To further explore the role of H2O2 in S. pneumoniae-
induced DNA damage, we constructed a spxB mutant S. pneumoniae serotype 4 
by introducing kanamycin-resistance gene into the spxB gene of bacteria. The 
phenotypic change in spxB mutant bacteria was observed by deficiency in its 
ability to produce H2O2 (Fig. 3.6E). During infection of alveolar epithelial cells, we 
found that knocking out spxB eliminates the vast majority of the DNA damaging 
potential of serotype 4 (Fig. 3.6F). Given that the spxB mutant does not produce 
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any detectable H2O2 during infection, these results show a direct correlation 
between S. pneumoniae's genotoxicity and its ability to produce H2O2. Taken 
together, these data demonstrate that H2O2 secreted by S. pneumoniae causes a 
significant increase in the levels of DNA damage. 
 
Figure 3.6 DNA damage induced by S. pneumoniae is mediated by its H2O2 
production. (A) Analysis of H2AX foci in alveolar epithelial cells exposed to S. 
pneumoniae at high MOI (200-400), with (+) or without (-) catalase (1 mg/ml). 
Cells are considered positive if there are ≥ 5 foci. (B) Representative images of 
alveolar epithelial cells analyzed for H2AX after exposure to bacteria-free 
supernatant (Conditioned Media) from S. pneumoniae serotype 4, grown in F12-
K media with or without catalase. Images are representative of three independent 
experiments. (C-D) Using similar conditions as (A), apoptotic cells were 
quantified via Annexin V staining (C) and TUNEL assay (D). (E-F) Alveolar 
epithelial cells were exposed to serotype 4 wild type (Type 4) and H2O2-deficient 
ΔspxB mutant (Type 4 ΔspxB) at MOI 300 for 7 hours. (E) H2O2 in the bacteria-
free culture supernatant was quantified at 1, 4 and 7 hours post- infection. (F) 
Infected cells were analyzed for H2AX foci. For A-D, control indicates absence 
of bacteria, and results show mean  SEM for three independent experiments. *p 
< 0.05, unpaired Student’s t-test. 
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3.2.7 Ability of S. pneumoniae to secrete H2O2 is a significant virulence 
factor 
To determine the relevance of pneumococcal H2O2 in disease 
progression, we used an acute pulmonary infection model of S. pneumoniae in 
mice and used it to observe the virulence of S. pneumoniae serotype 4 and 
H2O2-deficient spxB mutant. Both Type 4 WT and ΔspxB were administered at 
similar CFU (2-3 x 107 CFU) via intra-tracheal route and the animals were 
monitored up to three days of infection. While Type 4 WT infection induced 
severe symptoms like lethargy, ruffled fur, hunched back and excess weight loss 
(>20%) in almost all of the animals after day two of infection, Type 4 ΔspxB were 
less toxic and induced morbid symptoms in only a few animals (3 out of 24) at 
day three post-infection (Fig. 3.7A). We determined the CFUs of bacteria in the 
pulmonary airways by plating out the broncho-alveolar lavage fluid (BALF) of 
infected animals every 24 hours. At day two and three post infection, we found 
that there were significantly more WT bacteria in the airways compared to ΔspxB 
bacteria (Fig. 3.7B). We then measured CFU in the blood of infected animals and 
found that spxB mutant bacteria were not able to invade the blood circulation as 
efficiently as the wild type (Fig. 3.7C). While we observed a significant advantage 
for bacteria that express spxB to invade the airways and blood circulation, we did 
not observe a significant difference in the CFUs of WT and ΔspxB in the lung 
homogenate after the BALF was drawn (Fig. 3.7D). These results show that the 
inability of S. pneumoniae to secrete H2O2 impairs its invasiveness into the lung 
airways and blood vasculature, and overall weakens its virulence during infection. 
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 promotes in vivo virulence and invasion. (A) 
Kaplan-Meier plot for animals infected with S. pneumoniae serotype 4 (Type 4) 
and H2O2-deficient spxB mutant (Type 4 spxB). Balb/c mice were infected with 
bacteria at ~2 x 10
7
 CFU per mouse via intra-tracheal inoculation (n = 23-24) and 
their mortality was monitored. Animals showing symptoms of severe illness 
(ruffled fur, hunch back, inactive) and ≥ 20% weight loss were humanely 
sacrificed and considered as a fatal case. (B-D) In this model, pneumococcal 
CFU was determined in (B) lung homogenate after lavage (n = 9), (C) broncho-
alveolar lavage fluid (BALF) (n = 9) and (D) blood of infected animals (n = 5). 
Data are shown in box and whisker plots with median (horizontal line), inner-






3.2.8 Pneumococcal H2O2 mediates pulmonary DNA damage 
To learn about the impact of pneumococcal H2O2 on the genome of cells 
in vivo, we measured the frequency of DNA damaged cells by analyzing for 
H2AX in the lung sections of animals infected with Type 4 WT and ΔspxB. 
Consistent with our in vitro study, we observed DNA damaged cells in lungs of 
animals infected with serotype 4, as indicated by H2AX foci formation (Fig. 3.8A). 
We found that only ~2% of lung cells were positive for H2AX on day one post-
infection for both WT and ΔspxB S. pneumoniae (Fig. 3.8A and B). However, on 
day 2 post-infection, we observed an increase in H2AX positive cells (> 8%) in 
mice lung infected with Type 4 WT, which was statistically significant compared 
to the frequency of H2AX positive cells for mice infected with Type 4 ΔspxB (Fig. 
3.8A, B). At day three post infection, there is difference between Type 4 WT and 
ΔspxB for the frequency of H2AX positive cells, but this is not statistically 
significant (Fig. 3.8A and B).  
During pneumococcal pneumonia, there is persistent infiltration of 
inflammatory immune cells in the lungs that could themselves produce DNA 
damaging-RONS (135, 147, 282). Hence, inflammation-driven collateral damage 
to pulmonary cell DNA is plausible during S. pneumoniae infection. In order to 
determine whether there is a more robust inflammatory response for the mice 
infected with Type 4 WT, the total number of macrophages and neutrophils were 
quantified. We observed that there was a statistically significantly lower number 
of neutrophils at day 2 and 3, and fewer macrophages at day 3 for animals 
infected with Type 4 WT as compared to Type 4 ΔspxB (Fig. 3.8C and D). If 
inflammation were to account for the observed DNA damage, one would expect 
to see reduced DNA damage for Type 4 WT infected animals, whereas we 
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observed the opposite. Therefore, the host inflammatory response does not 
account for the observed Type 4 WT-induced DNA damage. Importantly, the 
level of tumor necrosis factor (TNF-), a key pro-inflammatory cytokine, does not 
vary between Type 4 WT and Type 4 ΔspxB infection (Fig. 3.8E), suggesting 
similar overall levels of inflammation (Fig. 3.8E). Together with the results above, 
the reduced genotoxicity of S. pneumoniae Type 4 ΔspxB is consistent with a 
deficiency of H2O2 synthesis, rather than differences in inflammation, thus 
supporting the significant role of pneumococcal H2O2 in pulmonary genotoxicity 









 is a major genotoxic factor during pathogenesis. 
(A-B) Lung sections of animals infected with Type 4 and Type 4 ΔspxB were 
analyzed for H2AX at day 1, 2 and 3 post-infection (n = 9 per group, except for 
Type 4 at day 3 where n = 5). (A) Representative images of lung section at day 1, 
2 and 3 post-infection showing DAPI (blue), H2AX (yellow), and co-stained 
nuclei (arrows). Inset shows representative H2AX positive nucleus. (B) 
Frequency of H2AX positive cells (≥ 5 foci). (C-D) Inflammatory responses were 
evaluated at days 1, 2 and 3 post-infection. BALF from infected animals were 
analyzed by flow cytometry for (C) neutrophils and (D) macrophages (n = 9 per 
group, except for Type 4 at day 3 where n = 5). (E) TNF- concentration was 
determined in BALF using ELISA. Each data point represents data from one 
animal, and bars indicate the means. For B-D, results show mean  SEM. *p < 
0.05, unpaired Student’s t-test. 
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3.2.9 DNA repair deficiency in host cells exacerbates S. pneumoniae 
infection 
To reveal the potential importance of DNA repair during S. pneumoniae-
induced DNA damage, we knocked down Ku80, which is indispensable for NHEJ 
pathway, by introducing short hairpin (shRNA) specific against Ku80 mRNA. The 
Ku80 knocked down (Ku80 KD) cells were then infected with S. pneumoniae and 
the proportion of DNA damaged cells and apoptotic cells were quantified. At 4 
hours post-infection, there was a significantly greater increase in the 
accumulation of bacteria-induced DNA damage in Ku80 KD cells when compared 
to control epithelial cells (Fig. 3.9A). While there were no apoptotic cells stained 
by TUNEL at 4 hours (Fig. 3.9B), TUNEL positive Ku80 KD cells were significantly 
increased compared to control cells at 7 hours, indicating Ku80 knock down in 
alveolar epithelial cells increases susceptibility to S. pneumoniae-induced cell 
death. To further explore the potential role of Ku80 in response to S. 
pneumoniae, we exploited CHO cells that are null for Ku80. Similar to the results 
for knock down cells, we found that the Ku80-deficient CHO cells (CHO XRS6) 
were significantly more sensitive to S. pneumoniae-induced DNA damage (Fig. 
3.9C) and apoptosis (Fig. 3.9D). Taken together, we conclude that cells that are 
deficient in Ku80 are more susceptible to both S. pneumoniae-induced DNA 
damage and apoptosis. Thus, DNA repair plays a significant role in protecting 




Figure 3.9 Deficiency in DNA repair exacerbates S. pneumoniae-induced 
cytotoxicity. (A) H2AX was evaluated for alveolar epithelial cells with knocked 
down Ku80 (shKu80) exposed to S. pneumoniae serotype 4 at MOI 100. (B) In 
parallel, apoptotic cells were quantified for TUNEL staining. Negative control 
samples show data for shRNA against GFP (shGFP). (C-D) CHO cells deficient 
in Ku80 were infected with S. pneumoniae serotype 4 at MOI 40 for 7 hours. (C) 
Percent H2AX positive cells. (D) In parallel, apoptotic cells were quantified by 
TUNEL staining. For A-D, controls indicate absence of bacteria, and results show 












3.3   Discussion 
An understudied aspect of S. pneumoniae infection is its direct impact on 
host cells, and in particular its potential to induce cytotoxic DNA damage. Here, 
we investigated DNA damage and repair in the context of human alveolar 
epithelial cells exposed to three major virulent serotypes of S. pneumoniae 
(clinical isolate serotype 19F, serotype 3 Xen 10 and serotype 4 TIGR4) that 
commonly infect young children (283). Among these serotypes, we found that 
serotype 4 is the most genotoxic and can induce pulmonary DNA damage during 
acute bacteremic-pneumonia. Results show that S. pneumoniae elicits DNA 
damage responses in host cells and that serotype 4 is able to secrete high levels 
of H2O2, giving it the capacity to induce DNA damage and cell death. Moreover, 
pneumococcal H2O2 alone is able to induce discrete DSBs without bacterial 
contact. Consistent with a model wherein pneumoniae-induced DNA damage 
triggers apoptosis, we observed that cells deficient in DSBs repair have 
increased levels of apoptosis. Finally, results show that S. pneumoniae-secreted 
H2O2 plays a significant role in mediating pulmonary genotoxicity and systemic 
virulence in an animal model of acute pneumonia. This study underscores the 
genotoxic potential of pneumococcal H2O2 as well as the potential importance of 
DNA repair as a defense against S. pneumoniae-induced DNA damage and 
apoptosis. 
S. pneumoniae is the most common pathogen underlying community 
acquired pneumonia. Pneumonia is the major cause of death in children below 5 
years old, accounting for around 19% of children’s death worldwide (WHO report) 
and it also poses a serious threat to the elderly population (284). Moreover, 
pneumonia from S. pneumoniae infection is frequently the cause of fatal 
secondary infections during Influenza pandemics, such as the 1918 influenza 
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pandemic and the recent 2009 pandemic (285, 286). Additionally S. pneumoniae 
plays a major role in worsening morbidity associated with chronic obstructive 
pulmonary disease (COPD) (287). S. pneumoniae resistance to mainline 
therapeutics, such as penicillin and macrolides, has increased strikingly to more 
than 25% in recent years (288). Given the heavy disease burden and prevailing 
drug resistance associated with S. pneumoniae, novel approaches are needed 
for streptococcal disease mitigation.  
The plight of the host genome during infection-induced pathogenesis had 
been largely overlooked. Recently, however, certain pathogenic bacteria have 
been shown to cause damage to host DNA. For example, Chlamydia trachomatis 
(289) and H. pylori (267), have been proposed to elicit dysregulated cell 
proliferation and mutagenic DNA damage, which in turn are thought to promote 
bacterial-induced carcinogenesis (289). Interestingly, H. hepaticus and 
Camplyobacter jejuni have been shown to produce cytolethal distending toxin 
(CDT), a carcinogenic tripartite protein that shows DNase activity in host nuclei 
(290-292). Given these examples of pathogens that have evolved mechanisms to 
induce DNA damage in mammalian cells, it seemed plausible that the host 
genome might be an intended target of S. pneumoniae. Indeed, in the case of S. 
pneumoniae, while it was known that the spxB gene worsens infection (70, 128), 
our work points specifically to the ability of spxB gene to induce DNA damage as 
the underlying driver of spxB-associated virulence. Although we did not find any 
significant difference in spxB expression between the three serotypes, it is 
possible that pyruvate substrate utilization (in the media) by SpxB varies in these 
serotypes such that Type 4‘s SpxB is able to generate more products in the form 
of H2O2. Furthermore, to date, the link between pathogen-induced DNA damage 
and disease has been focused primarily on cancer, whereas here we show an 
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example of a pathogen-secreted DNA damaging factor that has a direct 
association with pathogen-induced morbidity and mortality during infection. 
Severe DNA damage can lead to apoptosis and necrosis (202, 293), 
which in turn lead to disintegration of lung architecture, promoting pulmonary 
failure. Here, we observed that S. pneumoniae could cause greater permeability 
of the cell membrane of host cells (observed as PI uptake), indicative of necrosis. 
H2O2 may contribute to necrosis, as well as exposure to the pneumococcal cell 
wall, which has previously been reported to be a necrosis-inducing factor (25, 27). 
With regard to apoptosis, we show that H2O2 secreted by S. 
pneumoniae serotype 4 leads to DNA damage in a contact-independent fashion 
and the levels of H2O2 are sufficiently high as to induce significant apoptosis 
(Annexin V and TUNEL positive cells). These observations are consistent with 
previous in vitro studies that implicate possible contribution of secreted H2O2 to S. 
pneumoniae-induced cytotoxicity (270). H2O2-induced DNA damage and 
resultant cell death is anticipated to enable invasion of S. pneumoniae into the 
blood circulation. It is known that spxB mutant pneumococci are less virulent in 
animal models of pneumonia (61, 78). Indeed, we observed reduced bacterial 
titres in blood following infection by Type 4 spxB mutant bacteria as compared to 
Type 4 WT, underscoring the role of spxB and its H2O2 production in 
development of effective sepsis in our animal model.  
We also report an important and novel role of DNA repair protein Ku80 in 
suppressing S. pneumoniae-induced genotoxicity. This observation is consistent 
with the known role of Ku80 in protecting alveolar epithelial cells (and other cell 
types) from gamma irradiation-induced DSBs (294, 295). Overall, our data 
suggest a genotoxic model of pneumococcal pathogenesis whereby 
pneumococcal spxB-derived H2O2 induces host DNA damage that overwhelms 
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the Ku80-dependent NHEJ repair pathway, leading to cell death. Ultimately, via 
increased DNA damage, the resultant cell death and tissue damage could enable 
pneumococci to become more virulent and invasive. The manipulative interaction 
of pathogen with host DNA repair network is greatly under-studied, with only few 
reports (268, 289) on the role of DNA repair factors during bacterial infection. 
Previously, one study has shown that deficiency of base excision repair (BER) 
pathway glycosylase OGG1 (8-oxoguanine DNA glycosylase) could increase cell 
death and lung injury during Pseudomonas aeruginosa infection (268). Here, we 
show that deficiency of NHEJ pathway protein Ku80 during pneumococcal 
infection can directly increase the DSBs and lead to apoptosis in alveolar cells. 
In previous studies of pathogen-induced DNA damage, DSBs have been 
visualized by immunofluorescence detection of H2AX (267, 268, 289, 296, 297). 
In our analysis of H2AX foci, we found that a relatively high MOI produces 
sufficient H2O2 in the media to reach genotoxic levels. Interestingly, during S. 
pneumoniae infection of alveolar epithelial cells, we observed two patterns of 
H2AX staining depending on the MOI used. Low MOI (30-50) yielded foci of 
H2AX with 53BP1 in almost half of the total H2AX-positive population, while the 
other half portrayed pan-H2AX phosphorylation without any 53BP1 staining. At 
higher MOI (200-400), only pan-H2AX staining without 53BP1 was observed. 
During infection of animals, we observed that pan-H2AX constituted about 30% 
of the total H2AX analyzed in the lung sections (Fig. S10). The pan-H2AX 
staining has been reported to occur in human fibroblast cells subjected to Adeno-
associated virus (296, 298), Chlamydia (289), UV and ionizing radiation (275, 
299, 300). Recently, such nuclear-wide H2AX has been shown to occur in highly 
DNA damaged cells, and is mediated by ATM kinase (275). Here, we found that 
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most of the pan-H2AX phosphorylation was dependent on ATM kinase, and 
hence constituted part of the DNA damage response cascade induced by S. 
pneumoniae.  
While H2O2 clearly plays a significant role in the induction of DNA damage 
and downstream responses to S. pneumoniae, we also found evidence for H2O2-
independent induction of DSBs. During bacterial incubation with alveolar 
epithelial cells, we observed approximately 60% H2AX positive cells. 
Interestingly, only 30% of cells showed significant DNA damage when incubated 
with supernatant alone. It is possible that mammalian cell contact with S. 
pneumoniae causes DNA damage in host cells, independent of bacterial H2O2. 
One possibility is that direct contact of mammalian cells with S. pneumoniae 
could activate surface proteins in alveolar epithelial cells and produce signals 
that impact oxidative status and DNA damage response pathways. Indeed, S. 
pneumoniae is shown to activate cJun-NH2-terminal kinase (JNK) (270) pathway, 
which has the potential to phosphorylate H2AX (301). Direct contact-induced 
DNA damage is further supported by the observation that deletion of spxB (which 
is necessary for secretion of H2O2) in bacteria does not completely eliminate its 
ability to induce DNA damage. Thus, while it is clear that pneumococcal H2O2 
plays an important role in inducing DNA damage, there remains alternative 
mechanisms by which S. pneumoniae can contribute to H2O2-induced DNA 
damage. 
Given the low levels of H2O2 produced by serotype 19F and 3, the 
observation that catalase could suppress the ability of these strains to induce 
DNA damage was unexpected. However, it is important to consider the approach 
that was used to estimate H2O2 secretion, namely to sample the media. For 
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strains that have low-level production of H2O2, it may be that H2O2 is rapidly 
diluted in the media. However, if S. pneumoniae settle to form a layer above the 
human cells, the local concentration of H2O2 is anticipated to be far greater. 
Catalase would be anticipated to counteract genotoxicity of H2O2 under these 
conditions. Moreover, the fact that serotype 19F and 3 are not as cytotoxic as 
serotype 4 is consistent with H2O2 being a dominant mechanism for the induction 
of DNA damage and apoptosis.  
In this study, we have shown that S. pneumoniae creates high levels of 
H2O2, and that the levels of H2O2 are sufficiently high as to induce DNA damage 
and apoptosis. We have shown that suppressing the levels of pneumococcal 
H2O2, either by treatment with catalase or by knocking out the gene necessary 
for H2O2 biosynthesis, suppresses S. pneumoniae-induced DNA damage and 
apoptosis. Furthermore, H2O2 secreted by S. pneumoniae plays a key role in 
pathogenesis, as shown by an acute pneumonia animal model. Importantly, 
human alveolar epithelial cells knocked down for an essential component of the 
dominant DSBs repair pathway are more sensitive to S. pneumoniae-induced 
DNA damage and apoptosis, highlighting DNA repair as a potentially important 
susceptibility factor. In conclusion, the results of this study point to a role for S. 
pneumoniae-induced DNA damage in disease pathology and open doors to new 
avenues for developing therapeutic strategies that either suppress DNA damage 







3.4   Conclusion 
We investigated the DNA damage response in human alveolar epithelial 
cells induced by three strains of S. pneumoniae (clinical isolate, Xen 10 and 
TIGR4) belonging to virulent serotypes (19F, 3 and 4, respectively) that 
commonly infect young children. We showed that these S. pneumoniae strains 
could elicit strong DNA damage responses in host cells as evident by ATM-
mediated phosphorylation of histone H2AX and nuclear recruitment of 53BP1. 
DNA damage was mainly caused by H2O2 generated directly by S. pneumoniae 
(TIGR4 strain). This conclusion was derived from observations that (a) 
pneumococci secreted H2O2 alone can directly induce DSBs without bacterial 
contact, (b) the natural inability of certain pneumococcal strains (19F and Xen 10) 
to produce H2O2 strikingly attenuate their capacity to induce DNA damage, (c) 
direct neutralization of H2O2 by catalase drastically reduces the induced DNA 
damage and (d) deficiency of H2O2 producing enzyme SpxB decreases the 
bacterial genotoxicity. Furthermore, our study showed that the DNA damage 
induced by S. pneumoniae occurred before the cell commits to undergo 
apoptosis, indicating an a priori role of DNA damage in deciding cellular fate 
during infection.  
We demonstrated the in vivo genotoxicity of S. pneumoniae in an acute 
pneumonia mouse model. Previously, it has been shown that H2O2-deficient S. 
pneumoniae are less virulent to cause pneumonia in animals (61, 78). However, 
these studies lacked any direct evidence of effect of pneumococcal H2O2 in vivo 
and its role in pneumococcal pathogenesis are based on in vitro studies (58). In 
our animal model, we demonstrated that pulmonary DNA damage induced by 
pneumococcal H2O2 is a potential factor that correlates with pneumococcal 
virulence and disease outcome during pneumonia.  
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Importantly, we discovered that cells deficient in DNA repair protein Ku80 
are more susceptible to the genotoxic assault of S. pneumoniae and were more 
likely to undergo apoptosis during infection. Dysfunctional DSB repair 
mechanism during DNA damage response against S. pneumoniae could prove 
disastrous for cell survival. Indeed, using Ku80-deficient cellular system we 
showed that if the repair system is not fully functional, DSBs induced by 
pneumococcal H2O2 at first get accumulated, followed by onset of apoptosis. This 
demonstrates a crucial role of DNA repair for cell survival during S. pneumoniae 
infection, whereby disruption in the DNA repair mechanisms exacerbate the 
severity of DNA damage and drive the cell signaling from survival to apoptotic 
pathway. Hence, a coordinated network between DNA damage, DNA repair and 
apoptosis possibly determines the cytotoxicity of S. pneumoniae.  
Impact of the work: 
The rise of antibiotic resistant bacteria calls attention to the need for 
alternative strategies for mitigating disease. Furthermore, although the capsular 
polysaccharide-based vaccines have been able to reduce the prevalence of 
vaccine-targeted invasive serotypes in past two decades (302), the serotypes not 
covered by these vaccines are still prevalent and invasive especially in patients 
with cardiopulmonary co-morbidities or compromised immunity (21). Developing 
our understanding of the molecular processes that modulate the progression of 
pneumococcal disease is therefore an important step in advancing alternative 
treatment approaches for S. pneumoniae infection.  
While immune cell induced ROS and RNS play a role in fighting infections, 
these inflammatory chemicals can also lead to collateral tissue damage. 
Furthermore, bacterially secreted H2O2 may exacerbate tissue damage caused 
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by inflammation-induced RONS. Importantly, S. pneumoniae strains that secrete 
H2O2 clearly must have mechanisms to tolerate H2O2, and these mechanisms 
may render them resistant to H2O2 produced by immune cells. Thus, the use of 
H2O2-neutralizing antioxidants, in concert with antibiotic regime, may be 
appropriate during severe pneumococcal pneumonia. Indeed, antioxidants have 
been shown to confer positive outcome during pneumococcal meningitis in a rat 
model (266). Constant secretion of such oxidants by serotypes colonizing the 
upper respiratory tract (URT) can potentially damage the URT epithelia, 
destabilizing its normal barrier function [e.g., ciliary velocity (84) and mucus 
production (303)], and facilitating carriage of S. pneumoniae to become more 
invasive. Given that certain strains of S. pneumoniae are resistant to H2O2 (62), 
and that H2O2 increases disease pathogenicity, our data suggests that 
determining the status of the spxB gene in pneumococcal isolates could prove 
helpful in guiding the use of antioxidants in disease treatment. 
Our finding that DNA repair is important to suppress the cytotoxicity of a 
genotoxic pneumococcal strain reveals DNA damage and repair as a host factor 
that could modulate disease severity. This finding could shed some light over the 
relationship between pneumonia and lung cancer, that is evident in cancer 
studies but mechanistically less understood. Retrospective studies indicate that 
pneumonia is one of the common underlying causes of respiratory failure and 
early death during lung cancer (304-306). These studies show that severe 
pneumonia is associated with cancer patients undergoing chemotherapy and 
radiotherapy. Majority of anti-cancer therapy functions by damaging the DNA of 
actively growing cancerous cells in order to destroy tumors by apoptosis  (307). 
Indeed, H2AX foci are detected during genotoxic cancer therapy (308). In such 
scenario, invasion of genotoxic strain of S. pneumoniae could synergize with 
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therapy-induced DNA damage resulting in overwhelming pulmonary DNA 
damage that can cause cell death, tissue injury and could lead to respiratory 
failure. Importantly, DNA repair pathways are known to be perturbed to promote 
cancerous growth and DNA repair capacity has been reported to be reduced in 
peripheral blood lymphocytes during lung cancer (309, 310). Given our 
observation that DNA repair is crucial to prevent exacerbation of pneumococcal 
cytotoxicity, diminished DNA repair capacity of host cells during cancer 
















4. Persistence of S. pneumoniae in Lungs induce 
Inflammation-associated Pulmonary DNA Damage 
 
4.1. Introduction 
Disease progression during pneumococcal pneumonia depends on the 
pulmonary damage done by S. pneumoniae and the extent of inflammatory 
responses elicited by the pneumococcal invasion (32). In Chapter 4, we showed 
that pneumococcal H2O2 is an important virulence factor of S. pneumoniae that 
can directly cause pulmonary DNA damage, contribute to cell death and confer 
lethal virulence to the pneumococci. In addition to H2O2, pneumococci is also 
known to produce cytotoxins that can directly cause tissue injury as well as 
induce inflammation in lungs. There are also reports that show certain strains of 
serotype 1 that are H2O2-deficient and some strains that produce non-functional 
cytotoxin, can still cause invasive pneumococcal disease (IPD) (93, 311). 
Previously, we have shown that pneumococcal H2O2–mediated pulmonary DNA 
damage is an important aspect of a successful S. pneumoniae infection. Hence, 
considering the diverse forms of pneumococcal serotypes that can cause 
pneumococcal disease, there is need to explore possible factors (besides 
bacterial-derived H2O2) that could adversely affect the pulmonary genome during 
pneumococcal pneumonia.  
While the pneumococcal virulence factors represent a primary cause that 
initiates pathogenesis, the dysregulated inflammatory response generated by 
pneumococci and their virulence factors in lungs is critical for disease outcome. It 
is evident from clinical and animal model studies of pneumococcal disease that 
the pneumococci strains that cause severe disease in humans also evoke severe 
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pro-inflammatory responses (32, 148, 312). Pneumococcal pneumonia is 
characterized by excess inflammatory reactions at the onset of infection that 
drive disease progression (137). The rapid effect of aberrant inflammation during 
severe pneumonia could lead to acute lung injury (ALI), sepsis, lack of clinical 
responses to therapy and death (313, 314). The major host factor that could 
cause collateral tissue injury associated with severe pneumonia is neutrophilic 
infiltration (143, 149). Neutrophils, although necessary to control subclinical 
doses of S. pneumoniae, have also been shown to cause more damage to lungs 
rather than help in resolution of pneumonia (145). Accumulation of neutrophils 
are known to disrupt the alveolar epithelium (143, 149, 150) and produce 
cytokines that fuels abnormal inflammatory responses (149). Neutrophils 
potentially mediate tissue injury by secreting various proteases and orchestrates 
pulmonary oxidative stress by producing highly reactive radicals called reactive 
oxygen species (ROS) (149). While neutrophil proteases are known to 
disintegrate epithelium and alveolar structures, ROS secretion could have 
adverse oxidizing effect on host bio-molecules including genomic DNA (149, 153).  
ROS-mediated damage to DNA results in nucleotide base lesions, single 
strand breaks (SSBs) and double strand breaks (DSBs) (184-186, 188). DSBs 
are the most toxic form of DNA damage that can lead to not only harmful 
chromosomal rearrangements but also programmed cell death (261, 262). 
Presence of pulmonary DNA damage, by using marker of strand breaks i.e. 
phosphorylation of H2AX (H2AX), has been demonstrated during airways 
inflammation and oxidative stress condition like chronic obstructive pulmonary 
disorder (COPD) (246, 315). Pulmonary DNA damage during COPD has been 
associated with apoptosis and senescence of alveolar epithelium and implicated 
in pathogenesis (246, 316). This raises possibility of DNA damage being induced 
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during condition of acute and exaggerated inflammatory response like 
pneumococcal pneumonia.    
 . It has been shown that different serotypes or clonal types of S. 
pneumoniae can potentially induce different degree of inflammatory responses 
that could lead to disease severity (32, 317-319). Although different virulence 
factors could be attributed to the way different serotypes behave in vivo, one 
common observation that has been reported in various animal models is that 
fatal pneumonia is associated with high bacterial number and concomitant 
neutrophilic infiltration during later stages of infection (32, 133, 134, 146, 147). 
Given that S. pneumoniae elicits inflammatory pathways to drive pneumococcal 
pathogenesis and inflammation generates genotoxic oxidative stress, in this 
study, we explored the possibility of serotype-dependent pulmonary DNA 
damage during pneumococcal pneumonia. 
 We used animal model of pneumonia to investigate the virulence and 
genotoxicity of three S. pneumoniae serotypes, namely -19F, 3 and 4. Previously, 
we have shown that in vitro serotype 4 is the most genotoxic due to its ability to 
produce high amount of H2O2 (Section 3.2), compared to serotype 19F and 3. 
Here, we found that serotype 3 is as efficient as serotype 4 in causing virulence 
in vivo. This virulence is potentially conferred by greater degree of capsulation of 
serotype 3, which was able to multiply and persist longer to generate greater 
neutrophilic infiltrates in the airways. Importantly, we observed that pulmonary 








4.2.1. Pneumococcal virulence is serotype-dependent 
We have shown that S. pneumoniae Type 4 is virulent in a mouse model 
of pneumonia (3.2.7). To learn about the virulence of Type 3 and 19F and their 
possible virulence factors, we used similar mouse model of pneumonia. Animals 
were infected intra-tracheally with 2-3 x 107 CFU of S. pneumoniae and 
monitored for mortality and sick symptoms for up to three days. We observed 
that Type 3 was as virulent as Type 4 in vivo and both of the serotypes induced 
sickness and lethality after day two post-infection, while Type 19F did not induce 
any disease symptoms (ruffled fur, inactive) or weight loss (Fig. 4.1A). Given that 
during pneumonia the pneumococcal number directly influences the disease 
progression, we determined the number of bacteria in the infected lung. 
Interestingly we found that in vivo, Type 3 was able to stay alive and multiply 
much faster than either Type 4 or 19F (Fig. 4.1B). The superior persistence of 
Type 3 over Type 4 and 19F was striking at day two and three post-infection, 






        
 
Figure 4.1 Comparative virulence of S. pneumoniae serotypes 19F, 3 and 4 in 
animal model of pneumonia. (A) Kaplan-Meier plot for animal infected with 
S.pneumoniae serotype 19F (Type 19F), 3 (Type 3) and 4 (Type 4). Balb/c mice 
were infected with ~2-3 x 107 CFU per mouse via intra-tracheal route (n = 8-14) 
and their mortality was monitored. Animals showing symptoms of severe illness 
(ruffled fur, hunch back, inactive) and ≥ 20% weight loss were humanely 
sacrificed and considered as a fatal case. (B) Lungs were harvested every day 
for up to three days post-infection, homogenized and CFU was determined for 
each condition (n = 5-8). Data are shown in box and whisker plots with median 
(horizontal line), inner-quartile range (box) and maximum/minimum range 
(whisker). *p < 0.05, Mann-Whitney test. 
 
4.2.2. Persistent S. pneumoniae serotype 3 has thickest capsule 
In order to understand the ability of Type 3 to survive better in the lungs, 
we studied the encapsulation of the three serotypes since pneumococcal capsule 
provides effective protection against host immunity. We used dextran-exclusion 
method where FITC-labelled 2000 kDa dextran molecules are incubated with 
pneumococci and by observing the zone of exclusion of dextran, the degree of 
capsulation can be observed (22). We observed that Type 3 showed significantly 
greater area of FITC-dextran exclusion (black area) than other two serotypes (Fig. 
2A), indicating presence of thick capsules that excludes the high molecular 
weight dextran. We also performed negative staining of log-phase pneumococci 
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by India ink and observed that Type 3 has clear halo zone around the 
diplococcus bacterium indicative of a thick capsule area as compared to Type 4 
and 19F (Fig. 2A). It is known that capsular polysaccharide interferes with 
pneumococcal adherence to host cells (320, 321). Presence of thick capsule 
could possibly mask the bacterial membrane proteins responsible for adhesion 
and thus reduce the adherence (51). We hypothesized that if Type 3 has the 
thickest capsule then it will adhere less to alveolar cells in vitro. Indeed, when we 
performed adhesion assay (61) on all three serotypes, we observed that 
adherence of Type 3 to host cells was the least regardless of the number of 
bacteria incubated with cells (Fig. 2B). This result further supports our 
microscopy observation that Type 3 has the thickest capsule among the 
serotypes used. Given the importance of capsular polysaccharide in protecting 
the pneumococci against host immunity, these data suggest that lethality of Type 
3 is mainly due to increased pneumococcal persistence conferred by the 
capsular polysaccharides.  
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Figure 4.2. S. pneumoniae Type 3 has comparatively thicker capsule than Type 
19F and 4. (A) Log-phase bacteria was mixed with FITC-dextran (2000 kDa) in 
PBS and viewed at 100X magnification under FITC and bright field (BF) channel. 
Pneumococci were also mixed with India ink and observed for halo capsule 
regions, at 100X magnification under BF channel. (B) Log-phase S. pneumoniae 
were labeled with FITC (1 mg/ml for 1 hour), and incubated with alveolar cells for 
1.5 hours at 37C. The alveolar cells were then washed and residual FITC-
labeled bacteria were counted in a blinded fashion and expressed as the number 
of adherent bacteria per field. Results show mean  SEM for three to five 
independent experiments. *p < 0.05, Student’s t-test between Type 3 and 19F or 







4.2.3. Pneumococcal persistence in lungs correlate with pulmonary DNA 
damage  
To learn about the condition of pulmonary DNA during fatal pneumonia, 
we observed the frequency of DNA damage in lung cells by analyzing the lung 
sections for H2AX phosphorylation (H2AX). We observed that < 4% of lung cells 
are positive for H2AX on day one after infection by all three serotypes (Fig. 
4.3B). On day two and three, the serotype-dependent effect on pulmonary DNA 
damage was strikingly evident. The virulent pneumococcal serotypes Type 3 and 
4 were able to induce greater degree of DNA damage in the lungs than the Type 
19F (Fig. 4.3A and B), which was found to be less virulent in our animal model. 
Although, there was no significant difference between frequency of total H2AX 
positive cells induced in the lungs by Type 3 and Type 4, the presence of 
nuclear-wide H2AX (pan H2AX) was significantly higher in lungs infected by 
Type 3 than Type 4 on day two and three post-infection (Fig. 4.3B). In corollary, 
the discrete foci form of H2AX was higher in lungs infected by Type 4 as 
compared to Type 3. These data suggest that besides the H2O2–mediated 
genotoxicity of pneumococcal serotype like Type 4 (3.2.8), certain serotypes like 
Type 3, that multiplies better in lungs also induces significant pulmonary DNA 
damage during lethal pneumonia. 
An interesting observation in S.pneumoniae Type 3-induced pulmonary 
H2AX was that out of the total H2AX, >50% has pan-H2AX pattern and most 
of the pan-H2AX positive cells have smaller nuclei (as seen by DAPI staining) 
when compared to nuclei harboring focal H2AX (Figure 4.3B). Pan-H2AX 
positive cells have nuclear-wide phosphorylation of H2AX, which has been 
shown to occur in response to severe and localized DNA damage by ionizing 
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radiation (275). Our in vitro results also indicate that at high MOI, S. pneumoniae 
induce pan-H2AX in alveolar cells (3.2.1). Interestingly, pan-H2AX has also 
been implicated as an apoptotic event activated by death receptor pathway (322). 
Hence, to understand whether the nuclear-wide H2AX phosphorylation in lungs is 
molecular consequence of apoptotic DNA fragmentation, we analyzed same lung 
section for both DNA fragmentation (by TUNEL) as well as H2AX. We found that 
the there was not any co-localization of TUNEL and H2AX positive cells (Fig. 
4.3C). In fact, the pulmonary regions with apoptotic cells and those with DNA 
damaged cells were always separated in space. This result, along with our 
previous observation that H2O2-producing Type 4 induce lesser pan-H2AX, 
suggest that the DNA damage observed as a dominant pan-H2AX response to 
Type 3 infection is not a consequence of apoptosis and is potentially unique to 






Figure 4.3 S. pneumoniae induces DNA damage in vivo. (A-B) Lung sections of 
animals infected with Type 19F, 3 and 4 pneumococci at day 1, 2 and 3 post-
infection were analyzed for H2AX (n = 7-11). (A) Representative image of 
sections at day 2 post-infection showing nucleus (DAPI, blue), broncho-
epithelium (red) and H2AX (yellow). Co-localization of nuclei with H2AX is 
indicated by arrows. Inset shows representative H2AX positive nuclei. (B) 
Frequency of H2AX positive cells (≥ 5 foci). Results show mean  SEM. *p < 
0.05, unpaired Student’s t-test. (C) Representative image of lung section serially 
stained with TUNEL and then H2AX. Lung section was first analyzed with 
TUNEL assay, mounted with reagent containing DAPI and images were taken. 
TUNEL positive cells (green) are indicated by arrows. The section was then 
processed for heat-based antigen retrieval to analyze for H2AX (antigen 
retrieval on an already mounted slide resulted in loss of some DAPI staining). 






4.2.4. Increased persistence of serotype 3 determines extent of 
neutrophilic infiltration 
During pneumococcal pneumonia, overwhelming bacteria number in 
lungs is one of the key factors that drives excess host-inflammatory responses 
and lead to severe disease outcome. To learn the importance of pulmonary 
persistence and multiplication of Type 3 in pathogenesis, we used the approach 
of antibiotic treatment to eliminate the bacteria in lungs. Animals infected with 
bioluminescent Type 3 were treated with two different antibiotics: ampicillin (-
lactam) and moxifloxacin (quinolone) on day one post-infection via intra-tracheal 
route (Fig. 4.4A). The bacterial number in lungs was monitored everyday by live 
animal imaging during the course of disease progression. Both antibiotics were 
effective against Type 3 and prevented bacterial multiplication, development of 
pneumonia and any morbidity or mortality. To test our hypothesis that reduced 
bacterial number reduces host-inflammatory response, we analyzed 
bronchoalveolar lavage fluid (BALF) of the infected animals for inflammatory cells 
infiltrating the airways at day three post-infection. Consistent with previous 
reports (323), we observed that the total cellular infiltrates were greatly reduced 
in antibiotic treated animals (Fig. 4.4B). It has been shown that excess neutrophil 
in lungs could induce lung damage (143, 149) and aid in pneumococcal 
pathogenesis. In this animal model, we found that neutrophil infiltration was 
significantly reduced with the reduction of bacterial number by antibiotics. We 
also analyzed macrophage numbers in BALF and found that there was not any 
significant impact of bacterial number in macrophage recruitment. Further, we 
noted that Type 3 was able to elicit more cellular and neutrophilic recruitments in 
the lungs than Type 4, which is equally virulent but less persistent in lungs (3.2.7). 
Taken together, these results indicate that persistence of Type 3 pneumococci 
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results in prolong accumulation of neutrophils that could mediate lung injury and 
hence reducing the bacterial number attenuate excess neutrophil infiltration and 
prevents pneumonia.  
 
 
Figure 4.4 Reducing number of pneumococci decreases cellular infiltration. (A) 
Animals were infected with bioluminescent S. pneumoniae Type 3 at 2 x 107 CFU 
per mouse via intra-tracheal route. Following day, ampicillin and moxifloxacin 
was administered once via intra-tracheal route, each at a dose of 125 g in 50 l/ 
mouse. Development of pneumonia as indicated by bacterial multiplication and 
increase in luminescent signal was monitored everyday for up to three days. 
Images of live animals are shown (n = 3-5). (B) At day three post-infection, BALF 
was drawn from infected lungs and total cell count was determined by trypan 
blue method. BALF was then analyzed by flow cytometer for neutrophils and 
macrophages (n = 4-5). Data for Type 4 has already been shown in Figure 3.8. 




4.2.5. Reducing serotype 3 pneumococci in lungs alleviates pulmonary 
DNA damage  and injury 
To learn the impact of Type 3 pneumococci and neutrophil accumulation 
in pulmonary DNA damage, we analyzed the lung sections of antibiotic treated 
animals for H2AX. We observed that the overall DNA damage is reduced in 
lungs of animals promptly treated with antibiotic before the onset of pneumonia 
(Fig. 4.5A). Pneumococcal elimination by ampicillin treatment resulted in 
significant decrease of pulmonary H2AX positive cells, while moxifloxacin-
induced bacterial killing resulted in decrease of DNA damage, but this was 
statistically not significant when compared to untreated lungs. Treatment with 
both antibiotics significantly reduced the population of specific pan-H2AX 
positive cells in lungs. These data indicate that reducing Type 3 number and 
excess neutrophilic infiltration results in overall well-being of pulmonary DNA.  
We further analyzed the pulmonary architecture of lung sections by H&E 
staining (Fig. 4.5B). We observed that the lethal Type 3 infection resulted in 
disruption of the honey-comb alveolar structures with vascular leakage, profuse 
infiltration of leukocytes in the airways as well as edema and fibrinous exudates, 
which are histopathologic characteristic of pneumonia (Fig. 4.5B). Infected lungs 
rescued with antibiotic treatment showed only few occurrences of leukocyte 
infiltration and edema fluid in the alveolar spaces. Here, one thing to note is that 
the antibiotic treatment was done within 24 hours of infection when the bacteria 
were still dividing and hence the antibiotic-mediated lysis, that releases 
inflammatory bacterial products, possibly causes only minimal damage to 
pulmonary tissue. Indeed, the timely elimination of pneumococci by antibiotic 
reduced the damage done by bacteria as well as collateral damage done by host 
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inflammatory responses.  Overall, the reduction in pulmonary tissue injury and 
prevention of pneumonia by antibiotic treatment is consistent with reduction in 
pulmonary DNA damage, indicating pneumococci Type 3-driven inflammatory 
responses as potential cause of pulmonary DNA damage. 
                  
Figure 4.5  Pulmonary DNA damage associated with serotype 3 infection 
correlates with  inflammation-induced lung injury. (A) Lung sections of animals 
infected with Type 3 pneumococci at day three post-infection were analyzed for 
H2AX and frequency of H2AX positive cells (≥ 5 foci) are presented (n = 4-5). 
Results show mean  SEM. *p < 0.05, unpaired Student’s t-test. (B) 
Representative H&E image of alveolar structures at day three with mock infection 
(PBS), with Type 3 infection (Type 3) and infected lungs treated with ampicillin 





It is known that S. pneumoniae can cause direct damage to host cells and 
result in necrotic or apoptotic cell death (100, 324). Here, we investigated 
pulmonary DNA damage and disease progression during infection by three major 
virulent serotypes of S. pneumoniae - clinical isolate serotype 19F, serotype 3 
Xen 10 and serotype 4 TIGR4 that commonly infect young children (283). We 
found that serotype 3 and 4 are highly virulent and cause significant pulmonary 
DNA damage and mortality whereas serotype 19F induces the least DNA 
damage and does not cause any disease symptoms. Greater capsulation of 
serotype 3 made it more viable in lungs and consequently elicited greater 
inflammatory response than serotype 4. We observed that pulmonary injury and 
specifically DNA damage induced by serotype 3 is dependent on bacterial 
number and degree of neutrophil infiltration. Interestingly, we noted that H2AX 
formation in lungs with serotype 3 infection is dominantly nuclear-wide H2AX 
(pan-H2AX), which does not co-localize with apoptotic DNA fragmentation. 
Overall, our results suggest that degree of pulmonary DNA damage during 
pneumococcal pneumonia could be serotype-dependent and affected by host-
inflammatory responses. 
There are evidence suggesting that patho-physiology and disease 
progression during pneumococcal infection are dependent on the serotype of 
pneumococci (32, 317-319, 325). Indeed, a comparative study of serotype 3 and 
4 in an animal model has suggested an organ-specific pathogenesis for each 
serotype (319) whereas isolates of serotype 19F is mainly found as carrier 
serotype rather than an invasive one (31). One explanation is that different 
serotypes express their virulence genes differently in different anatomical sites in 
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vivo and hence elicit varying degree of inflammatory responses (128, 325) that 
could affect disease severity. Such virulent factors can either induce tissue injury 
directly (such as pneumolysin and H2O2) or possibly help the pneumococci to 
persist in an anatomical niche (such as adhesins and capsule) and thereby 
eliciting continuous inflammatory responses that causes collateral injury including 
DNA damage.  
While our previous study suggested H2O2 as a major factor of virulence 
and genotoxicity for serotype 4 (TIGR4 strain) (3.2.8), our present study indicates 
that serotype 3 (A66.1 Xen 10 strain) uses the classical virulence factor –
capsular polysaccharides to persist and induce injury in lungs. Pneumococcal 
capsule is known to confer virulence, mainly by allowing the bacteria to evade 
host immune attack such as immunoglobulin-mediated or opsonin-mediated 
phagocytosis (45). By using microscopy, we showed that the strain of serotype 3 
used in this study is heavily encapsulated than strains of serotype 4 and 19F, 
which most likely prevented phagocytosis (22) and allowed serotype 3 to survive 
in greater numbers. One explanation for thicker encapsulation of serotype 3 
could be that serotype 3 capsule constitution is the simplest among the 
pneumococcal serotypes i.e. made up of repeating dissacharide units of D-
glucuronic acid (GlcA) and D-glucose (Glc) (43), compared to at least three 
sugar-derivatives required for serotype 19F and 4 (Figure 1.2). Hence, this would 
make the serotype 3 capsule production energetically the most economical and 
allow serotype 3 to have greater capsulation. This was also evident in thick 
mucoid colonies of serotype 3 when compared to colonies of serotype 4 and 19F 
(data not shown). We did not observe any difference between capsule size of 
serotype 4 and 19F, and consistently there was not much difference in bacterial 
number between these two serotypes in the infected lungs. 
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The pulmonary DNA damage induced by each serotype correlated with 
the pneumococcal disease outcome. Virulent serotype 3 and 4 induced greater 
number of H2AX positive cells in lungs than the less virulent serotype 19F. 
Although there was no significant difference in total H2AX positive lung cells 
induced by serotype 3 and 4 at day two and three post-infection, greater 
population of serotype 3 was able to induce greater cellular infiltration, including 
neutrophils. Due to the ability of neutrophils to produce genotoxic ROS in vivo, 
they have been associated with collateral DNA damage (261) and lung injury 
(143, 149). Excess neutrophilic infiltration in lungs has been shown to induce 
significant guanosine adducts in pulmonary DNA (192), and during excision 
repair these adducts could get converted to strand breaks (326). Given that 
serotype 4 (TIGR4) induced pulmonary DNA damage is mediated by 
pneumococcal H2O2 and serotype 3 (Xen 10) does not produce any significant 
amount of H2O2 in vitro (Section 3.2), it is possible that serotype 3-induced DNA 
damage is predominantly due to oxidative stress created by excess neutrophils. 
Although, our results do not rule out the possibility of serotype 3 secreting 
unidentified genotoxic factor, experiments using antibiotic treatment did show 
that reducing overwhelming number of serotype 3, decreased exaggerated 
neutrophilic infiltration and reduced pulmonary DNA damage.  
The observation that greater pneumococcal numbers results in increased 
accumulation of neutrophils is consistent with results reported in previous 
pneumonia models (32, 133, 134, 146, 147). In addition to the viable 
pneumococcal population, their autolysis in vivo (96) could release significant 
amount of inflammatory factors such as cell wall materials (teichoic acid, 
phosphorylcholine) and cytotoxin (8, 137, 327) or unknown factors (328) that 
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could further fuel the pulmonary oxidative stress to induce DNA damage and 
disease severity (165, 168). Indeed, administration of pneumococcal cell wall in 
animals has been shown to directly influence leukocytosis (329). Additionally, it 
should be noted that pneumococcal disease progression and outcome is not just 
only determined by bacterial numbers, as it has been reported that harboring 
large numbers of certain type of pneumococci in the lungs is not lethal to animals 
(330). Hence, besides the pneumococcal number that could directly affect 
inflammation-induced oxidative stress and determine disease severity, the 
genetic makeup of pneumococci that determines expression of virulence factors, 
could also play crucial role in pathogenesis. There is growing evidence that 
demonstrate differential expression of important virulence genes could be strain-
dependent and could elicit different inflammatory responses (32, 325, 330). In 
line with this concept, we observed that infection of serotype 19F isolate, which 
has lungs CFU similar to serotype 4, induced significantly less DNA damage on 
day two and did not cause any disease symptoms compared to serotype 4. One 
possible explanation could be that serotype 19F produces relatively less 
transcripts of spxB gene (responsible for genotoxic H2O2 production) and 
subsequently does not produce any detectable H2O2 compared to serotype 4 
(3.2.5). It is also possible that the isolate of serotype 19F, used in this study, is 
able to survive in lungs without producing aberrant inflammatory response. 
One interesting observation during serotype 3-induced pulmonary DNA 
damage was the pattern of H2AX phosphorylation. While majority of pulmonary 
H2AX observed during serotype 19F and 4 infection was H2AX phosphorylation 
in discrete foci forms, serotype 3 induced mostly (>50%) nuclear-wide 
phosphorylation of H2AX (pan-H2AX). pan-H2AX staining has been reported to 
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occur in human fibroblast cells exposed to Adeno-associated virus (296, 298), 
Chlamydia (289), UV and ionizing radiation (275, 299, 300). Although, the exact 
significance of pan-H2AX in DNA damage response is not clearly understood, 
recently such nuclear-wide H2AX has been shown to be induced by cytokine 
(IL-1, TNF-)-mediated nitric oxide (NO) production in mammalian cells (331). 
This study could give an explanation on our model of serotype 3-induced DNA 
damage, wherein presence of excess inflammation mediates formation of pan-
H2AX during acute pneumonia. In addition, pan-H2AX has also been reported 
in highly DNA damaged cells, and is mediated by ATM kinase (275). In line with 
this report, in vitro we have shown that infection of alveolar cells with serotype 3 
at high MOI of 200-400 results in pan-H2AX formation (3.2.1). Another possible 
explanation for pan-H2AX could be its function as a pre-apoptotic event 
activated by death receptor pathway (322) and UV radiation (277). Genome wide 
phosphorylation of H2AX could possibly cause global chromatin modification for 
facilitating accessibility of kinases or even nucleases during apoptosis (332). Our 
observation indicate that pan-H2AX positive pulmonary cells during serotype 3-
induced pneumonia are not apoptotic, as they do not co-localize with TUNEL 
positive cells, and most likely they are pre-apoptotic cells harboring irreversible 
DNA damage which could be a signature of inflammation-mediated DNA damage. 
Overall, this study has demonstrated the possibility of S. pneumoniae-
induced inflammatory response to cause pulmonary DNA damage during acute 
pneumonia. We observed that extent of pulmonary DNA damage correlated with 
disease severity induced by three different serotypes of S. pneumoniae. In 
addition to our previous finding that pneumococcal H2O2 directly contributes to 
pulmonary DNA damage, here we suggest that serotype-dependent host 
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inflammatory responses also play an important part in promoting DNA damage 
during pathogenesis. We showed that capsular polysaccharides could be one of 
the serotype-dependent bacterial factor that drives recruitment of neutrophils, 
which have potential to cause collateral DNA damage. Finally, we showed that 
early elimination of bacteria by antibiotic treatment significantly reduces 
overwhelming neutrophil recruitment and concomitantly decreases lung injury 
and damage to genomic DNA. Taken together, this study suggests that 
pulmonary genomic DNA damage could be an outcome of severe inflammation 
during acute pneumonia and further emphasizes the need to understand DNA 




















We investigated the status of pulmonary genomic DNA during infection by 
three different serotypes: 19F, 3 and 4 in a mouse model of pneumonia. In 
addition to the pneumococcal virulence factor -H2O2, secreted by serotype 4 
(Section 3), we found that the classical virulence factor –capsular 
polysaccharides, produced extensively by serotype 3, could also play a major 
role in promoting DNA damage during acute pneumonia. Our data suggest that 
capsule-induced DNA damage in lung cells is indirectly mediated by 
inflammatory neutrophils recruitment to lungs in response to unrelenting 
pneumococci population protected by thick capsules.  
It is known that disease progression during S. pneumoniae infection is 
dependent on degree of host inflammatory responses, which is in turn dependent 
on the arsenal of virulence factors being used by particular serotype during 
invasion (32, 317-319, 325). We observed that serotypes used in this study 
elicited different degree of host response, DNA damage and overall disease 
severity. Serotype 3 and 4 caused significantly greater extent of pulmonary DNA 
damage than serotype 19F after 24 hours of infection. This greater genotoxicity 
of serotype 3 and 4 was reflected in their greater virulence in animal model, 
where the least genotoxic serotype 19F proved to be less virulent. Further, using 
antibiotic-mediated killing of serotype 3 we were able to show that pulmonary 
DNA damage indeed correlates with tissue injury as well as disease severity and 
could be used as a measure of collateral damage during pneumonia. 
Impact of the work 
Our work has shown that virulence of a particular serotype affects its 
genotoxic ability, directly or indirectly via its virulence factors. Although the 
serotypes used in this study -19F, 3 and 4 are associated with global 
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pneumococcal disease burden and are covered by popular pneumococcal 
vaccines (Pneumovax and Prevnar), certain serotypes not covered by these 
vaccines are still prevalent and invasive (21). Moreover, rise in antibiotic 
ineffectiveness and resistance has underscored the need for alternative disease 
mitigation and management strategies (288). In this context, the ability to fine 
tune therapies that are aimed at suppressing excess inflammatory response, 
characteristic of pneumonia, could prove beneficial. Our work revealed 
inflammation-induced DNA damage as a novel aspect of pneumococcal 
pathogenesis and hence has underscored anti-inflammatory and anti-genotoxic 
treatment approaches for pneumonia. Although adverse effect of anti-
inflammatory agents like anti-TNF antibody is reported on pneumonia model 
(333, 334), clinical use of antibiotics with corticosteroids, which reduce 
inflammatory cytokines, have been shown to be beneficial in reducing treatment 
failures and improving resolution of community-acquired pneumonia (CAP) (335, 
336).  
S. pneumoniae is naturally transformative bacteria and hence lateral gene 
transfer between pneumococcal strains is a commonplace resulting in homology-
directed recombination of extra-cellular DNA  (30, 337, 338). Such recombination 
has been most commonly found to occur in capsule (cps) production loci allowing 
the pneumococcal strains to switch their serotype while keeping the same 
genotype (338, 339). Considering that Type 3 capsule is biologically more 
economical to produce (43), the results of this section suggest that recombination 
of Type 3’s cps loci to other colonizing strain may potentiate the virulence of the 
recipient strain and exacerbate pneumococcal pathogenesis. 
S. pneumoniae is known to play a major role in complications of chronic 
obstructive pulmonary disease (COPD) (287), as COPD patients are more 
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susceptible to pneumonia (340). COPD is generally characterized by episodes of 
exacerbations that increase as disease progresses (341). It has been proposed 
that pulmonary DNA damage (indicated by H2AX) during COPD could affect 
disease pathogenesis by inducing inappropriate apoptosis and senescence (246). 
Our observation that even a non-virulent serotype 19F can induce some amount 
of DNA damage in lungs during pneumonia, indicates the vulnerability of 
pulmonary DNA during synergistic pathogenesis of COPD and S. pneumoniae. 
Indeed, future studies to understand the role of pneumococci-induced DNA 
damage in triggering episodes of acute exacerbations could be important to 



















5. Pneumococcal toxin Pneumolysin induces DNA damage 
Response and Cell Cycle Arrest 
 
5.1 Introduction 
Severe pneumococcal pneumonia caused by Streptococcus pneumoniae 
is known to cause mortality despite antibiotic therapy (342, 343). One of the 
complicating conditions that could contribute to disease severity, even after 
clearance of bacteria, is pulmonary edema due to alveolar-capillary barrier 
destruction (343). Hence, it is important to understand the host responses 
towards pneumococcal proteins that could outlast the bacteria during disease 
pathogenesis and treatment. Pneumolysin is one of the major virulence factor 
that is known to be released during enzyme-mediated autolysis (96) and allolysis 
(327) or antibiotic-mediated lysis of pneumococci (97). It is known to be crucial 
for pneumococcal virulence and invasion in vivo (128, 129). While the toxic effect 
of pneumolysin resulting in cell death has been well-documented (77, 100-103), 
the molecular processes underlying its toxicity remain to be fully understood. 
Pneumolysin belongs to a cholesterol-dependent cytolysins (CDC) family 
of toxins, which are produced by gram positive bacteria (343). CDC primarily 
mediate host cell death by attacking cholesterol in the membrane and then 
oligomerizing to from cytolytic macromolecular pores. (344, 345). The lytic 
activity of pneumolysin has been associated with alveolar-capillary barrier 
destruction and disease severity in animal model of infection (126, 346). Indeed, 
purified pneumolysin has been shown to cause direct vascular leakage and 
edema (127). Moreover, the pro-inflammatory nature of pneumolysin can further 
exacerbate collateral damage during pneumonia (108, 109, 111). In addition to 
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the membrane-mediated toxicity and immune-modulatory function of 
pneumolysin, there is growing body of evidence that suggests the role of CDC 
toxins in cellular signaling and function of organelles (345). Pneumolysin has 
been shown to localize at membranes of mitochondria (101) and could contribute 
to lysosomal membrane permeabilization (105), leading to apoptosis. 
Pneumolysin-induced apoptosis has been demonstrated in vitro in alveolar 
epithelial cells (100), endothelial cells (102) and brain endothelial cells (the 
blood-brain barrier) (103), all of which could have serious implication during 
pneumococcal infection (107). Depending on cell type, pneumolysin can cause 
apoptosis via intrinsic mitochondrial pathway independent of caspases (77, 101) 
or p38 mitogen activated protein kinase (MAPK) pathway that is dependent of 
caspases (102). Although pneumolysin can potentially damage certain 
intracellular organelles and effectively modulate signaling pathways, the status of 
host genomic DNA during pneumolysin intoxication has not been investigated yet. 
DNA damage could determine global cellular fate by either leading to 
transient cell cycle arrest or to programmed cell death (347), most likely 
depending upon severity of damage (236, 237). DNA double strand breaks 
(DSBs) are known to be the most toxic form of DNA damage as they can cause 
growth arrest or loss of genetic information and chromosomal rearrangements 
during repair or even cause death (201-203). Cellular response to DNA damage 
is a coordinated network involving checkpoints that integrate the DNA repair 
pathways with cell cycle progression, in order to perpetuate only stable genome. 
In mammalian cells, the most common DNA damage response pathway to DSBs 
is mediated by ataxia-telangiectasia mutated (ATM) kinase (201). At the sites of 
DSBs, ATM phosphorylates the nearest histone variant H2AX at serine 139 
(called H2AX) (209) to facilitate formation of robust DNA repair foci that 
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orchestrate recruitment of repair proteins like 53BP1 (263). DSBs is commonly 
repaired by non-homologous end joining (NHEJ) in non-dividing cells (211). 
NHEJ pathway is activated by recognition and binding of DSBs with the 
heterodimer complex of Ku70-Ku80, which recruits the important catalytic subunit 
DNA-PKc to form the complete holoenzyme DNA-PK (207). DNA-PK then 
mediates processing of free termini (230) and ligation of processed ends (199, 
211). The ATM checkpoint pathway activated during response to DSBs causes 
cell cycle arrest, via checkpoint proteins (225) or p53-mediated regulation (228), 
to allow time for repair (229). Despite the presence of effective repair pathways, 
severe DNA damage is known to drive the cell response towards apoptosis, to 
remove the damaged cells (236, 237). 
In our previous study in 3.2, we showed that live S. pneumoniae induces 
DNA damage mainly by secretion of H2O2 and possibly through some H2O2-
independent mechanisms, depending on pneumococcal strain. Given that 
pneumolysin is associated with apoptosis in vitro (100) and DNA damage could 
trigger apoptosis (204, 234), we investigated any possible ability of pneumolysin 
to induce DNA damage. Here, we reveal that the genotoxic factor released 
during pneumococcal lysis is pneumolysin and that pneumolysin is able to induce 
DSBs in alveolar epithelial cells without causing significant lytic pore formation. 
Pneumolysin-induced DNA damage was found to be associated with cell cycle 
arrest at G2/M phase. We also showed that oligomerization of pneumolysin could 
play significant role in its genotoxicity. Importantly, we showed that DSBs 
induced by pneumolysin show active repair foci and inhibiting the DSB repair 





5.2.1. Pneumococcal lysis induces DNA Damage 
To understand the role of pneumolysin in S. pneumoniae-induced DNA 
damage, we first investigated whether pneumolysin could contribute to DNA 
damage mediated by live S. pneumoniae, as observed in 3.2. Although 
pneumolysin is mostly cytoplasmic without any secretory signal (95), it has been 
shown to be associated with the cell wall (348), and even reported to be detected 
in bacterial supernatants (99, 349). To explore the possible importance of 
pneumolysin in inducing DNA damage, we infected alveolar epithelial cells with S. 
pneumoniae serotype 19F, 3 and 4 and assayed the cell culture supernatant for 
the presence of pneumolysin by western. Consistent with its lack of a secretory 
signal, we did not detect pneumolysin in the F12-K media supernatant during 
infection of alveolar cells (Fig. 5.1A) and observed that almost all of the 
pneumolysin is present in pneumococcal cell pellets. Hence, we examined the 
ability of pneumococcal cell lysate to induce DNA damage. Alveolar epithelial 
cells were exposed to lysate of pneumococcal protoplast (prepared in F12-K 
media) for 7 hours and extent of DNA damage, indicated by H2AX formation, 
was determined. We found that pneumococcal lysates from all of the three 
serotypes were able to induce significant number of H2AX positive cells, 
regardless of the serotypes (Fig. 5.1B). This result show that in addition to 
metabolically active S. pneumoniae, lysis of S. pneumoniae could also result in 
DNA damage of host cells during infection. Given that pneumolysin is released 
during pneumococcal lysis (96), these data suggest that pneumolysin could be a 







Figure 5.1 (A) Pneumolysin is detected only in bacterial cells during in vitro 
infection. Alveolar epithelial cells (A549) were infected with S. pneumoniae 
serotypes 19F, 3 and 4 at high MOI (200-400) for 7 hours. The culture medium 
was centrifuged and the bacterial pellets were lysed. The supernatant was 
filtered through 0.2 m filters and concentrated using Amicon ultra. Equal volume 
(20 l) of bacterial cell lysate (cell) and supernatant (sup) were then probed for 
pneumolysin by western blot using anti-pneumolysin antibody. Recombinant 
pneumolysin (20 l) in different concentrations was also probed to estimate the 
amount of pneumolysin present in the bacteria cells and culture supernatant. 
Representative blot of three independent experiments showing pneumolysin 
presence only in bacterial cells. (B) Lysate of pneumococcal protoplast induces 
DNA damage in alveolar epithelial cells. S. pneumoniae serotypes 19F, 3 and 4, 
grown in bacteria media, are re-suspended in cell wall digestion buffer to isolate 
the protoplasts which are then physically lysed by Bead beater in F12-K culture 
media (Material and Methods). The pneumococcal lysate is then incubated with 
alveolar epithelial cells for 7 hours and analyzed for H2AX. Representative 




5.2.2. Pneumolysin induces double strand breaks (DSBs) and DNA 
damage response in lung epithelial cells 
To test the hypothesis that pneumolysin induces DNA damage in 
mammalian cells, we expressed recombinant pneumolysin (the plasmid was a 
gift from Larry S. McDaniel’s lab) and exposed them to alveolar epithelial cells for 
12 hours. We then examined the epithelial cells nuclei for H2AX foci as well as 
for 53BP1 that frequently co-localizes with H2AX, indicating sites of DNA DSBs 
(263). We observed that pneumolysin induces discrete foci of H2AX and 53BP1 
in epithelial cells in a concentration dependent manner (Fig. 5.2A). At 
concentration of 1 g/ml, pneumolysin induced greater number of DNA damaged 
cells than at 0.1 g/ml. In addition, we observed that majority of H2AX induced 
by pneumolysin co-localized with 53BP1 showing formation of DSBs. Using 
H2AX and 53BP1 as markers, we then investigated the time kinetics of DSBs 
formation in alveolar epithelial cells between 4 hours to 48 hours exposure to 
pneumolysin. We found that recombinant pneumolysin was able to induce DSBs 
in significant number of cells as early as 4 hours (Fig. 5.2B). After 4 hours, we 
observed a pneumolysin concentration-dependent increase of DNA damaged 
cells, with higher concentration of pneumolysin (1 g/ml) able to induce DSBs 
in >60% of host cells at 12 hours compared to ~40% induced by 0.1 g/ml 
pneumolysin.  
Given that pneumolysin primarily causes cellular toxicity by disrupting 
host cell membrane, we also analyzed for cytoplasmic lactate dehydrogenase 
(LDH) release as a measure of pneumolysin-induced cytotoxicity. We found that 
pneumolysin was able to induce significant LDH release from alveolar epithelial 
cells only at 1 g/ml concentration and did not cause any detectable cell lysis at 
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0.1 g/ml. These data indicate that pneumolysin is able to induce potent DSBs 
during lytic concentration and importantly induces DSBs even without disrupting 
host cell membrane. 
We also observed that after 24 hours of pneumolysin exposure, the 
frequency of alveolar epithelial cells harboring DSBs decreases, although 
insignificantly compared to 12 hours (Fig. 5.2B). Given that DSBs is able to 
activate repair processes as an integrative part of DNA damage response, the 
decline in number of DNA damaged alveolar cells could indicate effective repair 
of DSBs. To determine presence of repair processes at the sites of DSBs, we 
analyzed the pneumolysin-induced H2AX foci for presence of other repair 
proteins like MDC1. H2AX, mostly phosphorylated by ATM, is known to initiate 
its signaling cascade by directly binding the scaffold protein MDC1 to its 
phosphorylated region which promotes accumulation of repair proteins at DSBs 
(215). We observed that pneumolysin-induced H2AX foci has co-localized 
MDC1 protein indicating activation of DNA repair responses (Fig. 5.2C). 
H2AX/MDC1 complex acts as platform that amplifies ATM signaling pathway by 
recruitment of MRN (Mre11/Rad50/Nsb1) complex and ATM to further 
phosphorylate repair proteins like 53BP1 (215-217, 350). In consistent with 
accumulation of repair responses at pneumolysin-induced DSBs, we observed 
that 53BP1 co-localized with H2AX foci are also phosphorylated (Fig. 5.2D). 
Overall, these results suggest that pneumolysin is able to induce DSBs and 






Figure 5.2  Pneumolysin induces double strand breaks (DSBs) in alveolar 
epithelial cells. (A) Recombinant pneumolysin was incubated with alveolar 
epithelial cells at 0.1 g/ml and 1 g/ml concentration for 12 hours and analyzed 
for H2AX and 53BP1. Representative images showing DSBs in alveolar 
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epithelial cells with nuclei (blue), H2AX (red), 53BP1 (green) and co-localized 
foci (yellow). (B) Alveolar epithelial cells exposed to pneumolysin was analyzed 
for H2AX and 53BP1 at 4, 8, 12, 24 and 48 hours of incubation. H2AX and 
53BP1 positive cells (≥ 5 foci per nucleus) were quantified and expressed as 
percentage positive cells. The extent of cell toxicity induced by pneumolysin was 
quantified by using LDH assay and expressed as percent of total LDH release 
during lysis by 1% Triton X-100. Results show mean  SEM for three 
independent experiments. (C-D) Recombinant pneumolysin was incubated with 
alveolar epithelial cells at 0.1 g/ml and 1 g/ml concentration for 12 hours and 
analyzed for MDC1 and phospho53BP1 (Ser1775). (C) Representative images 
showing co-localization (yellow) of H2AX (red) with MDC1 (green). (D) 
Representative images showing co-localization (yellow) of H2AX (red) with 
phospho53BP1 (green). Images are from three independent experiments. 
 
5.2.3. Pneumolysin induces apoptosis when DSB Repair is inhibited 
To understand the role of DNA damage response pathways during 
pneumolysin-induced DSBs, we exploited specific inhibitors of PI3KK 
(phosphatidylinositol 3-kinase-like protein kinases) that are activated by DNA 
damage (199). DSBs is known to activate DNA damage response pathways that 
are centrally regulated by ATM kinase (351), which phosphorylates H2AX 
(H2AX) as a initial step to orchestrate DNA repair (209). To observe whether 
pneumolysin-induced DSBs activate the canonical ATM kinase pathway, we 
introduced ATM kinase inhibitor (KU55933) at 10 M and 20 M during exposure 
of pneumolysin to alveolar epithelial cells. We found that inhibition of ATM kinase 
significantly reduces formation of H2AX at 6 hours (Fig. 5.3A). Although there 
was no apoptotic epithelial cells detected at 6 hours, there was significant 
reduction in overall ATP content when epithelial cells were exposed to 
pneumolysin in presence of 20 M KU55933, indicating occurrence of cell death 
or possible metabolic arrest when ATM pathway is inhibited. The extent of 
reduction in ATP levels was found to be dependent on pneumolysin 
136 
 
concentration, with higher genotoxic concentration (1 g/ml) (Fig. 5.2B) causing 
greater reduction in ATP levels.  
DNA-PKc is another response protein of PI3KK family that is also 
activated to phosphorylate H2AX at DSBs (220). Importantly, DNA-PKc interacts 
with Ku heterodimer to form DNA-PK holoenzyme, which is the key player during 
DSB repair via non-homologous end joining (NHEJ) pathway (199, 207). Under 
condition where DNA-PK was inhibited by NU7441, we observed that there was 
significant reduction in pneumolysin-induced H2AX formation, accompanied by 
apoptosis of alveolar epithelial cells at higher concentration of pneumolysin (Fig. 
5.3A). In addition, inhibition of DNA-PK during pneumolysin exposure resulted in 
overwhelming decrease of ATP levels in alveolar cells, indicating loss of viable 
cells and parallel increase in number of detached cells (live and dead) found in 
the culture supernatant (Fig. 5.3B). Like in the case of ATM inhibition, cellular 
effect of DNA-PK inhibition was observed to be dependent on concentration of 
inhibitor as well as pneumolysin. However, inhibition of DNA-PK during 
pneumolysin-induced DNA damage has greater detrimental effect on cell survival 
than ATM inhibition. Most likely this is because DNA-PK is an indispensable part 
of NHEJ repair pathway and its inhibition impairs DNA repair and lead to cell 
death. Overall, these results indicate that pneumolysin-induced DSBs activate 
ATM pathway and inhibition of DNA-PK results in pneumolysin-induced 
apoptosis and loss of cell viability, which is consistent with a model whereby 





Figure 5.3 Pneumolysin-induced DNA damage response is mediated by ATM 
and activates DNA-PK-mediated repair. (A) Pneumolysin was incubated with 
alveolar epithelial cells at 0.1 g/ml and 1 g/ml concentration for 6 hours, in the 
presence of 10 M and 20 M of ATM inhibitor (KU55933) or DNA-PK inhibitor 
(NU7441). Representative images showing inhibition of H2AX formation by 
KU55933 and NU7441 as well as apoptosis induction by NU7441, with nuclei 
(blue), H2AX (red) and TUNEL (green). Images are representative from four 
independent experiments. (B) Alveolar epithelial cells exposed to pneumolysin 
for 6 and 12 hours, with KU55933 or NU7441, was analyzed for ATP content (red 
lines) and is expressed as percent of negative control (No PLY) used. The 
number of detached cells was determined in the supernatant using 
hemocytometer (green lines) and is expressed as percent of cells initially seeded 
(1 x 105). Results show mean  SEM for three independent experiments. *p < 
0.05, unpaired Student’s t-test.  
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5.2.4. Pneumolysin induces Cell Cycle arrest at G2/M checkpoint 
DNA damage results in coordinated activation of DNA damage 
checkpoint proteins and DNA repair proteins to arrest cell cycle progression and 
allow some time for repair (352). One of the major processes that decide cellular 
fate between transient arrest and apoptosis is fine-tuning of p53 activation (236-
238). Given that, we did not observe any apoptosis induced by pneumolysin in 
alveolar epithelial cells (Fig. 5.3A), we investigated the status of p53 levels in 
pneumolysin treated cells. We observed that there was not any striking difference 
in protein levels of p53 after exposure to pneumolysin (Fig. 5.4A). One of the 
important target genes of p53 is p21, which is known to inhibit cyclin-dependent 
kinases (CDKs) including CDK1/2, to sustain cell arrest signals during DNA 
damage (228). We found that there was significant increase of p21 levels after 24 
hours of pneumolysin treatment, indicating possibility of pneumolysin-induced 
cell cycle arrest (Fig. 5.3A). Indeed, when the cell cycle status of pneumolysin-
treated cells was determined by analyzing their DNA content, we observed that 
significant percent of cells were arrested at G2-M transition phase (Fig. 5.3B). 
Similar to the genotoxicity of pneumolysin, the extent of pneumolysin-induced cell 
arrest was also dependent on its concentration, with greater genotoxic 
concentration inducing greater population in G2-M cell arrest. Overall, the data 
suggest that pneumolysin-induced DSBs are able to cause G2-M cell cycle arrest 







Figure 5.4 Pneumolysin-induced DNA damage is associated with cell cycle 
arrest. (A) Alveolar epithelial cells exposed to pneumolysin was lysed at different 
time-points during incubation and the lysate was probed for p53 and p21 by 
western blot. -actin was probed as loading control. Blot is representative from 
three independent experiments. (B) Alveolar epithelial cells exposed to 
pneumolysin were also analyzed for cell cycle status using propidium iodide and 
flow cytometry. Representative histogram of three independent experiments, 
showing alveolar epithelial cell cycle arrest at G2/M phase after treatment with 
pneumolysin for 24 hours. Similarly, alveolar epithelial cells exposed to 
pneumolysin for 12, 24 and 48 hours were quantified for percent cell arrest at 
G2/M. Results show mean  SEM for three independent experiments. *p < 0.05, 





5.2.5. Inhibiting pneumolysin oligomerization prevents DNA damage 
Pneumolysin is known to make pores in cell membrane by first 
oligomerization of 35-47 monomers at membrane to form pre-pore structure that 
undergoes drastic conformational changes penetrating the membrane to form 
complete ring-shaped pore, characteristic of CDC family (344). To understand 
any potential role of oligomerization of pneumolysin subunits in pneumolysin-
induced DSBs, we used a monoclonal antibody (mAb) (developed by Kwang’s 
lab) that targets the oligomerization domain residues of pneumolysin. Given that 
pneumolysin oligomerization is crucial for its lytic activity, first we showed that the 
anti-pneumolysin mAb was indeed able to neutralize hemolytic activity of 
recombinant pneumolysin (Fig. 5.5A) as well as reduce cytolytic activity against 
alveolar epithelial cells (Fig. 5.5B). We then evaluated the effect of neutralizing 
the oligomerization domain on the genotoxicity of pneumolysin. We observed that 
exposing pneumolysin to alveolar epithelial cells, in the presence of the mAb, 
significantly reduced the formation of DSBs as indicated by H2AX staining (Fig. 
5.5C). Interestingly, the neutralizing mAb reduces DSBs induced by non-lytic 
concentration of pneumolysin (0.1 g/ml), indicating that some form of 
pneumolysin oligomerization could be important to induce DNA damage 
response, independent of cell lysis. Finally, when alveolar epithelial cells were 
exposed to pneumococcal lysate, along with the mAb, the frequency of H2AX 
positive cells decreased significantly (Fig. 5.5D). These data suggest that 
pneumolysin released during bacterial lysis is the genotoxic factor of bacterial 
lysate and pneumolysin subunit oligomerization could be an important event that 





Figure 5.5 Neutralizing oligomerization domain of pneumolysin prevents its 
genotoxicity. (A) Hemolysis assay was performed to test the ability of anti-
Pneumolysin monoclonal antibody (mAb) to neutralize the lytic activity of 25 
ng/ml pneumolysin against RBCs. Extent of hemoglobulin released during 
pneumolysin-mediated RBC lysis is expressed as percent of total hemolysis 
during RBC treatment by lysis buffer. (B) Pneumolysin was exposed to alveolar 
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epithelial cell for 12 hours in the presence of anti-pneumolysin mAb. LDH assay 
was performed in the culture supernatant and expressed as percent of total LDH 
release during lysis by 1% Triton X-100. Results show mean  SEM for three 
independent experiments. *p < 0.05, unpaired Student’s t-test.  (C) Similarly, 
alveolar epithelial cells exposed to pneumolysin, in the presence of anti-
pneumolysin mAb, was analyzed for H2AX. Representative images showing 
prevention of DNA damage by mAb, with nuclei (blue) and H2AX (red). (D) 
Alveolar epithelial cells exposed to pneumococcal lysate for 7 hours, in the 
presence of anti-pneumolysin mAb, Representative images showing prevention 
of DNA damage by mAb, with nuclei (blue) and H2AX (red). Images are 






















We investigated the genotoxicity of the conserved pneumococcal toxin 
pneumolysin, which is present in almost all of the pathogenic pneumococcal 
strains (343). We showed that exogenous treatment of pneumolysin induces 
discrete foci of H2AX and colocalizing 53BP1 in alveolar epithelial cells, 
indicative of DSBs. Pneumolysin-induced H2AX foci formation is mediated by 
ATM and DNA-PK kinases and shows recruitment of the important repair protein 
MDC1 and subsequent decline in frequency of DNA damaged cells after 24 
hours. We observed that genotoxicity of pneumolysin does not require cytolytic 
pore formation. Interestingly, we found that neutralizing the oligomerization 
domain of pneumolysin prevents its genotoxicity, indicating a potential role of 
pneumolysin oligomerization for activating DNA damage response in host cells. 
Using the neutralizing antibody, we also showed that pneumolysin is the key 
DNA damaging factor that is released during lytic death of bacteria. 
Pneumolysin-induced DNA damage response results in p21-mediated growth 
arrest to possibly allow time for DNA repair, without any apoptosis. Consistent 
with this observation, we found that inhibiting the common NHEJ repair pathway 
by DNA-PK inhibitor drastically increases apoptosis and toxicity associated with 
pneumolysin. These results demonstrate the genotoxicity of pneumolysin and 
emphasize the importance of DNA repair in maintaining genomic stability and 
prevent pneumolysin-mediated cytotoxicity. 
Pneumolysin is mostly cytoplasmic and stored inside pneumococci as it 
lacks any secretory signal (95). Although pneumolysin has been shown to be 
associated with bacterial cell wall (348) and detected in bacterial supernatants 
(99, 349), consistent with its lack of secretory signal, we found that pneumolysin 
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was not actively secreted in the F12-K media supernatant during infection of 
alveolar cells. The ability of pneumococcal lysate as well as purified pneumolysin 
to induce DNA damage was neutralized by anti-pneumolysin monoclonal 
antibody, clearly indicating that pneumolysin is the key factor that makes lytic 
death of pneumococci a genotoxic process.  
We observed that the extent of DNA damage, cell cycle arrest and cell 
lysis was dependent on pneumolysin concentration. Pneumolysin has been 
found to be present at up to 180 ng/ml concentration in cerebral spinal fluid of 
patients with pneumococcal meningitis (97). At low concentration of pneumolysin 
used in this study (i.e. 100 ng/ml), the toxin was not able to induce any cell lysis 
as measured by LDH release but was able to induce discrete foci of DSBs, 
suggesting that pneumolysin-induced DNA damage is independent of its 
characteristic function as cytolytic toxin. Cytolytic pore formation by CDC toxin 
like pneumolysin is generally measured by hemoglobin release from RBC, LDH 
release from mammalian cells or visualization of membrane pores by microscopy 
(345). Here, we found that although 25 ng/ml pneumolysin was enough for 
complete lysis of RBCs, 100 ng/ml pneumolysin was unable to induce lysis in 
alveolar epithelial cells while 1 g/ml pneumolysin was able to cause LDH 
release. One reason for this observation could be that the size of the pore is 
possibly determined by pneumolysin concentration. While pneumolysin pore 
formation is dependent on oligomerization of 35-47 monomers on membrane to 
form ring-shaped pore of around 26 nm diameter (344), oligomerization of CDC 
toxin has been shown to depend on its concentration in solution, with smaller 
oligomer forming smaller pores (353). Hence, it is possible that at ≤ 100 ng/ml 
concentration, pneumolysin predominantly forms smaller “micropores” that allows 
hemoglobin (~64 kDa) leakage but prevents LDH (~146 kDa) leakage. 
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Oligomerization of pneumolysin into micropores could then lead to activation of 
DNA damage response in host cells without significant lysis. Indeed, in 
consistent with this hypothesis, we found that neutralizing the oligomerization of 
pneumolysin prevented the H2AX induction by the non-lytic 100 ng/ml 
pneumolysin concentration.  
Pneumolysin pore formation has been shown to result in increased 
calcium influx into the cytoplasm that results in activation of different signaling 
pathways (104, 354, 355), since calcium can be used as a secondary messenger 
(356). Similarly, mitochondrial membrane permeabilization of pneumolysin (101) 
can also result in increased calcium accumulation inside the mitochondria. One 
of the pathways activated by increased calcium content in cytosol and 
mitochondria that could lead to DNA damage is intracellular reactive oxygen 
species (ROS) production. Increased calcium levels can stimulate electron 
transport chain and membrane enzymes like NADPH-oxidase to cause 
dysregulated production of ROS (357, 358), which can cause direct DNA 
damage (179). Indeed, ≤ 100 ng/ml pneumolysin has been shown to elevate 
intracellular ROS production in neuronal cells (101) and neutrophils (110). 
Increased calcium levels in cytosol can also induce DNA damage via activation 
of endonucleases that requires calcium for their activity to cleave DNA strands 
(359). In context of pneumolysin effect on nuclear DNA, so far one study has 
demonstrated that toxins of CDC family is able to influence histone modification; 
specifically the study showed that pneumolysin induces dephosphorylation of 
histone H3 at serine 10 residue through unidentified pathways (360). Here, we 
show that pneumolysin is able to induce H2AX phosphorylation at serine 139, 
which is indicative of DSBs. Further understanding of the mechanisms by which 
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oligomerized pneumolysin induce DNA damage in host cells would be interesting 
to explore in future studies. 
We observed that the pneumolysin-induced DSBs in alveolar cells induce 
ATM kinase pathway within hours and causes cell cycle arrest via p53/p21 
pathway after 24 hours. p53 levels can be stabilized by phosphorylation from 
ATM or checkpoint proteins (Chk1 and Chk2) (226, 227). Although p53 protein 
levels after pneumolysin treatment did not show strong increase than untreated 
control, p21 was significantly upregulated during pneumolysin treatment. One 
reason that p53 level is observed to be only mildly induced could be that during 
repairable DNA damage, p53 is activated in short pulses that causes cell arrest; 
until repair is completed (236, 237). However, during severe DNA damage, p53 
levels are greatly increased and sustained to execute apoptosis (236-238). 
Hence, given the observation that pneumolysin-induced DNA damage does not 
cause apoptosis, the resulting cell cycle arrest is possibly activated without 
strong increase in p53 expression.  
In summary, this study reveals a previously unidentified ability of 
pneumococcal toxin pneumolysin to induce DSBs in concentration that is 
physiologically relevant during pathogenesis. Interestingly, the genotoxicity of 
pneumolysin is dependent on the subunit oligomerization on the host cell 
membrane and does not require membrane lysis. Importantly, we showed that 
pneumolysin-induced DSBs elicit DNA damage response that involves activation 
of NHEJ pathway to repair the DSBs and subsequent p21-mediated cell cycle 






Our finding that a cholesterol-dependent cytolysin (CDC) toxin, 
pneumolysin, is able to cause DSBs foci in mammalian cells adds to a growing 
body of evidence that suggests the role of CDC toxin in intracellular signaling, in 
addition to their classical function of membrane lysis (345). Although the exact 
mechanism of how pneumolysin induces DSBs remains to be understood, we 
have shown that DSBs foci, indicated by H2AX, recruits important repair 
proteins like MDC1 and 53BP1, which helps in repair process, and decrease the 
frequency of DNA damaged cells. We showed that the pneumolysin-induced 
DSBs activate the canonical ATM kinase pathway that initiates DNA damage 
response by phosphorylation of H2AX and the repair of the DSBs involves the 
common DNA-PK mediated NHEJ pathway. Importantly, we showed that the 
toxin-induced DNA damage results in cell cycle arrest of alveolar epithelial cells 
and causes apoptosis when NHEJ repair pathway is inhibited. We also found that 
preventing the oligomerization of pneumolysin subunits inhibited pneumolysin-
induced DSBs, indicating that toxin oligomerization on cell surface not only plays 
a crucial role for pore formation but also for activating pathways that could result 
in DNA damage.  
Impact of the work:  
The main aim of present strategy for treatment of pneumococcal 
pneumonia is quite straight forward -killing of pneumococci by antibiotic to 
prevent further escalation of tissue damage and inflammatory reactions (361). 
Although, combination therapy of -lactam and macrolides antibiotics has proven 
very effective during CAP treatment (362), there are studies that have shown 
antibiotic therapy to be insufficient for disease treatment in patients in intensive 
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care unit (342). One of the commonly used frontline antibiotics for pneumonia 
treatment is -lactams (361) that function by lysing the pneumococci. Lysis of 
significant number of bacteria could release substantial amount of potent 
inflammatory factors like pneumococcal cell wall and pneumolysin (329). Indeed, 
use of -lactam based antibiotics is shown to cause greater release of 
pneumolysin than non--lactams (97, 363). Given that pulmonary DNA damage 
is associated with severity of pneumococcal pneumonia (Section 3 and 4), here 
we showed that bacterial lysis releases pneumolysin as a genotoxic factor, 
suggesting that use of bacteriolytic antibiotics could influence the inflammatory 
responses and exacerbate DNA damage in pneumonia. Consistent with this line 
of thought, using animal model of pneumococcal pneumonia that occurs 
secondary to influenza infection, it has been shown that -lactam antibiotic is not 
effective in decreasing mortality of dual infected animals when compared to non-
-lactams, despite clearance of live pneumococci (364). Given that pneumolysin 
is released during bacteriolytic antibiotic therapy, our study suggests that 
pneumolysin-induced DSBs could be a significant toxic factor to pulmonary DNA 
during treatment condition. 
Although, our data showed that pneumolysin-induced DSBs was not 
associated with any apoptotic events, pneumolysin was able to induce cell cycle 
arrest at G2/M phase. It is possible that pneumolysin-induced alveolar growth 
arrest could impair lung repair and regeneration processes during recovery from 
pneumonia treatment. Regeneration of alveolar cells is critical during repair of 
alveolar epithelia to restore functional pulmonary architecture in the aftermath of 
pathogen-induced lung injury (365, 366). Pneumolysin-induced cell arrest may 
delay the tissue repair and affect recovery phase of pneumonia. 
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So far CDC toxins have been known mainly for its role in cell lysis (353). 
Here, we showed that oligomerizing activity of one such CDC toxin- pneumolysin 
on the cell surface could cause DNA DSBs in the nucleus. Previously, 
pneumolysin has been shown to affect membrane permeabilization of 
intracellular organelles like mitochondria (101) and lysosome (105). In sub-lytic 
concentration (< 100 ng/ml) (107), pneumolysin is known to modulate 
inflammatory responses of phagocytes by stimulating production of cytokines 
(111) and inflammatory lipids and enzymes (108, 109). In context of potential 
effect of pneumolysin on nucleus, the toxin has been shown to activate histone 
dephosphorylation (360) and induce intracellular ROS production in certain cells 
that could lead to potential DNA damage (101, 110). Our study shows that 
pneumolysin, indeed, can induce DNA damage as DSBs that activates the ATM 
and DNA-PK-mediated repair response. Pneumolysin is closely related with other 
toxins of the CDC family like listeriolysin O produced by Listeria monocytogenes 
(that causes gastroenteritis, meningitis), streptolysin O produced by 
Streptococcus pyogenes (that causes respiratory infections) and perfingolysin O 
produced by Clostridium perfringens (that causes gas gangrene) (367). Given 
that pneumolysin shares 40-70% sequence identity as well as mode of operation 
with these toxins (367), it would be interesting to explore if other CDC toxins 









This thesis demonstrates pulmonary genomic DNA as a previously 
unidentified host factor that is affected during S. pneumoniae pathogenesis. S. 
pneumoniae induces host DNA damage in the form of strand breaks, mediated 
by virulence factors like H2O2 and pneumolysin and possibly by collateral effect 
of exaggerated host inflammatory response. We found that virulence factors-
mediated DNA damage results in either apoptosis or cell arrest and impairing 
DNA repair capacity exacerbates the toxicity of the virulence factors. Importantly, 
using animal models of pneumonia, we found that pulmonary DNA damage is 
associated with serotype-dependent pneumococcal virulence and mortality.  
 The study described in Chapter 3 was a key step towards understanding 
the genotoxicity of S. pneumoniae. Here, we found that S. pneumoniae induces 
DNA double strand breaks, as indicated by ATM kinase-mediated 
phosphorylation of H2AX, and that the genotoxicity is mainly conferred by ability 
of pneumococci to create oxidative stress through H2O2 production. We showed 
that different strains (serotype 19F clinical strain, serotype 4 TIGR4 and serotype 
3 Xen10) of S. pneumoniae showed different ability to produce H2O2, which is 
consistent with previous reports (368). We found that the pneumococcal serotype 
4 (TIGR4 strain) that produced genotoxic levels of H2O2, induced DNA damage 
at higher levels and subsequently caused greater extent of apoptosis in alveolar 
epithelial cells. Pneumococcal H2O2 was determined to be the key factor that 
induces host DNA damage as bacterial supernatant that has H2O2 was enough to 
induce DSBs and both supernatant and live bacteria-induced DNA damage was 
prevented by presence of catalase during co-incubation. Importantly, we 
observed that streptococcus pyruvate oxidase (spxB) gene’s product is the major 
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determinant of pneumococcal H2O2 production and hence pneumococci without 
spxB gene, lost their genotoxicity. In agreement with a model wherein 
pneumococci-induced DSBs cause apoptosis, we found that inhibiting the 
common DSB repair pathway, NHEJ, further exacerbates pneumococci-induced 
cytotoxicity. In particular, absence of functional Ku80, which is an indispensable 
part of Ku complex that binds the DSBs to initiate NHEJ pathway, was found to 
make host cells susceptible to pneumococci-induced DNA damage and 
apoptosis. These results indicate an important role of DNA repair in suppressing 
pneumococcal genotoxicity, and reveal the ability to repair DNA as a host factor 
that could affect disease pathogenesis. 
In consistent with these in vitro observations, we found that ability of S. 
pneumoniae (serotype 4) to produce H2O2 is important to cause pulmonary DNA 
damage and virulence in animal model of pneumonia. S. pneumoniae spxB 
mutants unable to induce DNA damage showed strikingly reduced pneumococcal 
invasion in blood and airways and was less virulent in animal infection model. 
Increasing antibiotic resistance in S. pneumoniae (288) and problems of 
nonresponsive pneumonia in up to 15% CAP patients (361), has called attention 
to a better disease management strategy. In such scenario, these studies not 
only underscore pulmonary DNA damage as a novel aspect of pneumococcal 
pathogenesis but also offer alternative perspective on pneumonia disease 
treatment. 
In Chapter 4, we described the study of pulmonary DNA damage during 
infection by all three pneumococcal serotypes: 19F, 3 and 4. As observed during 
in vitro experiments, we found that the less cytotoxic serotype 19F was also less 
virulent in acute pneumonia model; but interestingly serotype 3 was found to be 
as lethal as H2O2–producing cytotoxic serotype 4, indicating that the 
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pneumococcal strains that do not actively secrete H2O2 use other virulence 
factors that promote disease progression. Indeed, we found that serotype 3 
produces thicker capsule than other two serotypes, making it easier for serotype 
3 to persist and multiply in the lungs. Consistent with our observation in Chapter 
3 that significant pulmonary DNA damage is associated with disease severity, 
here we found that lungs infected with lethal serotype 3 also exhibited greater 
frequency of DNA damage, as indicated by H2AX staining. Comparing the in 
vivo genotoxicity of serotype 19F, 3 and 4, we observed that serotype 19F which 
is unable to produce H2O2 or capsule caused the least pulmonary DNA damage 
while H2O2–producing serotype 4 and capsulated serotype 3 caused greater 
DNA damage and lethality.  
Given the increased multiplication of serotype 3 in lungs (~ 2 log10 CFU 
greater) compared to other serotypes, we hypothesized that inflammatory 
infiltration during lethal serotype 3 infection would be more exaggerated than 
lethal serotype 4 infection. Indeed, we found that neutrophilic infiltration, which is 
characteristically the earliest innate response against pneumococci (142), is 
significantly higher in serotype 3 than in serotype 4. In addition, eliminating the 
bacteria by antibiotic treatment, as early as 24 hours post-infection, reduced the 
number of inflammatory neutrophils. Given that neutrophil functions to produce 
genotoxic reactive oxygen species (ROS) like superoxide, H2O2 and hydroxyl 
radical (149, 153), accumulation of neutrophils in serotype 3 infected lungs could 
be the causative agent of pulmonary DNA damage. Indeed, reduced neutrophil 
numbers are associated with significant decrease in pulmonary DNA damage. 
These observations are consistent with a model wherein overwhelming 
pneumococcal number elicits excess neutrophilic recruitment that in turn causes 
collateral pulmonary DNA damage. Overall, the work of chapter 4 reiterates one 
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of the key findings of chapter 3 -that the DNA damage in pneumonic lungs is 
strongly associated with pneumococcal disease severity, and offers a possibility 
that exaggerated neutrophil response could also cause pulmonary DNA damage. 
 In addition to pneumococcal virulence factors, such as H2O2 and capsule, 
that induces pulmonary DNA damage directly and indirectly (via host factors), S. 
pneumoniae’s virulence is also dependent on the highly conserved 
pneumococcal toxin pneumolysin (91). Pneumolysin is a classical cytolytic toxin  
as well as a potent inflammatory factor (109, 110), that can cause direct 
pulmonary injury (127) when released by bacterial lysis [bacterial enzyme 
mediated (96) or antibiotic mediated (97)]. In Chapter 5, we described a novel 
genotoxic property of pneumolysin - that the toxin induces DSBs in alveolar 
epithelial cells independent of any significant cell lysis. Using monoclonal 
antibody raised against recombinant pneumolysin, we found that pneumococcal 
lysate is genotoxic and the genotoxicity is due to pneumolysin stored inside the 
bacteria.  In addition, our observations also indicated that oligomerization of 
pneumolysin on the cell surface is a necessary event for pneumolysin to induce 
DSBs in the host cells.  
Pneumolysin-induced DNA damage recruits crucial repair proteins to sites 
of DSBs, resulting in subsequent decrease of H2AX positive DNA damaged 
cells after 24 hours. Similar to pneumococci-induced H2AX formation, 
pneumolysin-induced H2AX was also dependent on the canonical ATM pathway 
that is activated by DSBs (209). We found that the DNA damage response 
against pneumolysin drives the alveolar cells to cell cycle arrest at G2/M phase. 
In addition, inhibition of DNA-PK also caused decrease in pneumolysin-induced 
H2AX and importantly rendered the cells susceptible to death by pneumolysin, 
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indicating the significance of DNA-PK-mediated NHEJ pathway in repairing 
pneumolysin-induced DNA damage and thereby preventing apoptosis.  
There are well documented reports on various host factors such as aging, 
genetic deficiencies and polymorphisms, that affect disease pathogenesis and 
predispose the host to pneumococcal diseases. Age-related immune dysfunction 
(such as reduced phagocytosis (369), decline in adaptive immunity) and chronic 
inflammation associated with aging (“inflammaging”) (370) could influence 
pneumococcal pathogenesis. One recent study in aged mouse model has 
revealed presence of dysregulated immune response with exaggerated 
chemokine production against pneumococci (371), suggesting that inflammatory 
response could contribute to immunopathology in elderly with pneumococcal 
disease. Besides such immune dysregulation in aged population, individuals with 
genetic deficiencies in components of complement system such as C2 (372), 
mannose-binding lectin-associated serine protease 2 (MASP2) (373), that are 
central to innate immunity, are known to have increased susceptibility to infection 
by encapsulated bacteria like S. pneumoniae. Genetic polymorphisms in 
complement system such as mutations in mannose-binding lectin (MBL) (374) or 
its promoter (375), which decreases overall MBL production, has also been 
associated with increased risk of pneumococcal diseases.  
Genetic deficiencies in the components of toll-like receptors (TLRs)- 
signaling pathways are known to cause susceptibility towards bacterial infection 
(376). TLR-mediated recognition of pathogenic structures are crucial to activate 
cytosolic adaptor MyD88 which initiates downstream NFB inflammatory 
response against pathogens via IL-1R-associated kinase (IRAK) complex (377). 
There are studies that report specific single nucleotide polymorphisms (SNPs) in 
TLR2 and 4, which are important in recognition of pneumococcal cell wall and 
155 
 
pneumolysin toxin (106) respectively, could increase the susceptibility towards 
invasive pneumococcal diseases (378, 379). Individuals with deficiency in MyD88 
or IRAK-4 have impaired TLR signaling and hence vulnerable to severe invasive 
bacterial infection, most commonly by S. pneumonia (376, 380). Further, 
hypomorphic mutations in NFB essential modulator (NEMO), a subunit of 
kinase complex that regulates NFB activation, is known to be associated with 
reduced cytokine response and antibody deficiency (381, 382), predisposing the 
host to capsular pneumococcal infection (383). To add to the growing evidence 
that implicates genetic variations of host response pathways in pneumococcal 
infection, this thesis shows that pulmonary DNA is a pathogenic target during 
pneumococcal pneumonia and suggests that host DNA repair is a potential 
susceptibility factor for pneumococcal diseases.  
It is well known that defects in DNA repair pathway, such as NHEJ, cause 
severe immunodeficiency diseases, arising due to failure in V(D)J recombination 
that generates diverse T and B cells (233). Hypomorphic and loss-of-function 
mutations in NHEJ components such as Artemis, ligase IV and XRCC4 ligation 
factor are found to be associated with immune-deficient patients (233). Although, 
studies that associate human DNA repair deficiency to pneumococcal infection 
have not been done yet, there are reports of patients with deficiency in Artemis 
having recurrent pulmonary infection (384, 385). Such studies, including this 
thesis work, encourage future investigation to explore DNA repair as an 
important host factor during invasive pneumococcal diseases.      
In summary, this thesis reveals the susceptibility of the host genomic 
DNA during pneumococcal infection, either mediated directly by bacterial factors, 
like H2O2 and pneumolysin, or indirectly via excess inflammatory response acting 
156 
 
against capsulated pneumococci, depending upon the pneumococcal strains. We 
found that S. pneumoniae-induced DNA damage is associated with disease 
severity, independent of the agent mediating the genotoxicity. Importantly, we 
identified DNA repair as an important host factor that suppresses the 
pneumococcal cytotoxicity, underscoring the unsuspected network of DNA 
damage and repair factors that can modulate disease pathology. 
 
 
Figure 6.1 S. pneumoniae induces DNA damage in host cells via production of 
H2O2 as well as by pneumolysin that is released during bacterial lysis. Indirectly, 
S. pneumoniae could cause pulmonary DNA damage via recruitment of 
neutrophils. While pneumococcal toxin-induced DNA damage causes cell cycle 
arrest in alveolar cells, pulmonary DNA damage during pneumococcal 
pneumonia could lead to cell death and is associated with exacerbation of 
disease pathogenesis. DNA repair via Non-homologous end joining pathway is 






7 Future studies 
7.1 Importance of DNA repair during pneumococcal virulence in vivo 
In Chapter 3 and 4, one of our key observations is that pulmonary DNA 
damage is associated with pneumococcal virulence and subsequent animal 
mortality. This conclusion would be stronger if there are additional data that 
demonstrate a causative effect for DNA damage in vivo. In our in vitro Ku80-
deficient experiments, we found that lack of Ku80 exacerbates pneumococcal 
toxicity indicating the impact of DNA damage and the need for repair in this in 
vitro model. To demonstrate a causative effect of DNA damage on 
pneumococcal virulence in animal model, an infection model based on DNA 
repair mutant mice, that are deficient on DSB repair, would be ideal. Alternatively, 
using small molecule inhibitors targeting various DNA repair proteins may prove 
useful to investigate the role of DNA damage and repair in infection. We need to 
keep in mind, however, that such studies are likely to suffer from the confounding 
effects of impact on the immune system, since proteins involved in DSB repair 
also play a role in V(D)J recombination for production of effective antibody as 
well as T-cell receptors against S. pneumoniae (386). Indeed, disabling key 
repair proteins like DNA-PKc or Ku proteins of NHJE pathway is known to cause 
growth defects and immunodeficiency in mice (387-389). Hence, choosing 
appropriate DNA repair deficient system and setting up an animal model, with 
possible adoptive transfer of immune cells, would be important to understand the 
role of pulmonary DNA repair in pneumococcal pneumonia. In the light of our 
present findings, it would also be interesting to test the effect of novel DNA repair 




 7.2 Understanding the types of DNA damage induced by S. pneumoniae 
In our work, we used H2AX as a sole marker of DNA damage induced by 
S. pneumoniae. H2AX is a key signaling event for repair of strand breaks that 
occurs as a result of direct oxidative stress (391) as well as during replication 
stress (223), and is used as standard marker for DSBs (392). Reactive oxygen 
species like H2O2, superoxide and hydroxyl radical formed during oxidative stress 
not only induces direct strand breaks (188) but most commonly results in base 
modifications (184-186) that could result in strand breaks during repair and 
replication. Exaggerated neutrophil recruitment to the lungs is directly associated 
with increased guanosine adducts in pulmonary DNA (192), which could get 
converted to strand breaks during excision repair of adducts (326). Our study did 
not investigate the possible pneumococci- or inflammation-induced base lesions, 
which could be formed a priori to strand breaks. Hence future studies on 
determining whether pneumonia-associated oxidative stress causes host DNA 
modification, would help in understanding the molecular mechanisms behind 
strand breaks formation. 
One interesting observation in analysis of pulmonary DNA damage 
induced by S. pneumoniae was the pattern of H2AX formation in the damaged 
nuclei. Our in vitro observation showed that both serotype 3 and 4 induce foci as 
well as nuclear-wide H2AX (pan-H2AX) at MOI of 30-50 whereas at higher MOI 
we observed pan-H2AX, which also do not stain for 53BP1, to be the dominant 
form. Similarly, in vivo we found that serotype 3, which populates the lungs in 
greater number than serotype 4, predominantly induces pan-H2AX in lung 
sections. Previously, pan-H2AX is shown to be induced by cytokine (IL-1, TNF-
)-mediated nitric oxide production (331) and during concentrated DNA damage 
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by ionizing radiation (275). Pan-H2AX has also been proposed as a pre-
apoptotic event activated by death receptor pathway (322).  While we found that 
the pan-H2AX nuclei do not co-localize with apoptotic TUNEL staining in vivo 
and precedes apoptosis in vitro, the significance of pneumococci-induced pan-
H2AX, whether it represents pre-apoptotic signals or irreversible DNA damage, 
would be interesting to explore in future studies.  
 
7.3 Strain-dependent regulation of H2O2 production in S. pneumoniae 
 In chapter 3, we observed that serotype 4 TIGR4 strain is most genotoxic 
because it produced greater amount of H2O2 than serotype 19F and serotype 3. 
Regulation of H2O2-producing spxB gene has been understudied and so far, only 
one spxB regulator has been reported (368). Although, we found that the lower 
spxB transcripts in serotype 19F compared to serotype 4 could explain its 
inability to produce H2O2, we also observed that serotype 3 did not have any 
decrease in spxB transcripts, indicating transcription-independent regulation of 
spxB. There are studies reporting mutations in spxB that are associated with 
either increased production of H2O2, for example mutations like N95D and T282A 
(393) or like G389D and P449L (368) that are associated with decreased 
production of H2O2 without change in spxB transcript levels. Sequence 
comparisons of spxB between serotype 19F, 3 and 4, reveals only one significant 
mutation that was found in serotype 4 as P545L (data not shown). The 
importance of this previously unreported single mutation in driving serotype 4 to 
produce greater amount of H2O2, is yet to be experimentally confirmed. We 
showed that ability of S. pneumoniae to produce genotoxic level of H2O2 causes 
cell death and can affect virulence in vivo. Hence, further study of the regulatory 
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processes that drive H2O2 production is crucial to understand virulence of certain 
pneumococcal strains that could possibly help devise personal disease treatment. 
 
7.4   Reducing oxidative stress during pneumococcal disease treatment 
 While our observations in chapter 3 implicates pneumococci-induced 
oxidative stress as a key virulence factor during pneumococcal pneumonia, in 
chapter 4 our results suggest that inflammation-induced oxidative stress could be 
an additional factor in pathogenesis, as indicated by pulmonary DNA damage. 
There is mouse model (328) as well as studies in pneumonia patients (168, 394, 
395) that demonstrate increase oxidative stress during S. pneumoniae infection. 
Given that H2O2-producing spxB gene of S. pneumoniae is shown to be required 
for resistant to exogenous H2O2 stress (396), it is possible that H2O2-producing S. 
pneumoniae may not to be sensitive to host ROS/RNS. Hence, suppressing the 
pneumonia-associated oxidative stress during disease treatment could have 
beneficial effect on disease outcome. There are reports of positive effect of 
antioxidants like N-acetyl cysteine on reducing brain tissue injury during 
pneumococcal meningitis (266, 397), vitamin E in reducing inflammation-
associated ROS during pneumococcal sepsis (398) and vitamin C in decreasing 
ROS in peripheral blood cells of pneumonia patients (395). These data, along 
with the results presented here, suggest that use of proper antioxidants to 
attenuate the damaging effect of genotoxic pneumococcal strains as well as of 
excess inflammatory response, could improve disease outcome. Hence, 
investigating the use of antioxidants, possibly in combination with prevalent 





7.5  Limitations of the study and future experiments 
   In Chapter 4, we described the possible role of neutrophils for immuno-
pathology during pneumococcal pneumonia. Here, it has to be noted that 
although excess and prolonged activation of neutrophils could be harmful, 
neutrophils are very crucial against bacterial infection (144) and absence of 
neutrophils or neutropenia has been associated with susceptibility to 
pneumococcal infection (399). Although it is difficult to fine-tune the neutrophil 
infiltration into the lungs, exaggerated inflammatory response and concurrent 
oxidative stress has been shown to be reduced by using corticosteroids (335, 
336) or antioxidants (395). 
 We also note that the Type 4 ΔspxB mutant bacteria was not 
complemented to rule out secondary recombination, although phenotypically we 
did observe that ΔspxB mutants do not produce any significant H2O2. It would 
also be interesting to understand the role of intracellular S. pneumoniae in 
inducing any possible DNA damage in alveolar cells, as pneumococci are known 
to be taken up by A549 cells in vitro (320). This experiment would be interesting 
in light of our observation where serotype 19F and 3, which does not produce 
H2O2, are able to induce cause DNA damage neutralized by catalase.  
Further, future experiments on the ability of S. pneumoniae to resist self-
produced H2O2 would be interesting. Iron-quenching enzyme such as Dpr, which 
could prevent genotoxicity associated with H2O2 (400, 401), has been found to be 
present in pneumococci (401). In addition, lysogenicity of pneumococcal strain 
has also been shown to cause sensitivity to DNA damaging agent such as 
mitomycin C, resulting in activation of lytic prophages (402). These experiments 
could reveal more insights into the ability of certain S. pneumoniae strain to 
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